Nothing Special   »   [go: up one dir, main page]

WO2008076044A1 - Novel 2-amino-5, 5-diaryl-imidazol-4-ones - Google Patents

Novel 2-amino-5, 5-diaryl-imidazol-4-ones Download PDF

Info

Publication number
WO2008076044A1
WO2008076044A1 PCT/SE2007/001117 SE2007001117W WO2008076044A1 WO 2008076044 A1 WO2008076044 A1 WO 2008076044A1 SE 2007001117 W SE2007001117 W SE 2007001117W WO 2008076044 A1 WO2008076044 A1 WO 2008076044A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
imidazol
methyl
amino
benzofuran
Prior art date
Application number
PCT/SE2007/001117
Other languages
French (fr)
Inventor
Stefan Berg
Jesper Hallberg
Katharina HÖGDIN
Sofia KARLSTRÖM
Annika Kers
Niklas Plobeck
Laszlo Rakos
Original Assignee
Astrazeneca Ab
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astex Therapeutics Ltd filed Critical Astrazeneca Ab
Publication of WO2008076044A1 publication Critical patent/WO2008076044A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to novel compounds and their pharmaceutical compositions.
  • the present invention relates to therapeutic methods for the treatment and/or prevention of A ⁇ -related pathologies such as Downs syndrome, ⁇ -amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • a ⁇ -related pathologies such as Downs syndrome, ⁇ -amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage
  • disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment")
  • Alzheimer Disease memory loss
  • BACE was found to be a pepsin-like aspartic proteinase, the mature enzyme consisting of the N-terminal catalytic domain, a transmembrane domain, and a small cytoplasmic domain.
  • BACE has an optimum activity at pH 4.0-5.0 (Vassar et al, 1999) and is inhibited weakly by standard pepsin inhibitors such as pepstatin. It has been shown that the catalytic domain minus the transmembrane and cytoplasmic domain has activity against substrate peptides (Lin et al, 2000).
  • BACE is a membrane bound type 1 protein that is synthesized as a partially active proenzyme, and is abundantly expressed in brain tissue.
  • a ⁇ amyloid- ⁇ -protein
  • a ⁇ or amyloid- ⁇ -protein is the major constituent of the brain plaques which are characteristic of Alzheimer's disease (De Strooper et al, 1999).
  • a ⁇ is a 39-42 residue peptide formed by the specific cleavage of a class 1 transmembrane protein called APP, or amyloid precursor protein. Cleavage of APP by BACE generates the extracellular soluble APP ⁇ fragment and the membrane bound CTF ⁇ (C99) fragment that is subsequently cleaved by ⁇ -secretase to generate A ⁇ peptide.
  • Alzheimer's disease is estimated to afflict more than 20 million people worldwide and is believed to be the most common form of dementia.
  • Alzheimer's disease is a progressive dementia in which massive deposits of aggregated protein breakdown products - amyloid plaques and neurofibrillary tangles accumulate in the brain. The amyloid plaques are thought to be responsible for the mental decline seen in Alzheimer's patients.
  • Alzheimer's disease increases with age, and as the aging population of the developed world increases, this disease becomes a greater and greater problem.
  • this disease becomes a greater and greater problem.
  • any individuals possessing the double mutation of APP known as the Swedish mutation (in which the mutated APP forms a considerably improved substrate for BACE) have a much higher risk of developing AD, and also of developing the disease at an early age ⁇ see also US 6,245,964 and US 5,877,399 pertaining to transgenic rodents comprising APP-Swedish). Consequently, there is also a strong need for developing a compound that can be used in a prophylactic fashion for these individuals.
  • APP The gene encoding APP is found on chromosome 21 , which is also the chromosome found as an extra copy in Down's syndrome.
  • Down's syndrome patients tend to develop Alzheimer's disease at an early age, with almost all those over 40 years of age showing Alzheimer's-type pathology (Oyama et al., 1994). This is thought to be due to the extra copy of the APP gene found in these patients, which leads to overexpression of APP and therefore to increased levels of A ⁇ causing the high prevalence of Alzheimer's disease seen in this population.
  • inhibitors of BACE could be useful in reducing Alzheimer's-type pathology in Down's syndrome patients.
  • Drugs that reduce or block BACE activity should therefore reduce A ⁇ levels and levels of fragments of A ⁇ in the brain, or elsewhere where A ⁇ or fragments thereof deposit, and thus slow the formation of amyloid plaques and the progression of AD or other maladies involving deposition of A ⁇ or fragments thereof (Yankner, 1996; De Strooper and Konig, 1999).
  • BACE is therefore an important candidate for the development of drugs as a treatment and/or prophylaxis of A ⁇ -related pathologies such as Downs syndrome, ⁇ - amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • a ⁇ -related pathologies such as Downs syndrome, ⁇ - amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage
  • disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment")
  • Alzheimer Disease memory loss
  • the compounds of the present invention show beneficial properties compared to the potential inhibitors known in the art, e.g. improved hERG selectivity.
  • the present invention further provides potent BACE inhibitors of formula I:
  • R 1 is selected from phenyl, heteroaryl, optionally substituted with a C 3 . ⁇ cycloalkyl, C 2-6 alkenyl optionally substituted with a Cs ⁇ cycloalkyl, heterocyclyl, C 3 . ⁇ cycloalkyl, Cs- ⁇ cycloalkenyl, halo and cyano, said phenyl or heteroaryl optionally substituted with one or more R 3 ;
  • R 2 is independently selected from hydrogen, cyano or halo;
  • A is phenyl or heteroaryl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is optionally substituted with one or more R 4 ;
  • R 3 is independently selected from halo, cyano, Ci ⁇ alkyl, trifluoromethyl, methoxy, trifluoromethoxy and acetyl;
  • R 4 is independently selected from halo, cyano, methyl and methoxy; provided that said bicyclic ring of A, is substituted with at least one R 4 in the heterocyclyl part, when it is a 1,3-benzodioxole or 2,3-dihydro-l,4-benzodioxine ring system;
  • R 5 is Ci_ 6 alkyl optionally substituted with halogen, cyano, NH 2 , OH, CO 2 H, OCi- ⁇ alkyl,
  • NC(O)(aryl) 2 heteroaryl, Oheteroaryl, C(O)heteroaryl, C(O)Oheteroaryl,
  • the present invention further provides potent BACE inhibitors of formula I: .
  • R 1 is selected from phenyl, heteroaryl, Ci_6alkyl optionally substituted with a C 3- ⁇ cycloalkyl, C 2 - 6 alkenyl optionally substituted with a C 3 _ 6 cycloalkyl, heterocyclyl, C 3 .
  • R 2 is independently selected from hydrogen, cyano or halo
  • A is phenyl or heteroaryl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is optionally substituted with one or more R ;
  • R 3 is independently selected from halo, cyano, trifluoromethyl, methoxy and trifluoromethoxy;
  • R 4 is independently selected from halo, cyano and methyl; provided that said bicyclic ring of A, is substituted with at least one R 4 in the heterocyclyl part, when it is a 1,3-benzodioxole or 2,3-dihydro-l,4-benzodioxine ring system;
  • R 5 is Ci- ⁇ alkyl optionally substituted with halogen, cyano, NH 2 , OH, CO 2 H, OCi- ⁇ alkyl, SO 2 H, C(O)C 1-6 alkyl, C(O)OC 1-6 alkyl, C(O)NH 2 , C(O)NHC 1-6 alkyl, C(O)N(C i- 6 alkyl) 2 , SO 2 Ci. 6 alkyl, SO 2 NHCi -6 alkyl, SO 2 N(C ,. 6 alkyl) 2 , NH(C 1-6 alkyl), N(Ci. 6 alkyl) 2 ,
  • the present invention further provides potent BACE inhibitors of formula I:
  • R 1 is selected from phenyl, heteroaryl, Ci- 6 alkyl optionally substituted with a C 3 . ⁇ cycloalkyl, C 2 . 6 alkenyl optionally substituted with a C 3 _ 6 cycloalkyl, heterocyclyl, C 3 . ⁇ cycloalkyl, Cs ⁇ cycloalkenyl, halo and cyano, said phenyl or heteroaryl optionally substituted with one or more R 3 ;
  • R 2 is independently selected from hydrogen, cyano or halo
  • A is phenyl or heteroaryl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is optionally substituted with one or more R 4 ;
  • R 3 is independently selected from halo, cyano, trifluoromethyl, methoxy and trifluoromethoxy;
  • R 4 is independently selected from halo, cyano and methyl; provided that said bicyclic ring of A, is substituted with at least one R 4 in the heterocyclyl part, when it is a 1,3-benzodioxole or 2,3-dihydro-l,4-benzodioxine ring system;
  • R 5 is Ci- ⁇ alkyl optionally substituted with halogen, cyano, NH 2 , OH, CO 2 H, OCi ⁇ alkyl, SO 2 H, C(O)Ci. 6 alkyl, C(O)OC 1-6 alkyl, C(O)NH 2 , C(O)N(C 1-6 alkyl) 2 , SO 2 C 1-6 alkyl, SO 2 NHC 1-6 alkyl, SO 2 N(C i.
  • n is O, 1 or 2; provided that the following compounds are excluded: 2-Amino-5-(2,3-dihydro-l-benzofliran-5-yl)-5-(3'-methoxybiphenyl-3-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one;
  • R 1 is heteroaryl, optionally substituted with one or more R 3 ;
  • R 2 is independently selected from halo and cyano;
  • A is phenyl or heteroaryl, said phenyl or heteroaryl being optionallyfused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is optionally substituted with one or more R 4 ;
  • R 3 is independently selected from halo, trifluoromethyl and methoxy
  • R 4 is independently selected from halo, methyl, cyano and methoxy; provided that said bicyclic ring of A, is substituted with at least one R 4 in the heterocyclyl part, when it is a 1,3-benzodioxole or 2,3-dihydro-l,4-benzodioxine ring system;
  • R 5 is Ci- ⁇ alkyl
  • R 1 is pyridine.
  • R 1 is pyridine substituted with one or two R 3 and said R 3 is independently selected from halo, trifluoromethyl and methoxy.
  • A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system.
  • A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is substituted with from one to four R 4 .
  • said bicyclic ring system is substituted with one R 4 , said R 4 being halo.
  • said bicyclic ring system is substituted with two R 4 , said R 4 being halo. In another embodiment of this aspect, said bicyclic ring system is substituted with four R 4 , said R 4 being halo.
  • said bicyclic ring system is substituted with two R 4 , said R 4 being methyl.
  • said bicyclic ring system is substituted with one R 4 , said R 4 being cyano.
  • A is selected from:
  • A is selected from:
  • R is pyrimidine
  • R 1 is pyrimidine
  • A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system.
  • R 1 is pyrimidine
  • A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is substituted with from one to four R 4 .
  • R 1 is pyrimidine
  • A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system, said bicyclic ring system is substituted with one R 4 , said R 4 being halo.
  • R 1 is pyrimidine
  • A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system, said bicyclic ring system is substituted with two R 4 , said R 4 being halo.
  • R 1 is pyrimidine
  • A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system, said bicyclic ring system is substituted with four R 4 , said R 4 being halo.
  • R 1 is pyrimidine, and A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system, said bicyclic ring system is substituted with two R 4 , said R 4 being methyl.
  • A is selected from:
  • R 1 is thiazole.
  • composition comprising as active ingredient a therapeutically effective amount of a compound of formula I, in association with pharmaceutically acceptable excipients, carriers or diluents.
  • a compound of formula I as a medicament for treating or preventing an A ⁇ -related pathology, wherein said A ⁇ -related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • a ⁇ -related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI (“mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer Disease, dementia of mixed vascular origin, dementia
  • a ⁇ -related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • MCI mimild cognitive impairment
  • a method of inhibiting activity of BACE comprising contacting said BACE with a compound of formula I.
  • a method of treating or preventing an A ⁇ -related pathology in a mammal comprising administering to said patient a therapeutically effective amount of a compound of formula I.
  • a method of treating or preventing an A ⁇ -related pathology in a mammal comprising administering to said patient a therapeutically effective amount of a compound of formula I, wherein said A ⁇ -related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • Ln another aspect of the invention there is provided a method of treating or preventing Alzheimer's Disease, comprising administering to said patient a therapeutically effective amount of a compound of formula I.
  • a method of treating or preventing an A ⁇ -related pathology in a mammal comprising administering to said patient a therapeutically effective amount of a compound of formula I, wherein said A ⁇ -related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, wherein said mammal is a human.
  • MCI mimild cognitive impairment
  • a method of treating or preventing an A ⁇ -related pathology in a mammal comprising administering to said patient a therapeutically effective amount of a compound of formula I and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor.
  • a method of treating or preventing an A ⁇ -related pathology in a mammal comprising administering to said patient a therapeutically effective amount of a compound of formula I and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, wherein said A ⁇ - related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • Ln another aspect of the invention there is provided a method of treating or preventing an A ⁇ -related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of formula I and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, wherein said A ⁇ - related pathology is Alzheimer Disease.
  • a method of treating or preventing an A ⁇ -related pathology in a mammal comprising administering to said patient a therapeutically effective amount of a compound of formula I and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, wherein said A ⁇ - related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, wherein said mammal is a human.
  • Some compounds of formula I may have stereogenic centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical isomers, enantiomers, diastereoisomers, atropisomers and geometric isomers.
  • the present invention relates to the use of compounds of formula I as hereinbefore defined as well as to the salts thereof.
  • Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I.
  • the present invention provides compounds of formula I, or pharmaceutically acceptable salts, tautomers or in v/vo-hydrolysable precursors thereof, for use as medicaments.
  • the present invention provides compounds described here in for use as medicaments for treating or preventing an A ⁇ -related pathology.
  • the A ⁇ -related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • MCI mimild cognitive impairment
  • the present invention provides use of compounds of formula I or pharmaceutically acceptable salts, tautomers or in vrvo-hydrolysable precursors thereof, in the manufacture of a medicament for the treatment or prophylaxis of A ⁇ -related pathologies.
  • the A ⁇ -related pathologies include such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • MCI mimild cognitive impairment
  • the present invention provides a method of inhibiting activity of BACE comprising contacting the BACE with a compound of the present invention.
  • BACE is thought to represent the major ⁇ -secretase activity, and is considered to be the rate- limiting step in the production of amyloid- ⁇ -protein (A ⁇ ).
  • a ⁇ amyloid- ⁇ -protein
  • BACE is an important candidate for the development of drugs as a treatment and/or prophylaxis of A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated
  • the present invention provides a method for the treatment of A ⁇ - related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, presenile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, comprising administering to a mammal (including human) a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt, tautomer or in vz ' v ⁇ -hydrolysable precursor thereof.
  • a ⁇ - related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angi
  • the present invention provides a method for the prophylaxis of A ⁇ - related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre- senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration comprising administering to a mammal (including human) a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, tautomer or in v/vo-hydrolysable precursors.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid ang
  • the present invention provides a method of treating or preventing A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre- senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration by administering to a mammal (including human) a compound of formula I or a pharmaceutically acceptable salt, tautomer or in v/vo-hydrolysable precursors and a cognitive and/or memory enhancing agent.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid ang
  • the present invention provides a method of treating or preventing A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, presenile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration by administering to a mammal (including human) a compound of formula I or a pharmaceutically acceptable salt, tautomer or in vzv ⁇ -hydrolysable precursors thereof wherein constituent members are provided herein, and a choline esterase inhibitor or anti-inflammatory agent.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such
  • the present invention provides a method of treating or preventingA ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, or any other disease, disorder, or condition described herein, by administering to a mammal (including human) a compound of the present inventionand an atypical antipsychotic agent.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders
  • Atypical antipsychotic agents includes, but not limited to, Olanzapine (marketed as Zyprexa), Aripiprazole (marketed as Ability), Risperidone (marketed as Risperdal), Quetiapine (marketed as Seroquel), Clozapine (marketed as Clozaril), Ziprasidone (marketed as Geodon) and Olanzapine/Fluoxetine (marketed as Symbyax).
  • the mammal or human being treated with a compound of the invention has been diagnosed with a particular disease or disorder, such as those described herein. In these cases, the mammal or human being treated is in need of such treatment. Diagnosis, however, need not be previously performed.
  • the present invention also includes pharmaceutical compositions, which contain, as the active ingredient, one or more of the compounds of the invention herein together with at least one pharmaceutically acceptable carrier, diluent or excipent.
  • a variety of compounds in the present invention may exist in particular geometric or stereoisomeric forms.
  • the present invention takes into account all such compounds, including cis- and trans isomers, R- and S- enantiomers, diastereomers, (D)-isomers, (L)- isomers, the racemic mixtures thereof, and other mixtures thereof, as being covered within the scope of this invention.
  • Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
  • the compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms.
  • optically active forms such as by resolution of racemic forms, by synthesis from optically active starting materials, or synthesis using optically active reagents.
  • separation of the racemic material can be achieved by methods known in the art.
  • Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
  • substitution means that substitution is optional and therefore it is possible for the designated atom or moiety to be unsubstituted.
  • substitution means that any number of hydrogens on the designated atom or moiety is replaced with a selection from the indicated group, provided that the normal valency of the designated atom or moiety is not exceeded, and that the substitution results in a stable compound.
  • a substituent is methyl (i.e., CH 3 )
  • 3 hydrogens on the carbon atom can be replaced.
  • substituents include, but are not limited to: halogen, cyano, NH 2 , OH, CO 2 H, OCi ⁇ alkyl, CH 2 OH, SO 2 H, Ci. 6 alkyl, OC ⁇ alkyl, C(O)C i. 6 alkyl, C(O)OCi. 6 alkyl, C(O)NH 2 , C(O)NHCi. 6 alkyl, C(O)N(C 1-6 alkyl) 2 , SO 2 C,. 6 alkyl, SO 2 NHC 1-6 alkyl, SO 2 N(Ci.
  • 6 alkyl) 2 NH(Ci -6 alkyl), N(Ci- 6 alkyl) 2 , NHC(O)d. 6 alkyl, NC(O)(C i. 6 alkyl) 2 , aryl, Oaryl, C(O)aryl, C(O)Oaryl, C(O)NHaryl, C(O)N(aryl) 2 , S0 2 aryl, SO 2 NHaryl, SO 2 N(aryl) 2 , NH(aryl), N(aryl) 2 , NC(O) aryl, NC(O)(aryl) 2 , Cs- ⁇ heterocyclyl, OCs- ⁇ heterocyclyl, C(O)C 5 .
  • alkyl used alone or as a suffix or prefix, is intended to include both branched and straight chain saturated aliphatic hydrocarbon groups having from 1 to 12 carbon atoms or if a specified number of carbon atoms is provided then that specific number would be intended.
  • “Co- 6 alkyl” denotes alkyl having 0, 1, 2, 3, 4, 5 or 6 carbon atoms.
  • alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl.
  • a subscript is the integer 0 (zero) the group to which the subscript refers to indicates that the group may be absent, i.e. there is a direct bond between the groups.
  • alkenyl used alone or as a suffix or prefix is intended to include both branched and straight-chain alkene or olefin containing aliphatic hydrocarbon groups having from 2 to 12 carbon atoms or if a specified number of carbon atoms is provided then that specific number would be intended.
  • C 2 . 6 alkenyl denotes alkenyl having 2, 3, 4, 5 or 6 carbon atoms.
  • alkenyl examples include, but are not limited to, vinyl, allyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-enyl, 3-methylbut- 1-enyl, 1-pentenyl, 3-pentenyl and 4-hexenyl.
  • aromatic refers to hydrocarbonyl groups having one or more unsaturated carbon ring(s) having aromatic characters, (e.g. 4n + 2 delocalized electrons) and comprising up to about 14 carbon atoms.
  • heteromatic refers to groups having one or more unsaturated rings containing carbon and one or more heteroatoms such as nitrogen, oxygen or sulphur having aromatic character (e.g. 4n + 2 delocalized electrons).
  • aryl refers to an aromatic ring structure made up of from 5 to 14 carbon atoms. Ring structures containing 5, 6, 7 and 8 carbon atoms would be single-ring aromatic groups, for example, phenyl. Ring structures containing 8, 9, 10, 1 1, 12, 13, or 14 would be polycyclic, for example naphthyl.
  • the aromatic ring can be substituted at one or more ring positions with such substituents as described above.
  • aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, for example, the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
  • ortho, meta and para apply to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively.
  • the names 1 ,2-dimethylbenzene and ortho-dimethylbenzene are synonymous.
  • cycloalkyl is intended to include saturated ring groups, having the specified number of carbon atoms. These may include fused or bridged polycyclic systems. Preferred cycloalkyls have from 3 to 10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, and 6 carbons in the ring structure.
  • C 3-6 cycloalkyl denotes such groups as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • cycloalkenyl is intended to include unsaturated ring groups, having the specified number of carbon atoms. These may include fused or bridged polycyclic systems. Preferred cycloalkenyls have from 3 to 10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, and 6 carbons in the ring structure.
  • C 3 -6 cycloalkenyl denotes such groups as cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl.
  • halo or halogen refers to fluoro, chloro, bromo, and iodo.
  • heteroaryl refers to a heteroaromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.
  • Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroaryl groups include without limitation, pyridyl (i.e., pyridinyl), pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl (i.e.
  • furanyl quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1 ,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like.
  • the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 4 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heteroaryl group has 1 heteroatom.
  • heterocyclyl or “heterocyclic” or “heterocycle” refers to a saturated, unsaturated or partially saturated, monocyclic, bicyclic or tricyclic ring (unless otherwise stated) containing 3 to 20 atoms of which 1, 2, 3, 4 or 5 ring atoms are chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group is optionally be replaced by a -C(O)-; and where unless stated to the contrary a ring nitrogen or sulphur atom is optionally oxidised to form the N-oxide or S-oxide(s) or a ring nitrogen is optionally quarternized; wherein a ring -NH is optionally substituted by acetyl, formyl, methyl or mesyl; and a ring is optionally substituted by one or more halo.
  • heterocyclyl group is bi- or tricyclic then at least one of the rings may optionally be a heteroaromatic or aromatic ring provided that at least one of the rings is non-heteroaromatic. If the said heterocyclyl group is monocyclic then it must not be aromatic.
  • heterocyclyls include, but are not limited to, piperidinyl, N- acetylpiperidinyl, N-methylpiperidinyl, N-formylpiperazinyl, N-mesylpiperazinyl, homopiperazinyl, piperazinyl, azetidinyl, oxetanyl, morpholinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolinyl, tetrahydropyranyl, dihydro-2H-pyranyl, tetrahydrofuranyl and 2,5-dioxoimidazolidinyl.
  • protecting group means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations.
  • protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones respectively.
  • the field of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 3 rd ed.; Wiley: New York, 1999).
  • pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric acid.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like diethyl ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.
  • tautomer means other structural isomers that exist in equilibrium resulting from the migration of a hydrogen atom. For example, keto-enol tautomerism where the resulting compound has the porperties of both a ketone and an unsturated alcohol.
  • stable compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • Compounds of the invention further include hydrates and solvates.
  • the present invention further includes isotopically-labelled compounds of the invention.
  • An “isotopically” or “radio-labelled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
  • Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I and 131 I.
  • the radionuclide that is incorporated in the instant radio-labelled compounds will depend on the specific application of that radio-labelled compound. For example, for in vitro receptor labelling and competition assays, compounds that incorporate 3 H, 14 C, 82 Br, 125 1 , 131 1, 35 S or will generally be most useful. For radio-imaging applications 11 C, 18 F, 125 I, 123 I, 124 I, 131 1, 75 Br, 76 Br or 77 Br will generally be most useful.
  • a "radio-labelled compound” is a compound that has incorporated at least one radionuclide.
  • the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1 , 35 S and 82 Br.
  • the anti-dementia treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional chemotherapy.
  • chemotherapy may include one or more of the following categories of agents: acetyl cholinesterase inhibitors, anti-inflammatory agents, cognitive and/or memory enhancing agents or atypical antipsychotic agents.
  • Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • Such combination products employ the compounds of this invention.
  • Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
  • the dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
  • An effective amount of a compound of the present invention for use in therapy of dementia is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of dementia, to slow the progression of dementia, or to reduce in patients with symptoms of dementia the risk of getting worse.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
  • Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.
  • composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier.
  • this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
  • Liquid form compositions include solutions, suspensions, and emulsions.
  • Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
  • Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical compositions can be in unit dosage form.
  • the composition is divided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • compositions may be formulated for any suitable route and means of administration.
  • Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
  • conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc, an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • the compounds of the invention may be derivatised in various ways.
  • derivatives of the compounds includes salts (e.g. pharmaceutically acceptable salts), any complexes (e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or coordination complexes with metal ions such as Mn 2+ and Zn 2+ ), free acids or bases, polymorphic forms of the compounds, solvates (e.g. hydrates), prodrugs or lipids, coupling partners and protecting groups.
  • prodrugs is meant for example any compound that is converted in vivo into a biologically active compound.
  • Salts of the compounds of the invention are preferably physiologically well tolerated and non toxic. Many examples of salts are known to those skilled in the art. All such salts are within the scope of this invention, and references to compounds include the salt forms of the compounds.
  • the compounds may contain an amine function, these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of the invention.
  • Compounds containing an amine function may also form N-oxides.
  • a reference herein to a compound that contains an amine function also includes the N-oxide.
  • N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle.
  • N-Oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4 th Edition, Wiley Interscience, pages. More particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with w-chloroperoxybenzoic acid (MCPBA), for example, in an inert solvent such as dichloromethane. Where the compounds contain chiral centres, all individual optical forms such as enantiomers, epimers and diastereoisomers, as well as racemic mixtures of the compounds are within the scope of the invention.
  • an oxidizing agent such as hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid)
  • MCPBA w-chloroperoxybenz
  • the quantity of the compound to be administered will vary for the patient being treated and will vary from about 100 ng/kg of body weight to 100 mg/kg of body weight per day and preferably will be from 10 pg/kg to 10 mg/kg per day.
  • dosages can be readily ascertained by those skilled in the art from this disclosure and the knowledge in the art.
  • the skilled artisan can readily determine the amount of compound and optional additives, vehicles, and/or carrier in compositions and to be administered in methods of the invention.
  • Beta secretase including BACE
  • Inhibitors of beta secretase have been shown to be useful in blocking formation or aggregation of A ⁇ peptide and therefore have beneficial effects in treatment of Alzheimer's Disease and other neurodegenerative diseases associated with elevated levels and/or deposition of A ⁇ peptide. Therefore, it is believed that the compounds of the present invention may be used for the treatment of Alzheimer disease and disease associated with dementia
  • compounds of the present invention and their salts are expected to be active against age-related diseases such as Alzheimer, as well as other A ⁇ related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy. It is expected that the compounds of the present invention would most likely be used as single agents but could also be used in combination with a broad range of cognition deficit enhancement agents.
  • the present invention also relates to processes for preparing the compound of formula I as a free base or a pharmaceutically acceptable salt thereof.
  • suitable protecting groups will be added to, and subsequently removed from the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis.
  • Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are for example described in "Protective Groups in Organic Synthesis", T. W. Greene, P.G.M Wutz, Wiley-Interscience, New York, 1999. It is understood that microwaves can be used for the heating of reaction mixtures.
  • reaction may be carried out by reaction with a suitable reagent such as 1,3-propanedithiol in the presence of an acid such as hydrochloric acid or/?-toluenesulfonic acid, or a Lewis acid such as boron trifluoride or titanium tetrachloride or ruthenium(III) chloride.
  • a suitable reagent such as 1,3-propanedithiol in the presence of an acid such as hydrochloric acid or/?-toluenesulfonic acid, or a Lewis acid such as boron trifluoride or titanium tetrachloride or ruthenium(III) chloride.
  • a suitable solvent such as dichloromethane, acetonitrile, chloroform, toluene or diethyl ether, at a temperature between -78 0 C and reflux.
  • reaction III may be carried out by treating III with a suitable base such as an alkyllithium reagent e.g. «-butyl lithium or /-butyl lithium or lithium diisopropylamide, before addition of IV.
  • a suitable base such as an alkyllithium reagent e.g. «-butyl lithium or /-butyl lithium or lithium diisopropylamide
  • the reaction may be carried out in a solvent such as tetrahydrofuran or diethyl ether, or a mixture of tetrahydrofuran or diethyl ether with hexane, at a temperature between -100 °C and 25 0 C.
  • the reaction may be aided by the presence of reagents such as hexamethylphosphoric triamide or N,N,N,N-tetramethyl-l ,2-ethanediamine.
  • reaction may be carried out by: a) reaction with a suitable reagent such as 1,1,1 -tris(acetyloxy)- 1 , 1 -dihydro- 1 ,2- benziodoxol-3(lH)-one, bis(trifluoroacetoxy)iodobenzene, N-bromosuccinimide, or a mixture of trifluoroacetic acid with either sodium nitrite or formaldehyde, in a suitable solvent such as dichloromethane, acetonitrile, chloroform, acetone or water or a mixture thereof, between -5 0 C to 40 0 C.
  • a suitable reagent such as 1,1,1 -tris(acetyloxy)- 1 , 1 -dihydro- 1 ,2- benziodoxol-3(lH)-one, bis(trifluoroacetoxy)iodobenzene, N-bromosuccinimide, or a mixture of triflu
  • a suitable reagent or reagent combination such as N- chlorosuccinimide and silver nitrate, N-iodosuccinimide, 3-chloroperoxybenzoic acid, ammonium cerium(IV) nitrate, thallium(III) nitrate, mercury(II) chloride and calcium carbonate, or mercery(II) acetate.
  • the reaction may be preformed in a suitable solvent such as water, acetonitrile, methanol, acetone or diethyl ether or mixtures thereof, between -50 0 C and 50 0 C , followed or preceded by, oxidation with a reagent such as 1,1,1- tris(acetyloxy)-l,l-dihydro-l,2-benziodoxol-3(lH)-one, manganese dioxide, hydrogen peroxide, potassium permanganate, pyridinium chlorochromate, copper sulfate or bromine, in a suitable solvent such as dichloromethane, water, acetonitrile, chloroform or dimethyl formamide, at between 0 0 C and reflux.
  • a suitable solvent such as water, acetonitrile, methanol, acetone or diethyl ether or mixtures thereof, between -50 0 C and 50 0 C , followed or preceded by, oxidation with a reagent such as
  • N-substituted thiourea such as N- methyl thiourea
  • a suitable base such as potassium hydroxide or sodium hydroxide
  • a suitable solvent such as water, dimethyl sulfoxide, ethanol or methanol or mixtures thereof, between 20 0 C and reflux.
  • alkylhydroperoxide such as ⁇ -butylhydroperoxide in a solvent such as ethanol, methanol or water, or a mixture thereof, at 0 0 C to 50 0 C.
  • a suitable arylhalide such as a compound of formula II and an appropriate alkyne such as ethynyltrimethylsilane in the presence of copper(I) iodide and a suitable palladium catalyst such as dichlorobis(benzonitrile)palladium(II), bis(triphenylphosphine)palladium(II) dichloride, palladium(II) chloride, palladium(O) tetrakistriphenylphosphine with or without a suitable ligand such as tri-/er/-butylphosphine or triphenylphosphine, and a suitable base, such as trietylamine, diisopropylamine or piperidine may be used.
  • the reaction may be performed in a solvent such as tetrahydrofuran or N,N-dimethylformamide, at temperatures between 20 °C and 100 0 C.
  • reaction may be performed using silver(I) nitrate or a suitable base such as potassium hydroxide, sodium hydroxide, lithium hydroxide or potassium carbonate, or using a fluoride ion- mediated desilylation using a suitable compound such as tetrabutylammonium fluoride or potassium fluoride.
  • a suitable base such as potassium hydroxide, sodium hydroxide, lithium hydroxide or potassium carbonate
  • fluoride ion- mediated desilylation using a suitable compound such as tetrabutylammonium fluoride or potassium fluoride.
  • the reaction may be performed in a solvent such as tetrahydrofuran, methanol, dichloromethane or water, or mixtures thereof, at temperatures between 0 0 C and 100 0 C.
  • reaction may be carried out by a reaction with: a) an alkyllithium such as butyllithium, or magnesium, and a suitable boron compound such as trimethyl borate or triisopropyl borate.
  • the reaction may be performed in a suitable solvent such as tetrahydrofuran, hexane or dichloromethane in a temperature range between -78 0 C and 20 0 C; or, b) a suitable boron species such as biscatecholatodiboron, bispinacolatodiboron or pinacolborane in the presence of a suitable palladium catalyst such as palladium(O) tetrakistriphenylphosphine, palladium diphenylphosphineferrocene dichloride or palladium acetate, with or without a suitable ligand such as 2-(dicyclohexylphosphino)biphenyl, and a suitable base, such as a tertiary
  • the reaction may be performed in a solvent such as dioxane, toluene, acetonitrile, water, ethanol or 1 ,2-dimethoxyethane, or mixtures thereof, at temperatures between 20 °C and 160 0 C.
  • a solvent such as dioxane, toluene, acetonitrile, water, ethanol or 1 ,2-dimethoxyethane, or mixtures thereof, at temperatures between 20 °C and 160 0 C.
  • reaction may be preformed using a suitable catalyst such as palladium-on-charcoal, Raney nickel or Wilkinson's catalyst, and hydrogen.
  • a suitable catalyst such as palladium-on-charcoal, Raney nickel or Wilkinson's catalyst, and hydrogen.
  • the reaction may be preformed in a suitable solvent such as ethyl acetate, methanol or ethanol, at temperatures between 20 °C and reflux.
  • reaction may be preformed using a metal hydride reducing agent such as diisopropylaluminium hydride or lithium aluminum hydride.
  • a metal hydride reducing agent such as diisopropylaluminium hydride or lithium aluminum hydride.
  • the reaction may be preformed in a suitable solvent such as dichlorometane, toluene or benzene, at a temperature between -78 0 C and 25 °C.
  • reaction may be carried out by a reaction with: a) an alkyllithium such as butyllithium, or magnesium, and a suitable boron compound such as trimethyl borate or triisopropyl borate.
  • the reaction may be performed in a suitable solvent such as tetrahydrofuran, hexane or dichloromethane in a temperature range between -78 0 C and 20 0 C; or, b) a suitable boron species such as biscatecholatodiboron, bispinacolatodiboron or pinacolborane in the presence of a suitable palladium catalyst such as palladium(O) tetrakistriphenylphosphine, palladium diphenylphosphineferrocene dichloride or palladium acetate, with or without a suitable ligand such as 2-(dicyclohexylphosphino)biphenyl, and a suitable base, such as a tertiary
  • the reaction may be performed in a solvent such as dioxane, toluene, acetonitrile, water, ethanol or 1 ,2-dimethoxyethane, or mixtures thereof, at temperatures between 20 0 C and 160 0 C.
  • a solvent such as dioxane, toluene, acetonitrile, water, ethanol or 1 ,2-dimethoxyethane, or mixtures thereof, at temperatures between 20 0 C and 160 0 C.
  • XXI (XXE) may be performed by reaction with a suitable reagent or mixture of reagents, such as sodium periodate and ruthenium dioxide, iodine and dimethyl sulfoxide, palladium chloride and dimethyl sulfoxide, oxone, hydrogen peroxide, oxygen, potassium permanganate, ruthenium tetroxide, or selenium dioxide, in a suitable solvent such as dimethyl sulfoxide, dichloromethane, acetonitrile, water, acetone, chloroform or carbon tetrachloride at a temperature between -78 0 C and 150 0 C.
  • a catalyst such as ruthenium(III) chloride or iron(III) chloride.
  • N-substituted guanidine such as N- methylguanidine, N-ethylguanidine, or N-propylguanidine
  • a suitable base such as potassium hydroxide, sodium hydroxide or sodium carbonate
  • a suitable solvent such as water, dimethyl sulfoxide, dioxane, ethanol or methanol or mixtures thereof, between 20 °C and reflux.
  • XXIII may be preformed by treating XXIII with: a) a formylation agent such as methylchloroformate, dichloromethoxymethane, dichlorobutoxymethane, formaldehyde, carbon monoxide, hydrogen cyanide or a combination of phosphorous oxychloride with N-methyl-N-phenyl formamide or N ⁇ V- dimethylformamide.
  • a formylation agent such as methylchloroformate, dichloromethoxymethane, dichlorobutoxymethane, formaldehyde, carbon monoxide, hydrogen cyanide or a combination of phosphorous oxychloride with N-methyl-N-phenyl formamide or N ⁇ V- dimethylformamide.
  • the reaction can be performed with or without a suitable reagent such as titanium tetrachloride, tin tetrachloride, aluminium trichloride and copper(I) chloride or combinations thereof.
  • the reaction may be preformed with or without a suitable solvent such as dichloromethane, benzene, or 1,1,2,2-tetrachloroethane at a temperature between - 20 0 C and reflux; or, b) a bromination agent such as bromine or N-bromosuccinimide in a solvent such as chloroform, N ⁇ /V-dimethylformamide, tetrahydrofurane or hexane or mixtures thereof at a temperature between -78 0 C and reflux , followed by treatment with a base such as butyl lithium and subsequently a reagent such as N ⁇ /V-dimethylf ⁇ rmamide or acetic acid in a solvent such as tetrahydrofurane and/or hexane at a temperature between -78 0 C and 0 0 C.
  • a suitable solvent such as dichloromethane, benzene, or 1,1,2,2-tetrachloroethane
  • the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, sulphuric acid, a sulphonic acid such as methane sulphonic acid or a carboxylic acid such as acetic or citric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or dichloromethane or mixtures thereof, the reaction may occur between -30 0 C to 50 0 C.
  • a hydrogen halide such as hydrogen chloride, sulphuric acid, a sulphonic acid such as methane sulphonic acid or a carboxylic acid such as acetic or citric acid
  • a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or dichloromethane or mixtures thereof
  • These processes comprise; (a) conversion of a compound of formula XXV to a compound of formula I, wherein halo represents halogen such as chlorine, bromine or iodine, R 7 is as defined for A above, R 21 is as defined for R 5 above, R 1 , R 2 , R 5 and A is as defined above, R 14 is an optionally substituted aryl or heteroaryl and R 15 may be a group outlined in Scheme II above,
  • reaction may be carried out by a de-halogen coupling with a suitable compound of formula XXVI.
  • the reaction may be carried out by coupling of a compound of formula XXV with an appropriate aryl boronic acid or boronic ester of formula XXVI.
  • the reaction may be carried out using a suitable palladium catalyst such as tetrakis(triphenylphosphine)palladium(0), palladium diphenylphosphineferrocene dichloride or palladium acetate, together with, or without, a suitable ligand such as t ⁇ -tert- butylphosphine or 2-(dicyclohexylphosphino)biphenyl, or using a nickel catalyst such as nickel on charcoal or 1 ,2-bis(diphenylphosphino)ethanenickel dichloride together with zinc and sodium triphenylphosphinetrimetasulfonate.
  • a suitable palladium catalyst such as tetrakis(triphenylphosphine)palladium(0), palladium diphenylphosphineferrocene dichloride or palladium acetate
  • a suitable ligand such as t ⁇ -tert- butylphosphine or 2-(dic
  • a suitable base such as cesium fluoride, an alkyl amine such as triethyl amine, or an alkali metal or alkaline earth metal carbonate or hydroxide such as potassium carbonate, sodium carbonate, cesium carbonate, or sodium hydroxide may be used in the reaction, which may be performed in a temperature range between 20 0 C and 160 0 C, in a suitable solvent such as toluene, tetrahydrofuran, dioxane, dimethoxyethane, water, ethanol or N,N-dimethylformamide, or mixtures thereof.
  • a suitable solvent such as toluene, tetrahydrofuran, dioxane, dimethoxyethane, water, ethanol or N,N-dimethylformamide, or mixtures thereof.
  • reaction may be preformed using a suitable catalyst such as palladium-on-charcoal, Raney nickel or Wilkinson's catalyst, and hydrogen.
  • a suitable catalyst such as palladium-on-charcoal, Raney nickel or Wilkinson's catalyst, and hydrogen.
  • the reaction may be preformed in a suitable solvent such as ethyl acetate, methanol or ethanol, at temperatures between 20 0 C and reflux.
  • Microwave heating was performed in a Creator, Initiator or Smith Synthesizer Single- mode microwave cavity producing continuous irradiation at 2450 MHz.
  • 1H NMR spectra were recorded in the indicated deuterated solvent at 400 MHz.
  • the 400MHz spectra were obtained unless stated otherwise, using a Bruker av400 NMR spectrometer equipped with a 3 mm flow injection SEI ⁇ /D- 13 C probe head with Z- gradients, using a BEST 215 liquid handler for sample injection, or using a Bruker DPX400 NMR spectrometer equipped with a 4-nucleus probehead with Z-gradients. Chemical shifts are given in ppm down- and upfield from TMS. Resonance multiplicities are denoted s, d, t, q, m and br for singlet, doublet, triplet, quartet, multiplet, and broad respectively.
  • LC-MS analyses were recorded on a Waters LCMS equipped with a Waters X-Terra MS, C8-column, (3.5 ⁇ m, 100 mm x 3.0 mm i.d.).
  • the mobile phase system consisted of A: 10 mM ammonium acetate in water/acetonitrile (95:5) and B: acetonitrile.
  • a linear gradient was applied running from 0% to 100% B in 4-5 minutes with a flow rate of 1.0 mL/min.
  • the mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or negative ion mode.
  • the capillary voltage was 3 kV and the mass spectrometer was typically scanned between m/z 100-700.
  • LC-MS analyses were performed on a LC-MS consisting of a Waters sample manager 2111 C, a Waters 1525 ⁇ binary pump, a Waters 1500 column oven, a Waters ZQ single quadrupole mass spectrometer, a Waters PDA2996 diode array detector and a Sedex 85 ELS detector.
  • the mass spectrometer was configured with an atmospheric pressure chemical ionisation (APCI) ion source which was further equipped with atmospheric pressure photo ionisation (APPI) device.
  • APCI atmospheric pressure chemical ionisation
  • APPI atmospheric pressure photo ionisation
  • the mass spectrometer scanned in the positive mode, switching between APCI and APPI mode.
  • the mass range was set to m/z 120-800 using a scan time of 0.3 s.
  • the APPI repeller and the APCI corona were set to 0.86 kV and 0.80 ⁇ A, respectively.
  • the desolvation temperature (300 0 C), desolvation gas (400 L/Hr) and cone gas (5 L/Hr) were constant for both APCI and APPI mode. Separation was performed using a Gemini column Cl 8, 3.0 mm x 50 mm, 3 ⁇ m, (Phenomenex) and run at a flow rate of 1 ml/min. A linear gradient was used starting at 100 % A (A: 10 mM ammonium acetate in 5% methanol) and ending at 100% B (methanol). The column oven temperature was set to 40 0 C.
  • Mass spectra were run using an automated system with atmospheric pressure chemical (APCI or CI) or electrospray (+ESI) ionization. Generally, only spectra where parent masses are observed are reported. The lowest mass major ion is reported for molecules where isotope splitting results in multiple mass spectral peaks (for example when chlorine is present).
  • HPLC assays were performed using an Agilent HPl 100 Series system equipped with a Waters X-Terra MS, C 8 column (3.0 x 100 mm, 3.5 ⁇ m). The column temperature was set to 40 0 C and the flow rate to 1.0 mL/min. The Diode Array Detector was scanned from 200-300 nm. A linear gradient was applied, run from 0% to 100% B in 4 min. Mobile phase A: 10 mM ammonium acetate in water/acetonitrile (95:5), mobile phase B: acetonitrile.
  • Preparative HPLC was performed on a Waters Auto purification HPLC-UV system with a diode array detector using a Waters XTerra MS C 8 column (19x300 mm, 7 ⁇ m) and a linear gradient of mobile phase B was applied.
  • Mobile phase A 0.1 M ammonium acetate in water/acetonitrile (95:5) and mobile phase B: acetonitrile.
  • Flow rate 20 mL/min.
  • Thin layer chromatography (TLC) was performed on Merch TLC-plates (Silica gel 60 F 254 ) and spots were UV visualized. Flash chromatography was performed using Merck Silica gel 60 (0.040-0.063 mm), or employing a Combi Flash ® CompanionTM system using RediSep normal-phase flash columns.
  • the reaction mixture was stirred at room temperature for 2 h.
  • the crude mixture was diluted with ethyl acetate, washed with 1 M aqueous hydrochloric acid, water and saturated aqueous sodium hydrogen carbonate.
  • the organic layer was dried over magnesium sulfate, filtered and concentrated.
  • 6-[(3-Bromo-4-fluorophenyl)ethynyl]chromane (5.O g, 15.1 mmol) and palladium(II)dichloride (0.27 g, 1.5 mmol) were heated in dimethyl sulfoxide (70 mL) at 150 0 C under an atmosphere of argon for 3 h. After cooling to room temperature water was added and the mixture was extracted with dichloromethane. The combined organic layers were washed with 1 M hydrochloric acid, water and saturated aqueous sodium carbonate solution, dried over magnesium sulfate, filtered and concentrated.
  • reaction mixture was diluted with water and the p ⁇ was adjusted to 4-5 by addition of aqueous hydrochloric acid (1 M).
  • the mixture was extracted by dichloromethane. The combined0 organic layers were washed with water, dried over magnesium sulfate, filtrated and the solvent was evaporated.
  • tert-Butyl hydroperoxide (24.0 mL, 154.5 mmol, 70 wt% aq) was added to a solution of 5- (3-bromo-4-fluorophenyl)-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-2- thioxoimidazolidin-4-one (4.5 g, 10.3 mmol) in a 1 :3 mixture of methanol/ ammonium hydroxide (60:20 mL). The reaction was stirred at room temperature for 4 h, concentrated and the residue was dissolved in chloroform. The organic phase was washed with water, dried over magnesium sulfate, filtrated and the solvent was evaporated.
  • Dess-Martin periodinane (14.0 g, 32.8 mmol) was added to a solution of (3-bromo-4- fluorophenyl)[2-(2,3-dihydro-l-benzofuran-5-yl)-l,3-dithian-2-yl]methanol (5.9 g, 13.1 mmol) and ter/-butanol (4.2 mL, 45.8 mmol) in dichloromethane (250 mL) under an atmosphere of argon and the reaction mixture was stirred over night. A solution of sodium thiosulfate (12.5 g) in saturated aqueous sodium hydrogencarbonate (200 mL) was added and the resulting mixture was stirred for 30 min.
  • reaction mixture was diluted with water and the pH was adjusted to 4-5 by addition of aqueous hydrochloric acid (1 M).
  • the mixture was extracted with dichloromethane.
  • the combined organic layers were washed with water, dried over magnesium sulfate, filtrated and evaporated.
  • ter/-Butyl hydroperoxide (23.2 mL, 150.0 mmol, 70 wt% aq) was added to a solution of 5- (3-bromo-4-fluorophenyl)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-2- thioxoimidazolidin-4-one (4.2 g, 10.0 mmol) in a mixture of methanol (60 mL) and ammonium hydroxide (20 mL). The reaction was stirred for 4 h at room temperature, concentrated and the residue was dissolved in chloroform. The organic phase was washed with water and dried over magnesium sulfate, filtered and the solvent was evaporated.
  • Diisobutylaluminium hydride (18.5 mL, 18.5 mmol, 1 M in toluene) was added to a solution of 2,2,3,3-tetrafluoro-6-cyanobenzodioxene (3.60 g, 15.4 mmol) in dichloromethane (50 mL) at -78 0 C. The resulting mixture was stirred at -78 0 C for 1 h and then at room temperature over night. A solution of Rochelle's salt (1 M) was added and after 20 min the mixture was extracted with chloroform.
  • Example 56 The title compound was synthesized as described for Example 56 in 92% yield, starting from 6-iodochromane (described in: Togo H. et.al. J. Chem. Soc. Perkin Trans. 1, 1997, 787-793) and (3-bromophenyl)acetylene.
  • a suspension of ruthenium(III)chloride (25 mg, 0.12 mmol) was added dropwise to a solution of 5-formyl-2,3-dihydro-l-benzofuran-7-carbonitrile (2.13 g, 12.3 mmol, described in PCT Int. Appl. WO 2006/014580 Al) and 1,3-propandithiol (1.24 mL, 12.3 mmol) in acetonitrile (20 mL).
  • the reaction mixture was stirred at room temperature for 16 h under an atmosphere of argon. Water (20 mL) was added to the reaction mixture, the formed suspension was cooled to 0 0 C and stirred for 3 h.
  • Dess-Martin periodinane (1.3 g, 3.08 mmol) was added to a solution of 5- ⁇ 2-[(3-bromo-4- fluorophenyl)(hydroxy)methyl]-l,3-dithian-2-yl ⁇ -2,3-dihydro-l-benzofuran-7-carbonitrile (0.64 g, 1.37 mmol) and tert-butanol (0.36 g, 4.80 mmol) in dichloromethane (10 mL) under an atmosphere of argon and the reaction mixture was stirred overnight. Aqueous sodium thiosulfate (2.5 g) was added and the resulting mixture was stirred for 30 min.
  • Table 1 Representative examples synthesized as described for 5-[2-Amino-4-(4-fluoro-3- pyridin-3-ylphenyl)- 1 -methyl-5-oxo-4,5-dihydro- lH-imidazol-4-yl]-2,3-dihydro- 1 - benzofuran-7-carbonitrile. All the reactions were analyzed using LC-MS and those which showed a low level of conversion was irradiated in a microwave for another hour at 130 0C.
  • Phosphorous oxy chloride 37 mL, 404 mmol was added dropwise over 1 h to a stirred solution of a mixture of 3,3-dimethyl-2,3-dihydro-l-benzofuran and 2,2-dimethyl-2,3- dihydro-1-benzofuran (30 g, 202 mmol) in N,N-dimethylformamide (31 mL, 404 mmol).
  • the mixture was heated at 100 0 C for 1 h and a hot solution of sodium acetate (40 g) in water (40 mL) was carefully added dropwise.
  • the reaction mixture was allowed to cool down to room temperature, extracted with diethyl ether and the combined organic phases were evaporated.
  • a slurry of ruthenium chloride (61 mg, 0,30 mmol) in acetonitrile (25 mL) was added dropwise to a stirred solution of propane- 1,3-dithiol (3.2 g, 29.5 mmol) and a mixture of 3,3-dimethyl-2,3-dihydro-l-benzofuran-5-carbaldehyde and 2,2-dimethyl-2,3-dihydro-l- benzofuran-5-carbaldehyde (5.2 g, 29.5 mmol, 26:74) in acetonitrile (100 mL). The reaction was stirred for 3 h and water (300 mL) was added.
  • the resulting mixture was filtered through a short plug of celite and the filtrate was evaporated in vacuo.
  • the product was purified by column chromatography, using 0 to 10 % ⁇ 1 :9 ammonium hydroxide/methanol ⁇ in dichloromethane as the eluent, followed by preparative ⁇ PLC on a Chiralpak AD column (50 x 300 mm), using isopropanol/heptane (20/80) with 0.1 % trifluoroacetic acid as the eluent at a flow rate of 120 mL/min and after 20 min the eluent was changed to 100% isopropanol.
  • the enzyme used in the IGEN Cleavage-, Fluorescent-, TR-FRET- and BiaCore assays is described as follows: The soluble part of the human ⁇ -Secretase (AA 1 - AA 460) was cloned into the ASP2- FclO-1-IRES-GFP-neoK mammalian expression vector. The gene was fused to the Fc domain of IgGl (affinity tag) and stably cloned into HEK 293 cells. Purified sB ACE-Fc is stored in Tris buffer, pH 9.2 and has a purity of 95%.
  • the enzyme was diluted to 43 ⁇ g/ml in 40 mM MES pH 5.0.
  • the IGEN substrate was diluted to 12 ⁇ M in 40 mM MES pH 5.0.
  • Compounds were diluted to the desired concentration in dimethyl sulfoxide (final dimethyl sulfoxide concentration in assay is 5%).
  • the assay was performed in a 96 well PCR plate from Greiner (#650201). Compound in dimethyl sulfoxide (3 ⁇ L) and enzyme (27 ⁇ L) were added to the plate, and pre- incubated for 10 min. The reaction was started with substrate (30 ⁇ L). The final dilution of enzyme was 20 ⁇ g/ml and the final concentration of substrate was 6 ⁇ M.
  • reaction was stopped by removing 10 ⁇ L of the reaction mix and diluting it 1:25 in 0.2 M Trizma-HCl, pH 8.0.
  • the product was quantified by adding 50 ⁇ L of a 1 :5000 dilution of the neoepitope antibody to 50 ⁇ L of the 1:25 dilution of the reaction mix (all antibodies and the streptavidin coated beads were diluted in PBS containing 0.5% BSA and 0.5% Tween20).
  • the enzyme was diluted to 52 ⁇ g/ml in 40 mM MES pH 5.0.
  • the substrate (Dabcyl-Edans) was diluted to 30 ⁇ M in 40 mM MES pH 5.0.
  • Compounds were diluted to the desired concentration in dimethyl sulfoxide (final dimethyl sulfoxide concentration in assay is 5%).
  • the assay is done in a Corning 384 well round bottom, low volume, non-binding surface plate (Corning #3676). Enzyme (9 ⁇ L) together with 1 ⁇ L of compound in dimethyl sulfoxide were added to the plate and pre-incubated for 10 min.
  • Enzyme was diluted to 6 ⁇ g/mL and the substrate (Europium)CEVNLDAEFK(Qsy7) to 200 nM in reaction buffer (NaAcetate, chaps, triton x-100, EDTA pH 4.5). Compounds were diluted to the desired concentration in dimethyl sulfoxide (final dimethyl sulfoxide concentration in assay is 5%). The assay was done in a Costar 384 well round bottom, low volume, non-binding surface plate (Corning #3676). Enzyme (9 ⁇ L) and 1 ⁇ L of compound in dimethyl sulfoxide was added to the plate, mixed and pre-incubated for 10 min.
  • Substrate (10 ⁇ L) was added and the reaction proceeded in the dark for 15 min at RT.
  • the reaction was stopped with the addition of 7 ⁇ L NaAcetate, pH 9.
  • the fluorescence of the product was measured on a Victor II plate reader with an excitation wavelength of 340 nm and an emission wavelength of 615 nm.
  • the final concentration of the enzyme was 2.7 ⁇ g/ml and the final concentration of the substrate was 100 nM (Km of 290 nM).
  • the dimethyl sulfoxide control defined the 100% activity level and 0% activity was defined by exclusion of the enzyme (using reaction buffer instead).
  • BACE was assayed on a Biacore3000 instrument by attaching either a peptidic transition state isostere (TSI) or a scrambled version of the peptidic TSI to the surface of a Biacore CM5 sensor chip.
  • TSI transition state isostere
  • the surface of a CM5 sensor chip has 4 distinct channels that can be used to couple the peptides.
  • the scrambled peptide KFES-statine-ETIAEVENV was coupled to channel 1 and the TSI inhibitor KTEEISEVN-statine-VAEF was coupled to channel 2 of the same chip.
  • the two peptides were dissolved at 0.2 mg/mL in 20 mM sodium acetate pH 4.5, and then the solutions were centrifuged at 14K rpm to remove any particulates.
  • Carboxyl groups on the dextran layer were activated by injecting a one to one mixture of 0.5 M N-ethyl-N' (3-dimethylaminopropyl)-carbodiimide and 0.5 M N- hydroxysuccinimide at 5 ⁇ L/min for 7 min. Then the stock solution of the control peptide was injected in channel 1 for 7 min at 5 ⁇ L/min., and then the remaining activated carboxyl groups were blocked by injecting 1 M ethanolamine for 7 min at 5 ⁇ L/min.
  • the BACE Biacore assay was done by diluting BACE to 0.5 ⁇ M in sodium acetate buffer at pH 4.5 (running buffer minus dimethyl sulfoxide). The diluted BACE was mixed with dimethyl sulfoxide or compound diluted in dimethyl sulfoxide at a final concentration of 5% dimethyl sulfoxide. The BACE/inhibitor mixture was incubated for 30 minutes at RT before being injected over channel 1 and 2 of the CM5 Biacore chip at a rate of 20 ⁇ L/min. As BACE bound to the chip the signal was measured in response units (RU). BACE binding to the TSI inhibitor on channel 2 gave a certain signal.
  • RU response units
  • the presence of a BACE inhibitor reduced the signal by binding to BACE and inhibiting the interaction with the peptidic TSI on the chip. Any binding to channel 1 was non-specific and was subtracted from the channel 2 responses.
  • the dimethyl sulfoxide control was defined as 100% and the effect of the compound was reported as percent inhibition of the dimethyl sulfoxide control.
  • the pcDNA3.1 plasmid encoding the cDNA of human full-length APP695 was stably transfected into HEK-293 cells using the Lipofectamine transfection reagent according to manufacture's protocol (Invitrogen). Colonies were selected with 0.1-0.5 mg/mL of zeocin. Limited dilution cloning was performed to generate homogeneous cell lines. Clones were characterized by levels of APP expression and A ⁇ secreted in the conditioned media using an ELISA assay developed in-house. Cell culture for HEK293-APP695
  • HEK293 cells stably expressing human wild-type APP were grown at 37 0 C, 5% CO 2 in DMEM containing 4500 g/L glucose, GlutaMAX and sodium pyruvate supplemented with 10% FBS, 1% non-essential amino acids and 0.1 mg/mL of the selection antibiotic zeocin.
  • HEK293-APP695 cells were harvested at 80-90% confluence and seeded at a concentration of 0.2x10 6 cells/mL, 100 mL cell suspension/well, onto a black clear bottom 96-well poly-D-lysine coated plate. After over night incubation at 37 0 C, 5% CO 2 , the cell medium was replaced with cell culture medium with penicillin and streptomycin (100 U/mL, 100 ⁇ g/mL, respectively) containing test compounds in a final dimethyl sulfoxide concentration of 1%. Cells were exposed to the test compounds for 24 h at 37 0 C, 5% CO 2 .
  • test plate 100 ⁇ L cell medium was transferred to a round bottom polypropylene 96-well plate (assay plate). The cell plate was saved for the ATP assay, as described below.
  • 50 ⁇ L of primary detection solution containing 0.5 ⁇ g/mL of the rabbit anti-A ⁇ 40 antibody and 0.5 ⁇ g/mL of the biotinylated monoclonal mouse 6E10 antibody in DPBS with 0.5 %BSA and 0.5% Tween-20 was added per well and incubated over night at 4 0 C.
  • SH-SY5Y cells were grown 37 0 C with 5% CO 2 in DMEM/F-12 1 :1 containing GlutaMAX supplemented with 1 mM HEPES, 10% FBS and 1% non-essential amino acids.
  • SH-SY5Y cells were harvested at 80-90% confluence and seeded at a concentration of 1.5x10 6 cells/mL, 100 mL cell suspension/well, onto a black clear flat bottom 96-well tissue culture plate. After 7 hours of incubation at 37 °C, 5% CO 2 , the cell medium was replaced with 90 ⁇ l cell culture medium with penicillin and streptomycin (100 U/mL, 100 ⁇ g/mL, respectively) containing test compounds in a final dimethyl sulfoxide concentration of 1%. Cells were exposed to the test compounds for 18 h at 37 0 C, 5% CO 2 .
  • sAPP ⁇ microplates from Meso Scale Discovery were used and the assay was performed according to the manufacture's protocol. Briefly, 25 ⁇ L cell medium was transferred to a previously blocked MSD sAPP ⁇ microplate. The cell plate was saved for the ATP assay, as described below. The sAPP ⁇ was captured during shaking at RT for 1 hour, by antibodies spotted in the wells of the microplate. After multiple washes, SULFO-TAG labeled detection antibody was added (25 ⁇ L/well, final concentration InM) to the assay plate and the plate was incubated with shaking at RT for 1 hour. Following multiple washes, 150 ⁇ l/well of Read Buffer T was added to the plate. After 10 minutes at RT the plate was read in the SECTORTM Imager for electro-chemiluminescence.
  • MSD Meso Scale Discovery
  • the plate was used to analyze cytotoxicity using the ViaLightTM Plus cell proliferation/cytotoxicity kit from Cambrex BioScience that measures total cellular ATP.
  • the assay was performed according to the manufacture's protocol. Briefly, 50 ⁇ L cell lysis reagent was added per well. The plates were incubated at RT for 10 min. Two min after addition of 100 ⁇ L reconstituted ViaLightTM Plus ATP reagent, the luminescence was measured in a Wallac Victor 2 1420 multilabel counter.
  • the hERG-expressing Chinese hamster ovary Kl (CHO) cells described by (Persson, Carlsson, Duker, & Jacobson, 2005) were grown to semi-confluence at 37 0 C in a humidified environment (5% CO 2 ) in F- 12 Ham medium containing L-glutamine, 10% foetal calf serum (FCS) and 0.6 mg/ml hygromycin (all Sigma- Aldrich). Prior to use, the monolayer was washed using a pre-warmed (37°C) 3 ml aliquot of Versene 1 :5,000 (Invitrogen).
  • CHO-Kv 1.5 cells which were used to adjust the voltage offset on Ion WorksTM HT, were maintained and prepared for use in the same way.
  • a ⁇ -test Ion WorksTM HT from Essen Instrument was used. There is no capability to warm solutions in this device hence it was operated at room temperature (-21 °C), as follows.
  • the reservoir in the "Buffer” position was loaded with 4 ml of PBS and that in the "Cells” position with the CHO-hERG cell suspension described above.
  • Each compound plate was laid-out in 12 columns to enable ten, 8- point concentration-effect curves to be constructed; the.remaining two columns on the plate were taken up with vehicle (final concentration 0.33% DMSO), to define the assay baseline, and a supra-maximal blocking concentration of cisapride (final concentration 10 ⁇ M) to define the 100% inhibition level.
  • the fluidics-head (F-Head) of IonWorksTM HT then added 3.5 ⁇ l of PBS to each well of the PatchPlateTM and its underside was perfused with "internal" solution that had the following composition (in mM): K-Gluconate 100, KCl 40, MgCl 2 3.2, EGTA 3 and HEPES 5 (all Sigma- Aldrich; pH 7.25-7.30 using 10 M KOH).
  • the electronics-head (E-head) then moved round the PatchPlateTM performing a hole test (i.e. applying a voltage pulse to determine whether the hole in each well was open).
  • the F-head then dispensed 3.5 ⁇ l of the cell suspension described above into each well of the PatchPlateTM and the cells were given 200 seconds to reach and seal to the hole in each well. Following this, the E-head moved round the PatchPlateTM to determine the seal resistance obtained in each well. Next, the solution on the underside of the PatchPlateTM was changed to "access" solution that had the following composition (in mM): KCl 140, EGTA 1, MgCl 2 1 and HEPES 20 (pH 7.25-7.30 using 10 M KOH) plus 100 ⁇ g/ml of amphotericin B (Sigma- Aldrich).
  • the E-head moved round the PatchPlateTM 48 wells at a time to obtain pre-compound hERG current measurements.
  • the F-head then added 3.5 ⁇ l of solution from each well of the compound plate to 4 wells on the PatchPlateTM (the final DMSO concentration was 0.33% in every well). This was achieved by moving from the most dilute to the most concentrated well of the compound plate to minimise the impact of any compound carry-over.
  • the E-head then moved around all 384-wells of the PatchPlateTM to obtain post-compound hERG current measurements. In this way, non-cumulative concentration-effect curves could be produced where, providing the acceptance criteria were achieved in a sufficient percentage of wells (see below), the effect of each concentration of test compound was based on recording from between 1 and 4 cells.
  • the pre- and post-compound hERG current was evoked by a single voltage pulse consisting of a 20 s period holding at -70 mV, a 160 ms step to -60 mV (to obtain an estimate of leak), a 100 ms step back to -70 mV, a 1 s step to + 40 mV, a 2 s step to -30 mV and finally a 500 ms step to -7OmV.
  • a single voltage pulse consisting of a 20 s period holding at -70 mV, a 160 ms step to -60 mV (to obtain an estimate of leak), a 100 ms step back to -70 mV, a 1 s step to + 40 mV, a 2 s step to -30 mV and finally a 500 ms step to -7OmV.
  • Currents were leak- subtracted based on the estimate of current evoked during the +1OmV step at the start of the
  • any voltage offsets in IonWorksTM HT were adjusted in one of two ways.
  • a depolarising voltage ramp was applied to CHO- Kv 1.5 cells and the voltage noted at which there was an inflection point in the current trace (i.e. the point at which channel activation was seen with a ramp protocol).
  • the voltage at which this occurred had previously been determined using the same voltage command in conventional electrophysiology and found to be -15 mV (data not shown); thus an offset potential could be entered into the IonWorksTM HT software using this value as a reference point.
  • any offset was adjusted by determining the hERG tail current reversal potential in IonWorksTM HT, comparing it with that found in conventional electrophysiology (-82 mV) and then making the necessary offset adjustment in the IonWorksTM HT software.
  • the current signal was sampled at 2.5 kHz.
  • Pre- and post-scan hERG current magnitude was measured automatically from the leak subtracted traces by the IonWorksTM HT software by taking a 40 ms average of the current during the initial holding period at -70 mV (baseline current) and subtracting this from the peak of the tail current response.
  • the acceptance criteria for the currents evoked in each well were: pre-scan seal resistance >60 M ⁇ , pre-scan hERG tail current amplitude >150 pA; post-scan seal resistance >60 M ⁇ .
  • the degree of inhibition of the hERG current was assessed by dividing the post-scan hERG current by the respective pre-scan hERG current for each well.
  • Typical IC50 values for the compounds of the present invention are in the range of about 1 to about 2,000 nM.
  • Biological data on final compounds are given below in Table 2. TABLE 2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel compounds having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

Description

Novel 2-amino-5, 5-diaryl-imidazol-4-ones
The present invention relates to novel compounds and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Background of the invention Several groups have identified and isolated aspartate proteinases that have β-secretase activity (Hussain et al., 1999; Lin et. al, 2000; Yan et. al, 1999; Sinha et. al., 1999 and Vassar et. al., 1999). β-secretase is also known in the literature as Asp2 (Yan et. al, 1999), Beta site APP Cleaving Enzyme (BACE) (Vassar et. al., 1999) or memapsin-2 (Lin et al., 2000). BACE was identified using a number of experimental approaches such as EST database analysis (Hussain et al. 1999); expression cloning (Vassar et al. 1999); identification of human homologs from public databases of predicted C. elegans proteins (Yan et al. 1999) and finally utilizing an inhibitor to purify the protein from human brain (Sinha et al. 1999). Thus, five groups employing three different experimental approaches led to the identification of the same enzyme, making a strong case that BACE is a β- secretase. Mention is also made of the patent literature: WO96/40885, EP871720, U.S. Patents Nos. 5,942,400 and 5,744,346, EP855444, US 6,319,689, WO99/64587, WO99/31236, EP1037977, WOOO/17369, WO01/23533, WO0047618, WO00/58479, WO00/69262, WO01/00663, WO01/00665, US 6,313,268.
BACE was found to be a pepsin-like aspartic proteinase, the mature enzyme consisting of the N-terminal catalytic domain, a transmembrane domain, and a small cytoplasmic domain. BACE has an optimum activity at pH 4.0-5.0 (Vassar et al, 1999) and is inhibited weakly by standard pepsin inhibitors such as pepstatin. It has been shown that the catalytic domain minus the transmembrane and cytoplasmic domain has activity against substrate peptides (Lin et al, 2000). BACE is a membrane bound type 1 protein that is synthesized as a partially active proenzyme, and is abundantly expressed in brain tissue. It is thought to represent the major β-secretase activity, and is considered to be the rate-limiting step in the production of amyloid-β-protein (Aβ). It is thus of special interest in the pathology of Alzheimer's disease, and in the development of drugs as a treatment for Alzheimer's disease.
Aβ or amyloid-β-protein is the major constituent of the brain plaques which are characteristic of Alzheimer's disease (De Strooper et al, 1999). Aβ is a 39-42 residue peptide formed by the specific cleavage of a class 1 transmembrane protein called APP, or amyloid precursor protein. Cleavage of APP by BACE generates the extracellular soluble APPβ fragment and the membrane bound CTFβ (C99) fragment that is subsequently cleaved by γ-secretase to generate Aβ peptide.
Alzheimer's disease (AD) is estimated to afflict more than 20 million people worldwide and is believed to be the most common form of dementia. Alzheimer's disease is a progressive dementia in which massive deposits of aggregated protein breakdown products - amyloid plaques and neurofibrillary tangles accumulate in the brain. The amyloid plaques are thought to be responsible for the mental decline seen in Alzheimer's patients.
The likelihood of developing Alzheimer's disease increases with age, and as the aging population of the developed world increases, this disease becomes a greater and greater problem. In addition to this, there is a familial link to Alzheimer's disease and consequently any individuals possessing the double mutation of APP known as the Swedish mutation (in which the mutated APP forms a considerably improved substrate for BACE) have a much higher risk of developing AD, and also of developing the disease at an early age {see also US 6,245,964 and US 5,877,399 pertaining to transgenic rodents comprising APP-Swedish). Consequently, there is also a strong need for developing a compound that can be used in a prophylactic fashion for these individuals.
The gene encoding APP is found on chromosome 21 , which is also the chromosome found as an extra copy in Down's syndrome. Down's syndrome patients tend to develop Alzheimer's disease at an early age, with almost all those over 40 years of age showing Alzheimer's-type pathology (Oyama et al., 1994). This is thought to be due to the extra copy of the APP gene found in these patients, which leads to overexpression of APP and therefore to increased levels of Aβ causing the high prevalence of Alzheimer's disease seen in this population. Thus, inhibitors of BACE could be useful in reducing Alzheimer's-type pathology in Down's syndrome patients.
Drugs that reduce or block BACE activity should therefore reduce Aβ levels and levels of fragments of Aβ in the brain, or elsewhere where Aβ or fragments thereof deposit, and thus slow the formation of amyloid plaques and the progression of AD or other maladies involving deposition of Aβ or fragments thereof (Yankner, 1996; De Strooper and Konig, 1999). BACE is therefore an important candidate for the development of drugs as a treatment and/or prophylaxis of Aβ-related pathologies such as Downs syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
It would therefore be useful to inhibit the deposition of Aβ and portions thereof by inhibiting BACE through inhibitors such as the compounds provided herein.
The therapeutic potential of inhibiting the deposition of Aβ has motivated many groups to isolate and characterize secretase enzymes and to identify their potential inhibitors (see, e.g., WO01/23533 A2, EP0855444, WO00/17369, WO00/58479, WO00/47618, WO00/77030, WO01/00665, WO01/00663, WO01/29563, WO02/25276, US5,942,400, US6,245,884, US6,221,667, US6,21 1,235, WO02/02505, WO02/02506, WO02/02512, WO02/02518, WO02/02520, WO02/14264, WO05/05831 1, WO05/097767, WO06/041404, WO06/041405, WO06/0065204, WO06/0065277, US2006287294, WO06/138265, US20050282826, US20050282825, US20060281729, WO06/138217, WO06/138230, WO06/138264, WO06/138265, WO06/138266, WO06/099379, WO06/076284, US20070004786, US20070004730, WO07/011833, WO07/011810, US20070099875, US20070099898, WO07/058601, WO07/058581, WO07/058580, WO07/058583, WO07/058582, WO07/058602, WO07/073284, WO07/049532, WO07/038271, WO07/016012, WO07/005366, WO07/005404, WO06/0009653).
The compounds of the present invention show beneficial properties compared to the potential inhibitors known in the art, e.g. improved hERG selectivity.
Disclosure of the invention
The present invention further provides potent BACE inhibitors of formula I:
Figure imgf000005_0001
wherein
R1 is selected from phenyl, heteroaryl,
Figure imgf000005_0002
optionally substituted with a C3. δcycloalkyl, C2-6alkenyl optionally substituted with a Cs^cycloalkyl, heterocyclyl, C3. δcycloalkyl, Cs-βcycloalkenyl, halo and cyano, said phenyl or heteroaryl optionally substituted with one or more R3;
R2 is independently selected from hydrogen, cyano or halo; A is phenyl or heteroaryl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is optionally substituted with one or more R4;
R3 is independently selected from halo, cyano, Ci^alkyl, trifluoromethyl, methoxy, trifluoromethoxy and acetyl;
R4 is independently selected from halo, cyano, methyl and methoxy; provided that said bicyclic ring of A, is substituted with at least one R4 in the heterocyclyl part, when it is a 1,3-benzodioxole or 2,3-dihydro-l,4-benzodioxine ring system;
R5 is Ci_6alkyl optionally substituted with halogen, cyano, NH2, OH, CO2H, OCi-βalkyl,
SO2H, C(O)Ci-6alkyl, C(O)OC i.6alkyl, C(O)NH2, C(O)NHC 1-6alkyl, C(O)N(C 1-6alkyl)2,
S02d.6alkyl, SO2NHC1-6alkyl, SO2N(C i.6alkyl)2, NH^alkyl), N(Ci-6alkyl)2, NHC(O)C1-6alkyl, NC(O)(C1.6alkyl)2, aryl, Oaryl, C(O)aryl, C(O)Oaryl, C(O)NHaryl,
C(O)N(aryl)2, S02aryl, SO2NHaryl, SO2N(aryl)2, NH(aryl), N(aryl)2, NC(O)aryl,
NC(O)(aryl)2, heteroaryl, Oheteroaryl, C(O)heteroaryl, C(O)Oheteroaryl,
C(O)NHheteroaryl, C(O)N(heteroaryl)2, SO2heteroaryl, SO2NHheteroaryl,
SO2N(heteroaryl)2, NH(heteroaryl), N(heteroaryl)2, NC(O)heteroaryl, NC(O)(heteroaryl)2, Cs-βheterocyclyl, OCs-βheterocyclyl, C(O)C5-6heterocyclyl, C(O)OCs-6heterocyclyl,
C(O)NHC5-6heterocyclyl, C(O)N(C5.6heterocyclyl)2, SO2C5-6heterocyclyl, SO2NHC5. βheterocyclyl, SO2N(C5.6heterocyclyl)2, NH(C5-6heterocyclyl), N(C5-6heterocyclyl)2,
NC(O)C5-6heterocyclyl or NC(O)(C5.6heterocyclyl)2; n is O, 1 or 2; provided that the following compounds are excluded:
2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-5-(3'-methoxybiphenyl-3-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one;
2-Arnino-5-(2,3-dihydro-l-benzofuran-5-yl)-5-(2',5'-dimethoxybiphenyl-3-yl)-3-methyl-
3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-5-(2'-fluoro-5'-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-5-(2'-fluoro-3'-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
3'-[2-Amino-4-(2,3-dihydro-l-benzofuran-5-yl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol-
4-yl]-6-fluorobiphenyl-3-carbonitrile; 2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyI-5-[3'-(trifluoromethoxy)biphenyl-3- yl]-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(3'-chlorobiphenyl-3-yl)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-raethyl-3,5- dihydro-4H-imidazol-4-one;
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(3'-methoxybiphenyl-3-yl)-3-raethyl-3,5- dihydro-4H-imidazol-4-one;
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(2',5'-diraethoxybiphenyl-3-yl)-3-methyl-
3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(2'-fluoro-5'-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(2'-fluoro-3'-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
3'-[2-Amino-4-(3,4-dihydro-2H-chromen-6-yl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol-
4-yl]-4-fluorobiphenyl-3-carbonitrile;
3'-[2-Amino-4-(3,4-dihydro-2H-chroraen-6-yl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol- 4-yl]-6-fluorobiphenyl-3-carbonitrile;
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-5-[3'-(trifluoromethoxy)biphenyl-3- yl]-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(3'-chlorobiphenyl-3-yl)-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 5-(l-Acetyl-l,2,3,4-tetrahydroquinolin-6-yl)-2-amino-5-(2',5'-dimethoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
3'-[4-(l-Acetyl-l,2)3,4-tetrahydroquinolin-6-yl)-2-amino-l-methyl-5-oxo-4,5-dihydro-lH- imidazol-4-yl]biphenyl-3-carbonitrile;
3 '-[4-( 1 -Acetyl- 1 ,2,3 ,4-tetrahydroquinolin-6-y l)-2-amino- 1 -methyl-5 -oxo-4,5 -dihydro- 1 H- imidazol-4-yl]-4-fluorobiphenyl-3-carbonitrile;
5-(l-Acetyl-l,2,3,4-tetrahydroquinolin-6-yl)-2-amino-5-(2'-fluoro-5'-methoxybiphenyl-3- yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one; 5-(l -Acetyl- l,2,3,4-tetrahydroquinolin-6-yl)-2-amino-5-(2'-fluoro-3'-methoxybiphenyl-3- yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
5-(l-Acetyl-l,2,3,4-tetrahydroquinolin-6-yl)-2-amino-5-[3-(3-furyl)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-(3,4-dihydro-lH-isochromen-7-yl)-5-(2'-fluoro-5'-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
3 '-[2- Amino-4-(3 ,4-dihydro- lH-isochromen-7-yl)- 1 -methyl-5 -oxo-4,5-dihydro- 1 H- imidazol-4-yl]-6-fluorobiphenyl-3-carbonitrile; and
2-Amino-5-(3 ,4-dihydro- lH-isochromen-7-yl)-5-[3-(3-furyl)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.
The present invention further provides potent BACE inhibitors of formula I: .
Figure imgf000008_0001
wherein
R1 is selected from phenyl, heteroaryl, Ci_6alkyl optionally substituted with a C3- βcycloalkyl, C2-6alkenyl optionally substituted with a C3_6cycloalkyl, heterocyclyl, C3. δCycloalkyl, Cs-όCycloalkenyl, halo and cyano, said phenyl or heteroaryl optionally substituted with one or more R3;
R2 is independently selected from hydrogen, cyano or halo;
A is phenyl or heteroaryl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is optionally substituted with one or more R ; R3 is independently selected from halo, cyano,
Figure imgf000009_0001
trifluoromethyl, methoxy and trifluoromethoxy;
R4 is independently selected from halo, cyano and methyl; provided that said bicyclic ring of A, is substituted with at least one R4 in the heterocyclyl part, when it is a 1,3-benzodioxole or 2,3-dihydro-l,4-benzodioxine ring system;
R5 is Ci-βalkyl optionally substituted with halogen, cyano, NH2, OH, CO2H, OCi-βalkyl, SO2H, C(O)C1-6alkyl, C(O)OC 1-6alkyl, C(O)NH2, C(O)NHC 1-6alkyl, C(O)N(C i-6alkyl)2, SO2Ci.6alkyl, SO2NHCi-6alkyl, SO2N(C ,.6alkyl)2, NH(C1-6alkyl), N(Ci.6alkyl)2,
NHC(O)Ci.6alkyl, NC(O)(C 1-6alkyl)2, aryl, Oaryl, C(O)aryl, C(O)Oaryl, C(0)NHaryl, C(O)N(aryl)2, S02aryl, SO2NHaryl, SO2N(aryl)2, NH(aryl), N(aryl)2, NC(0)aryl, NC(O)(aryl)2, heteroaryl, Oheteroaryl, C(O)heteroaryl, C(O)Oheteroaryl, C(O)NHheteroaryl, C(O)N(heteroaryl)2, SO2heteroaryl, SO2NHheteroaryl, SO2N(heteroaryl)2, NH(heteroaryl), N(heteroaryl)2, NC(O)heteroaryl, NC(O)(heteroaryl)2, C5_6heterocyclyl, OCs.βheterocyclyl, C(O)C5-6heterocyclyl, C(O)OC5.6heterocyclyl, C(O)NHC5-6heterocyclyl, C(O)N(C5-6heterocyclyl)2, SO2C5.6heterocyclyl, SO2NHC5. δheterocyclyl, SO2N(C5^heterocyclyl)2, NH(Cs-6heterocyclyl), N(C5_6heterocyclyl)2, NC(O)C5.6heterocyclyl or NC(O)(C5-6heterocyclyl)2; n is O, 1 or 2; as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.
The present invention further provides potent BACE inhibitors of formula I:
Figure imgf000009_0002
wherein s R1 is selected from phenyl, heteroaryl, Ci-6alkyl optionally substituted with a C3. έcycloalkyl, C2.6alkenyl optionally substituted with a C3_6cycloalkyl, heterocyclyl, C3. βcycloalkyl, Cs^cycloalkenyl, halo and cyano, said phenyl or heteroaryl optionally substituted with one or more R3;
R2 is independently selected from hydrogen, cyano or halo;
A is phenyl or heteroaryl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is optionally substituted with one or more R4;
R3 is independently selected from halo, cyano,
Figure imgf000010_0001
trifluoromethyl, methoxy and trifluoromethoxy;
R4 is independently selected from halo, cyano and methyl; provided that said bicyclic ring of A, is substituted with at least one R4 in the heterocyclyl part, when it is a 1,3-benzodioxole or 2,3-dihydro-l,4-benzodioxine ring system;
R5 is Ci-βalkyl optionally substituted with halogen, cyano, NH2, OH, CO2H, OCi^alkyl, SO2H, C(O)Ci.6alkyl, C(O)OC1-6alkyl, C(O)NH2,
Figure imgf000010_0002
C(O)N(C 1-6alkyl)2, SO2C1-6alkyl, SO2NHC 1-6alkyl, SO2N(C i.6alky I)2, NH(Ci-6alkyl), N(Ci-6alkyl)2, NHC(O)C1-6alkyl, NC(O)(C i-6alkyl)2, aryl, Oaryl, C(O)aryl, C(O)Oaryl, C(O)NHaryl, C(O)N(aryl)2, S02aryl, SO2NHaryl, SO2N(aryl)2, NH(aryl), N(aryl)2, NC(O)aryl, NC(O)(aryl)2, heteroaryl, Oheteroaryl, C(O)heteroaryl, C(O)Oheteroaryl, C(O)NHheteroaryl, C(O)N(heteroaryl)2, SO2heteroaryl, SO2NHheteroaryl,
SO2N(heteroaryl)2, NH(heteroaryl), N(heteroaryl)2, NC(O)heteroaryl, NC(O)(heteroaryl)2, C5-6heterocyclyl, OCs-βheterocyclyl, C(O)C5-6heterocyclyl, C(O)OC5_6heterocycIyl, C(O)NHC5-6heterocyclyl, C(O)N(C5-6heterocyclyl)2, SO2C5-6heterocyclyl, SO2NHC5- δheterocyclyl, SO2N(C5.6heterocyclyl)2, NH(C5-6heterocyclyl), N(C5.6heterocyclyl)2, NC(O)C5.6heterocyclyl or NC(O)(C5.6heterocyclyl)2; n is O, 1 or 2; provided that the following compounds are excluded: 2-Amino-5-(2,3-dihydro-l-benzofliran-5-yl)-5-(3'-methoxybiphenyl-3-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one;
2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-5-(2',5'-dimethoxybiphenyl-3-yl)-3-methyl-
3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-5-(2'-fluoro-5'-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
2-Aniino-5-(2,3-dihydro-l-benzofuran-5-yl)-5-(2'-fluoro-3'-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazoI-4-one;
3'-[2-Amino-4-(2,3-dLhydro-l-benzofuran-5-yl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol- 4-yl]-6-fluorobiphenyl-3-carbonitrile;
2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-5-[3'-(trifluoromethoxy)biphenyl-3- yl]-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(3'-chlorobiphenyl-3-yl)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one; 2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(3'-methoxybiphenyl-3-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one;
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(2',5'-dimethoxybiphenyl-3-yl)-3-methyl-
3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(2'-fluoro-5'-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(2'-fluoro-3'-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
3'-[2-Amino-4-(3,4-dihydro-2H-chromen-6-yl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol-
4-yl]-4-fluorobiphenyl-3-carbonitrile; 3'-[2-Amino-4-(3,4-dihydro-2H-chromen-6-yl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol-
4-yl]-6-fluorobiphenyl-3-carbonitrile;
2-Arαino-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-5-[3'-(trifluoromethoxy)biphenyl-3- yl]-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(3'-chlorobiphenyl-3-yl)-5-(3,4-dihydro-2H-chroraen-6-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one;
5-(l-Acetyl-l,2,3,4-tetrahydroquinolin-6-yl)-2-amino-5-(2',5'-dimethoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one; 3'-[4-(l-Acetyl-l,2,3,4-tetrahydroquinolin-6-yl)-2-amino-l-methyl-5-oxo-4,5-dihydro-lH- imidazol-4-yl]biphenyl-3-carbonitrile;
3 '- [4-( 1 -Acetyl- 1 ,2,3 ,4-tetrahydroquinolin-6-y l)-2-amino- 1 -methyl-5 -oxo-4,5-dihydro- 1 H- imidazol-4-yl]-4-fluorobiphenyl-3-carbonitrile; 5-(l-Acetyl-l,2,3,4-tetrahydroquinolin-6-yl)-2-amino-5-(2'-fluoro-5'-raethoxybiphenyl-3- yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
5-(l-Acetyl-l,2,3,4-tetrahydroquinolin-6-yl)-2-amino-5-(2'-fluoro-3'-methoxybiphenyl-3- yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
5-(l-Acetyl-l,2,3,4-tetrahydroquinolin-6-yl)-2-amino-5-[3-(3-furyl)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one;
2-Amino-5-(3,4-dihydro-lH-isochromen-7-yl)-5-(2l-fluoro-5t-methoxybiphenyl-3-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
3 '-[2- Amino-4-(3 ,4-dihydro- 1 H-isochromen-7-yl)- 1 -methyl-5-oxo-4,5-dihydro- 1 H- imidazol-4-yl]-6-fluorobiphenyl-3-carbonitrile; or 2-Amino-5-(3,4-dihydro-lH-isochromen-7-yl)-5-[3-(3-furyl)phenyl]-3-methyl-3,5- dihydro-4H-imidazol-4-one; as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.
In one aspect of the invention there is provided compounds of formula I:
Figure imgf000012_0001
wherein
R1 is heteroaryl, optionally substituted with one or more R3;
R2 is independently selected from halo and cyano; A is phenyl or heteroaryl, said phenyl or heteroaryl being optionallyfused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is optionally substituted with one or more R4;
R3 is independently selected from halo, trifluoromethyl and methoxy;
R4 is independently selected from halo, methyl, cyano and methoxy; provided that said bicyclic ring of A, is substituted with at least one R4 in the heterocyclyl part, when it is a 1,3-benzodioxole or 2,3-dihydro-l,4-benzodioxine ring system;
R5 is Ci-βalkyl;
n is 0, 1 or 2; provided that when n= 0, R1 is substituted with at least one R3.
In one embodiment of this aspect, R1 is pyridine.
In another embodiment of this aspect, R1 is pyridine substituted with one or two R3 and said R3 is independently selected from halo, trifluoromethyl and methoxy.
In another embodiment of this aspect, A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system.
In another embodiment of this aspect, A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is substituted with from one to four R4.
In another embodiment of this aspect, said bicyclic ring system is substituted with one R4, said R4 being halo.
In another embodiment of this aspect, said bicyclic ring system is substituted with two R4, said R4 being halo. In another embodiment of this aspect, said bicyclic ring system is substituted with four R4, said R4 being halo.
In another embodiment of this aspect, said bicyclic ring system is substituted with two R4, said R4 being methyl.
In another embodiment of this aspect, said bicyclic ring system is substituted with one R4, said R4 being cyano.
In another embodiment of this aspect, A is selected from:
Figure imgf000014_0001
Figure imgf000014_0002
In another embodiment of this aspect, A is selected from:
Figure imgf000015_0001
In another embodiment of this aspect, R is pyrimidine.
In another embodiment of this aspect, R1 is pyrimidine, and A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system.
In another embodiment of this aspect, R1 is pyrimidine, and A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is substituted with from one to four R4.
In another embodiment of this aspect, R1 is pyrimidine, and A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system, said bicyclic ring system is substituted with one R4, said R4 being halo.
In another embodiment of this aspect, R1 is pyrimidine, and A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system, said bicyclic ring system is substituted with two R4, said R4 being halo.
In another embodiment of this aspect, R1 is pyrimidine, and A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system, said bicyclic ring system is substituted with four R4, said R4 being halo.
In another embodiment of this aspect, R1 is pyrimidine, and A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system, said bicyclic ring system is substituted with two R4, said R4 being methyl. In another embodiment of this aspect, A is selected from:
Figure imgf000016_0001
In another embodiment of this aspect, R1 is thiazole.
In another embodiment of this aspect, there is provided a compound, selected from:
2-Arnino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,2-dimethyl-3,4- dihydro-2H-chromen-6-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride;
2-Amino-5-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-5-(4-fluoro-3-pyridin-3- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride;
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(3,4-diJiydro-2H- chromen-6-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Arnino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,3-dihydro-l- benzofuran-5-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Ajnώo-5-(2,3-dmydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-3- methy 1-3 , 5 -dihydro-4H-imidazol-4-one ;
2-Ammo-5-(7-chloro-2,3-dmydxo-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidin-5- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)-5-[3-(5-chloro-2-fluoropyridin-3- yl)-4-fluorophenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyridin-3-ylphenyl)-3- methyl-3,5-dihydro-4Η-imidazol-4-one; 2-Amino-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidin-5- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,2-dimethyl-2,3- dihydro-l-benzofuran-5-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyridin-3- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-3-methyl-5-(2,2,3,3-tetrafluoro-2,3-dihydro- l,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one;
2-Axnino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-3-methyl-5-(2,2,3,3- tetrafluoro-2,3-dihydro- 1 ,4-benzodioxin-6-yl)-3 ,5-dihydro-4H-imidazol-4-one; 2-Amino-5-(4-fluoro-3-pyridin-3-ylphenyl)-3-methyl-5-(2,2,3,3-tetrafluoro-2,3-dihydro- l,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-5-(4-fluoro-3-pyriinidin-5-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,2-difluoro-l,3- benzodioxol-5-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-5-(4-fluoro-3-pyridin-3-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-[3-(4-chloropyridin-3-yl)phenyl]-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-
3,5-dihydro-4H-imidazol-4-one hydrochloride; 2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-3-raethyl-5-{3-[4-(trifluoromethyl)pyridin-3- yljphenyl} -3, 5-dihydro-4//-imidazol-4-one hydrochloride;
2-Amino-5-[3-(4-chloropyridin-3-yl)phenyl]-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-
3, 5-dihydro-4H-imidazol-4-one hydrochloride;
5-[2-Amino-4-(4-fluoro-3-pyridin-3-ylphenyl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol- 4-yl]-2,3-dihydro-l-benzofuran-7-carbonitrile 1.0 acetate;
5-{2-Amino-4-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-l-methyl-5-oxo-4,5- dihydro-lH-imidazol-4-yl}-2,3-dihydro-l-benzofuran-7-carbonitrile 0.5 acetate; 5-{2-Amino-4-[4-fluoro-3-(2-fluoropyridin-3-yl)phenyl]-l-methyl-5-oxo-4,5-dihydro-lH- imidazol-4-yl} -2,3-dihydro- 1 -benzofuran-7-carbonitrile;
2-Araino-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-5-[3-(l,3-thiazol-5-yl)phenyl]-3,5- dihydro-4H-imidazol-4-one hydrochloride; 5 2-Ajnino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidin-5- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyridin-3- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-[4-fluoro-3-(5- i o methoxypyridin-3 -yl)pheny 1] -3 -me thy 1-3 , 5 -dihydro-4H-imidazol-4-one ;
2-Amino-5-(2,2-dimethyl-2,3-dihydro-l-benzoflιran-5-yl)-5-[4-fluoro-3-(2-fluoropyridin-
3-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride;
2-Ajnino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-[4-fluoro-3-(2-fluoropyridin-
3 -yl)phenyl]-3 -methyl-3 ,5-dihydro-4H-imidazol-4-one; is 2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(3,3-dimethyl-2,3- dihydro-l-benzofuran-5-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one; and
2- Amino-5-(3 ,4-dihydro-2H-chromen-6-yl)-3 -methy 1-5 - { 3 -[4-(trifluoromethyl)pyridin-3 - yljphenyl} -3,5-dihydro-4H-imidazol-4-one acetate; as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof. 2o
In another aspect of the invention there is provided a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound of formula I, in association with pharmaceutically acceptable excipients, carriers or diluents.
25 In another aspect of the invention there is provided a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament.
In another aspect of the invention there is provided use of a compound of formula I as a medicament for treating or preventing an Aβ-related pathology.
30 In another aspect of the invention there is provided use of a compound of formula I as a medicament for treating or preventing an Aβ-related pathology, wherein said Aβ-related pathology is Downs syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
In another aspect of the invention there is provided use of a compound of formula I as a medicament for treating or preventing Alzheimer Disease.
In another aspect of the invention there is provided use of a compound of formula I in the manufacture of a medicament for treating or preventing an Aβ-related pathology.
In another aspect of the invention there is provided use of a compound of formula I in the manufacture of a medicament for treating or preventing an Aβ-related pathology, wherein said Aβ-related pathology is Downs syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
In another aspect of the invention there is provided use of a compound of formula I in the manufacture of a medicament for treating or preventing Alzheimer's Disease.
In another aspect of the invention there is provided a method of inhibiting activity of BACE comprising contacting said BACE with a compound of formula I. In another aspect of the invention there is provided a method of treating or preventing an Aβ-related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of formula I.
In another aspect of the invention there is provided a method of treating or preventing an Aβ-related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of formula I, wherein said Aβ-related pathology is Downs syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Ln another aspect of the invention there is provided a method of treating or preventing Alzheimer's Disease, comprising administering to said patient a therapeutically effective amount of a compound of formula I.
In another aspect of the invention there is provided a method of treating or preventing an Aβ-related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of formula I, wherein said Aβ-related pathology is Downs syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, wherein said mammal is a human. In another aspect of the invention there is provided a method of treating or preventing an Aβ-related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of formula I and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor.
In another aspect of the invention there is provided a method of treating or preventing an Aβ-related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of formula I and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, wherein said Aβ- related pathology is Downs syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
Ln another aspect of the invention there is provided a method of treating or preventing an Aβ-related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of formula I and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, wherein said Aβ- related pathology is Alzheimer Disease.
In another aspect of the invention there is provided a method of treating or preventing an Aβ-related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of formula I and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, wherein said Aβ- related pathology is Downs syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, wherein said mammal is a human.
Some compounds of formula I may have stereogenic centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical isomers, enantiomers, diastereoisomers, atropisomers and geometric isomers.
The present invention relates to the use of compounds of formula I as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I.
It is to be understood that the present invention relates to any and all tautomeric forms of the compounds of formula I.
Compounds of the invention can be used as medicaments. In some embodiments, the present invention provides compounds of formula I, or pharmaceutically acceptable salts, tautomers or in v/vo-hydrolysable precursors thereof, for use as medicaments. In some embodiments, the present invention provides compounds described here in for use as medicaments for treating or preventing an Aβ-related pathology. In some further embodiments, the Aβ-related pathology is Downs syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
In some embodiments, the present invention provides use of compounds of formula I or pharmaceutically acceptable salts, tautomers or in vrvo-hydrolysable precursors thereof, in the manufacture of a medicament for the treatment or prophylaxis of Aβ-related pathologies. In some further embodiments, the Aβ-related pathologies include such as Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
In some embodiments, the present invention provides a method of inhibiting activity of BACE comprising contacting the BACE with a compound of the present invention. BACE is thought to represent the major β-secretase activity, and is considered to be the rate- limiting step in the production of amyloid-β-protein (Aβ). Thus, inhibiting BACE through inhibitors such as the compounds provided herein would be useful to inhibit the deposition of Aβ and portions thereof. Because the deposition of Aβ and portions thereof is linked to diseases such Alzheimer Disease, BACE is an important candidate for the development of drugs as a treatment and/or prophylaxis of Aβ-related pathologies such as Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
In some embodiments, the present invention provides a method for the treatment of Aβ- related pathologies such as Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, presenile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, comprising administering to a mammal (including human) a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt, tautomer or in vz'vø-hydrolysable precursor thereof.
In some embodiments, the present invention provides a method for the prophylaxis of Aβ- related pathologies such as Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre- senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration comprising administering to a mammal (including human) a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, tautomer or in v/vo-hydrolysable precursors.
In some embodiments, the present invention provides a method of treating or preventing Aβ-related pathologies such as Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre- senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration by administering to a mammal (including human) a compound of formula I or a pharmaceutically acceptable salt, tautomer or in v/vo-hydrolysable precursors and a cognitive and/or memory enhancing agent.
In some embodiments, the present invention provides a method of treating or preventing Aβ-related pathologies such as Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, presenile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration by administering to a mammal (including human) a compound of formula I or a pharmaceutically acceptable salt, tautomer or in vzvø-hydrolysable precursors thereof wherein constituent members are provided herein, and a choline esterase inhibitor or anti-inflammatory agent.
In some embodiments, the present invention provides a method of treating or preventingAβ-related pathologies such as Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, or any other disease, disorder, or condition described herein, by administering to a mammal (including human) a compound of the present inventionand an atypical antipsychotic agent. Atypical antipsychotic agents includes, but not limited to, Olanzapine (marketed as Zyprexa), Aripiprazole (marketed as Ability), Risperidone (marketed as Risperdal), Quetiapine (marketed as Seroquel), Clozapine (marketed as Clozaril), Ziprasidone (marketed as Geodon) and Olanzapine/Fluoxetine (marketed as Symbyax).
In some embodiments, the mammal or human being treated with a compound of the invention has been diagnosed with a particular disease or disorder, such as those described herein. In these cases, the mammal or human being treated is in need of such treatment. Diagnosis, however, need not be previously performed.
The present invention also includes pharmaceutical compositions, which contain, as the active ingredient, one or more of the compounds of the invention herein together with at least one pharmaceutically acceptable carrier, diluent or excipent.
The definitions set forth in this application are intended to clarify terms used throughout this application. The term "herein" means the entire application.
A variety of compounds in the present invention may exist in particular geometric or stereoisomeric forms. The present invention takes into account all such compounds, including cis- and trans isomers, R- and S- enantiomers, diastereomers, (D)-isomers, (L)- isomers, the racemic mixtures thereof, and other mixtures thereof, as being covered within the scope of this invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention. The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms, by synthesis from optically active starting materials, or synthesis using optically active reagents. When required, separation of the racemic material can be achieved by methods known in the art. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents, positions of substituents and/or variables are permissible only if such combinations result in stable compounds.
As used in this application, the term "optionally substituted," means that substitution is optional and therefore it is possible for the designated atom or moiety to be unsubstituted. In the event a substitution is desired then such substitution means that any number of hydrogens on the designated atom or moiety is replaced with a selection from the indicated group, provided that the normal valency of the designated atom or moiety is not exceeded, and that the substitution results in a stable compound. For example when a substituent is methyl (i.e., CH3), then 3 hydrogens on the carbon atom can be replaced. Examples of such substituents include, but are not limited to: halogen, cyano, NH2, OH, CO2H, OCi^alkyl, CH2OH, SO2H, Ci.6alkyl, OC^alkyl, C(O)C i.6alkyl, C(O)OCi.6alkyl, C(O)NH2, C(O)NHCi.6alkyl, C(O)N(C 1-6alkyl)2, SO2C,.6alkyl, SO2NHC 1-6alkyl, SO2N(Ci.6alkyl)2, NH(Ci-6alkyl), N(Ci-6alkyl)2, NHC(O)d.6alkyl, NC(O)(C i.6alkyl)2, aryl, Oaryl, C(O)aryl, C(O)Oaryl, C(O)NHaryl, C(O)N(aryl)2, S02aryl, SO2NHaryl, SO2N(aryl)2, NH(aryl), N(aryl)2, NC(O) aryl, NC(O)(aryl)2, Cs-βheterocyclyl, OCs-δheterocyclyl, C(O)C5. βheterocyclyl, C(O)OC5-6heterocyclyl, C(O)NHC5.6heterocyclyl, C(O)N(C5-6heterocyclyl)2, SO2C5-6heterocyclyl, SO2NHC5.<>heterocyclyl, SO2N(C5.6heterocyclyl)2) NH(C5. eheterocyclyl), N(C5-6heterocyclyl)2, NC(O)C5-6heterocyclyl, NC(O)(C5-6heterocyclyl)2. As used herein, "alkyl", used alone or as a suffix or prefix, is intended to include both branched and straight chain saturated aliphatic hydrocarbon groups having from 1 to 12 carbon atoms or if a specified number of carbon atoms is provided then that specific number would be intended. For example "Co-6 alkyl" denotes alkyl having 0, 1, 2, 3, 4, 5 or 6 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl. In the case where a subscript is the integer 0 (zero) the group to which the subscript refers to indicates that the group may be absent, i.e. there is a direct bond between the groups.
As used herein, "alkenyl" used alone or as a suffix or prefix is intended to include both branched and straight-chain alkene or olefin containing aliphatic hydrocarbon groups having from 2 to 12 carbon atoms or if a specified number of carbon atoms is provided then that specific number would be intended. For example "C2.6alkenyl" denotes alkenyl having 2, 3, 4, 5 or 6 carbon atoms. Examples of alkenyl include, but are not limited to, vinyl, allyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-enyl, 3-methylbut- 1-enyl, 1-pentenyl, 3-pentenyl and 4-hexenyl.
As used herein, "aromatic" refers to hydrocarbonyl groups having one or more unsaturated carbon ring(s) having aromatic characters, (e.g. 4n + 2 delocalized electrons) and comprising up to about 14 carbon atoms. In addition "heteroaromatic" refers to groups having one or more unsaturated rings containing carbon and one or more heteroatoms such as nitrogen, oxygen or sulphur having aromatic character (e.g. 4n + 2 delocalized electrons).
As used herein, the term "aryl" refers to an aromatic ring structure made up of from 5 to 14 carbon atoms. Ring structures containing 5, 6, 7 and 8 carbon atoms would be single-ring aromatic groups, for example, phenyl. Ring structures containing 8, 9, 10, 1 1, 12, 13, or 14 would be polycyclic, for example naphthyl. The aromatic ring can be substituted at one or more ring positions with such substituents as described above. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, for example, the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls. The terms ortho, meta and para apply to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively. For example, the names 1 ,2-dimethylbenzene and ortho-dimethylbenzene are synonymous.
As used herein, the term "cycloalkyl" is intended to include saturated ring groups, having the specified number of carbon atoms. These may include fused or bridged polycyclic systems. Preferred cycloalkyls have from 3 to 10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, and 6 carbons in the ring structure. For example, "C3-6 cycloalkyl" denotes such groups as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
As used herein, the term "cycloalkenyl" is intended to include unsaturated ring groups, having the specified number of carbon atoms. These may include fused or bridged polycyclic systems. Preferred cycloalkenyls have from 3 to 10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, and 6 carbons in the ring structure. For example, "C3-6 cycloalkenyl" denotes such groups as cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl.
As used herein, "halo" or "halogen" refers to fluoro, chloro, bromo, and iodo.
As used herein, "heteroaryl" refers to a heteroaromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroaryl groups include without limitation, pyridyl (i.e., pyridinyl), pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl (i.e. furanyl), quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1 ,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like. In some embodiments, the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 4 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heteroaryl group has 1 heteroatom.
As used herein, the term "heterocyclyl" or "heterocyclic" or "heterocycle" refers to a saturated, unsaturated or partially saturated, monocyclic, bicyclic or tricyclic ring (unless otherwise stated) containing 3 to 20 atoms of which 1, 2, 3, 4 or 5 ring atoms are chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group is optionally be replaced by a -C(O)-; and where unless stated to the contrary a ring nitrogen or sulphur atom is optionally oxidised to form the N-oxide or S-oxide(s) or a ring nitrogen is optionally quarternized; wherein a ring -NH is optionally substituted by acetyl, formyl, methyl or mesyl; and a ring is optionally substituted by one or more halo. It is understood that when the total number of S and O atoms in the heterocyclyl exceeds 1, then these heteroatoms are not adjacent to one another. If the said heterocyclyl group is bi- or tricyclic then at least one of the rings may optionally be a heteroaromatic or aromatic ring provided that at least one of the rings is non-heteroaromatic. If the said heterocyclyl group is monocyclic then it must not be aromatic. Examples of heterocyclyls include, but are not limited to, piperidinyl, N- acetylpiperidinyl, N-methylpiperidinyl, N-formylpiperazinyl, N-mesylpiperazinyl, homopiperazinyl, piperazinyl, azetidinyl, oxetanyl, morpholinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolinyl, tetrahydropyranyl, dihydro-2H-pyranyl, tetrahydrofuranyl and 2,5-dioxoimidazolidinyl.
As used herein, the phrase "protecting group" means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones respectively. The field of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 3rd ed.; Wiley: New York, 1999). As used herein, "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric acid.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like diethyl ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.
As used herein, "tautomer" means other structural isomers that exist in equilibrium resulting from the migration of a hydrogen atom. For example, keto-enol tautomerism where the resulting compound has the porperties of both a ketone and an unsturated alcohol.
As used herein "stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. Compounds of the invention further include hydrates and solvates.
The present invention further includes isotopically-labelled compounds of the invention. An "isotopically" or "radio-labelled" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2H (also written as D for deuterium), 3H (also written as T for tritium), 11C, 13C, 14C, 13N, 15N, 150, 170, 180, 18F, 35S, 36Cl, 82Br, 75Br, 76Br, 77Br, 123I, 124I, 125I and 131I. The radionuclide that is incorporated in the instant radio-labelled compounds will depend on the specific application of that radio-labelled compound. For example, for in vitro receptor labelling and competition assays, compounds that incorporate 3H, 14C, 82Br, 1251 , 1311, 35S or will generally be most useful. For radio-imaging applications 11C, 18F, 125I, 123I, 124I, 1311, 75Br, 76Br or 77Br will generally be most useful.
It is understood that a "radio-labelled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3H, 14C, 1251 , 35S and 82Br.
The anti-dementia treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional chemotherapy. Such chemotherapy may include one or more of the following categories of agents: acetyl cholinesterase inhibitors, anti-inflammatory agents, cognitive and/or memory enhancing agents or atypical antipsychotic agents.
Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention.
Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
An effective amount of a compound of the present invention for use in therapy of dementia is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of dementia, to slow the progression of dementia, or to reduce in patients with symptoms of dementia the risk of getting worse.
For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify. Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
In some embodiments, the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
In addition to the compounds of the present invention, the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.
The term composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier. For example this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
Liquid form compositions include solutions, suspensions, and emulsions. Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art. The pharmaceutical compositions can be in unit dosage form. In such form, the composition is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
Compositions may be formulated for any suitable route and means of administration. Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc, an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975.
The compounds of the invention may be derivatised in various ways. As used herein "derivatives" of the compounds includes salts (e.g. pharmaceutically acceptable salts), any complexes (e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or coordination complexes with metal ions such as Mn2+ and Zn2+), free acids or bases, polymorphic forms of the compounds, solvates (e.g. hydrates), prodrugs or lipids, coupling partners and protecting groups. By "prodrugs" is meant for example any compound that is converted in vivo into a biologically active compound.
Salts of the compounds of the invention are preferably physiologically well tolerated and non toxic. Many examples of salts are known to those skilled in the art. All such salts are within the scope of this invention, and references to compounds include the salt forms of the compounds.
Where the compounds contain an amine function, these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of the invention.
Compounds containing an amine function may also form N-oxides. A reference herein to a compound that contains an amine function also includes the N-oxide.
Where a compound contains several amine functions, one or more than one nitrogen atom may be oxidised to form an N-oxide. Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle.
N-Oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages. More particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with w-chloroperoxybenzoic acid (MCPBA), for example, in an inert solvent such as dichloromethane. Where the compounds contain chiral centres, all individual optical forms such as enantiomers, epimers and diastereoisomers, as well as racemic mixtures of the compounds are within the scope of the invention.
Compounds may exist in a number of different geometric isomeric, and tautomeric forms and references to compounds include all such forms. For the avoidance of doubt, where a compound can exist in one of several geometric isomeric or tautomeric forms and only one is specifically described or shown, all others are nevertheless embraced by the scope of this invention.
The quantity of the compound to be administered will vary for the patient being treated and will vary from about 100 ng/kg of body weight to 100 mg/kg of body weight per day and preferably will be from 10 pg/kg to 10 mg/kg per day. For instance, dosages can be readily ascertained by those skilled in the art from this disclosure and the knowledge in the art. Thus, the skilled artisan can readily determine the amount of compound and optional additives, vehicles, and/or carrier in compositions and to be administered in methods of the invention.
Compounds of the present invention have been shown to inhibit beta secretase (including BACE) activity in vitro. Inhibitors of beta secretase have been shown to be useful in blocking formation or aggregation of Aβ peptide and therefore have beneficial effects in treatment of Alzheimer's Disease and other neurodegenerative diseases associated with elevated levels and/or deposition of Aβ peptide. Therefore, it is believed that the compounds of the present invention may be used for the treatment of Alzheimer disease and disease associated with dementia Hence, compounds of the present invention and their salts are expected to be active against age-related diseases such as Alzheimer, as well as other Aβ related pathologies such as Downs syndrome and β-amyloid angiopathy. It is expected that the compounds of the present invention would most likely be used as single agents but could also be used in combination with a broad range of cognition deficit enhancement agents. Methods of preparation
The present invention also relates to processes for preparing the compound of formula I as a free base or a pharmaceutically acceptable salt thereof. Throughout the following description of such processes it is understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are for example described in "Protective Groups in Organic Synthesis", T. W. Greene, P.G.M Wutz, Wiley-Interscience, New York, 1999. It is understood that microwaves can be used for the heating of reaction mixtures.
Preparation of Intermediates
The process, wherein R1, R2, R3, R4, R5 and A, unless otherwise specified, are as defined hereinbefore, comprises,
(i) conversion of a compound of formula II to obtain a compound of formula III, wherein R6 is a substituted phenyl,
Figure imgf000038_0001
(ii) (πi)
may be carried out by reaction with a suitable reagent such as 1,3-propanedithiol in the presence of an acid such as hydrochloric acid or/?-toluenesulfonic acid, or a Lewis acid such as boron trifluoride or titanium tetrachloride or ruthenium(III) chloride. The reaction may be preformed in a suitable solvent such as dichloromethane, acetonitrile, chloroform, toluene or diethyl ether, at a temperature between -78 0C and reflux.
(ii) reaction between a compound of formula IV with a compound of formula III to obtain a compound of formula V, wherein R6 is a substituted phenyl and R7 is defined as in A above,
Figure imgf000039_0001
(IV) (HI) (V)
may be carried out by treating III with a suitable base such as an alkyllithium reagent e.g. «-butyl lithium or /-butyl lithium or lithium diisopropylamide, before addition of IV. The reaction may be carried out in a solvent such as tetrahydrofuran or diethyl ether, or a mixture of tetrahydrofuran or diethyl ether with hexane, at a temperature between -100 °C and 25 0C. The reaction may be aided by the presence of reagents such as hexamethylphosphoric triamide or N,N,N,N-tetramethyl-l ,2-ethanediamine.
(iii) oxidative deprotection and oxidation of a compound of formula V to obtain a compound of formula VI, wherein R6 is a substituted phenyl and R7 is defined as in A above,
Figure imgf000039_0002
(V) (VI)
may be carried out by: a) reaction with a suitable reagent such as 1,1,1 -tris(acetyloxy)- 1 , 1 -dihydro- 1 ,2- benziodoxol-3(lH)-one, bis(trifluoroacetoxy)iodobenzene, N-bromosuccinimide, or a mixture of trifluoroacetic acid with either sodium nitrite or formaldehyde, in a suitable solvent such as dichloromethane, acetonitrile, chloroform, acetone or water or a mixture thereof, between -5 0C to 40 0C. The reaction may be aided by the presence of an alcohol such as /-butanol. or, b) hydrolysis by treatment with a suitable reagent or reagent combination such as N- chlorosuccinimide and silver nitrate, N-iodosuccinimide, 3-chloroperoxybenzoic acid, ammonium cerium(IV) nitrate, thallium(III) nitrate, mercury(II) chloride and calcium carbonate, or mercery(II) acetate. The reaction may be preformed in a suitable solvent such as water, acetonitrile, methanol, acetone or diethyl ether or mixtures thereof, between -50 0C and 50 0C , followed or preceded by, oxidation with a reagent such as 1,1,1- tris(acetyloxy)-l,l-dihydro-l,2-benziodoxol-3(lH)-one, manganese dioxide, hydrogen peroxide, potassium permanganate, pyridinium chlorochromate, copper sulfate or bromine, in a suitable solvent such as dichloromethane, water, acetonitrile, chloroform or dimethyl formamide, at between 0 0C and reflux.
(iv) conversion of a compound of formula VI to obtain a compound of formula VII, wherein R6 is a substituted phenyl and R7 is defined as in A above,
Figure imgf000040_0001
(VI) CVE)
may be carried out by reaction with an appropriately N-substituted thiourea, such as N- methyl thiourea, in the presence of a suitable base such as potassium hydroxide or sodium hydroxide in a suitable solvent such as water, dimethyl sulfoxide, ethanol or methanol or mixtures thereof, between 20 0C and reflux.
(v) conversion of a compound of formula VII to obtain a compound of formula VTII, wherein R6 is a substituted phenyl and R7 is defined as in A above,
Figure imgf000040_0002
may be carried out by reaction with ammonia, or an ammonia equivalent, together with an alkylhydroperoxide such as Λ-butylhydroperoxide in a solvent such as ethanol, methanol or water, or a mixture thereof, at 0 0C to 50 0C.
(vi) cross coupling of a compound of formula IX and a compound of formula X to obtain a compound of formula XI, wherein Halo is a halogen such as bromine, chlorine or iodine, R6 is a substituted phenyl, and R7 is defined as in A above or trimethylsilyl,
R-HaIo + -R0 -R°
(IX) (X) (XI)
may be performed with a suitable arylhalide such as a compound of formula II and an appropriate alkyne such as ethynyltrimethylsilane in the presence of copper(I) iodide and a suitable palladium catalyst such as dichlorobis(benzonitrile)palladium(II), bis(triphenylphosphine)palladium(II) dichloride, palladium(II) chloride, palladium(O) tetrakistriphenylphosphine with or without a suitable ligand such as tri-/er/-butylphosphine or triphenylphosphine, and a suitable base, such as trietylamine, diisopropylamine or piperidine may be used. The reaction may be performed in a solvent such as tetrahydrofuran or N,N-dimethylformamide, at temperatures between 20 °C and 100 0C.
(vii) desilylation of a compound of formula XII to a compound of formula XIII, wherein R7 is defined as in A above,
R7 — ^≡— Si(CH3), R- XIi xπi
may be performed using silver(I) nitrate or a suitable base such as potassium hydroxide, sodium hydroxide, lithium hydroxide or potassium carbonate, or using a fluoride ion- mediated desilylation using a suitable compound such as tetrabutylammonium fluoride or potassium fluoride. The reaction may be performed in a solvent such as tetrahydrofuran, methanol, dichloromethane or water, or mixtures thereof, at temperatures between 0 0C and 1000C.
(viii) borylation of a compound of formula XIII to obtain a compound of formula XTV, wherein R8 is cyclopropyl and R9 may be a group outlined in Scheme I, wherein R10 and R11 are groups such as OH, Ci-βalkylO or C2-3alkyl0 fused together to form a 5 or 6 membered boron containing heterocycle and the alkyl, cycloalkyl or aryl moieties may be optionally substituted,
R'- VP xm XVI
Figure imgf000042_0001
may be carried out by a reaction with: a) an alkyllithium such as butyllithium, or magnesium, and a suitable boron compound such as trimethyl borate or triisopropyl borate. The reaction may be performed in a suitable solvent such as tetrahydrofuran, hexane or dichloromethane in a temperature range between -78 0C and 200C; or, b) a suitable boron species such as biscatecholatodiboron, bispinacolatodiboron or pinacolborane in the presence of a suitable palladium catalyst such as palladium(O) tetrakistriphenylphosphine, palladium diphenylphosphineferrocene dichloride or palladium acetate, with or without a suitable ligand such as 2-(dicyclohexylphosphino)biphenyl, and a suitable base, such as a tertiary amine, such as trietylamine or diisopropylethylamine, or potassium acetate may be used. The reaction may be performed in a solvent such as dioxane, toluene, acetonitrile, water, ethanol or 1 ,2-dimethoxyethane, or mixtures thereof, at temperatures between 20 °C and 160 0C.
(ix) reduction of a compound of formula XV to a compound of formula XVI, wherein R12 is cyclopropyl and R13 is a substituted aryl,
R'
\_R 13
XV XVI
may be preformed using a suitable catalyst such as palladium-on-charcoal, Raney nickel or Wilkinson's catalyst, and hydrogen. The reaction may be preformed in a suitable solvent such as ethyl acetate, methanol or ethanol, at temperatures between 20 °C and reflux.
(x) reduction of a compound of formula XVII to a compound of formula XVIII, wherein R7 is defined as in A above,
O
R7-^N - 7X
R7/ H xvπ xviπ
may be preformed using a metal hydride reducing agent such as diisopropylaluminium hydride or lithium aluminum hydride. The reaction may be preformed in a suitable solvent such as dichlorometane, toluene or benzene, at a temperature between -78 0C and 25 °C.
(xi) borylation of a compound of formula XIX to obtain a compound of formula XX, wherein R14 is an optionally substituted aryl or heteroaryl and R15 may be a group outlined in Scheme II, wherein R16 and R17 are groups such as OH, Ci-βalkylO or C2-3alkylO fused together to form a 5 or 6 membered boron containing heterocycle and the alkyl, cycloalkyl or aryl moieties may be optionally substituted,
R14— halo R14— R15 XIX XX
Figure imgf000044_0001
may be carried out by a reaction with: a) an alkyllithium such as butyllithium, or magnesium, and a suitable boron compound such as trimethyl borate or triisopropyl borate. The reaction may be performed in a suitable solvent such as tetrahydrofuran, hexane or dichloromethane in a temperature range between -78 0C and 200C; or, b) a suitable boron species such as biscatecholatodiboron, bispinacolatodiboron or pinacolborane in the presence of a suitable palladium catalyst such as palladium(O) tetrakistriphenylphosphine, palladium diphenylphosphineferrocene dichloride or palladium acetate, with or without a suitable ligand such as 2-(dicyclohexylphosphino)biphenyl, and a suitable base, such as a tertiary amine, such as trietylamine or diisopropylethylamine, or potassium acetate may be used. The reaction may be performed in a solvent such as dioxane, toluene, acetonitrile, water, ethanol or 1 ,2-dimethoxyethane, or mixtures thereof, at temperatures between 20 0C and 1600C.
(xii) oxidation of a compound of formula XXI to obtain a compound of formula XXII, wherein R18 is defined as in A above and R19 is an optionally substituted phenyl,
Figure imgf000044_0002
(XXI) (XXE) may be performed by reaction with a suitable reagent or mixture of reagents, such as sodium periodate and ruthenium dioxide, iodine and dimethyl sulfoxide, palladium chloride and dimethyl sulfoxide, oxone, hydrogen peroxide, oxygen, potassium permanganate, ruthenium tetroxide, or selenium dioxide, in a suitable solvent such as dimethyl sulfoxide, dichloromethane, acetonitrile, water, acetone, chloroform or carbon tetrachloride at a temperature between -78 0C and 150 0C. The reaction may be aided by the presence of a catalyst such as ruthenium(III) chloride or iron(III) chloride.
(xiii) conversion of a compound of formula VI to obtain a compound of formula VIII, wherein R6 is a substituted phenyl and R7 is defined as in A and C above,
Figure imgf000045_0001
(VI) VIII)
may be carried out by reaction with an appropriately N-substituted guanidine such as N- methylguanidine, N-ethylguanidine, or N-propylguanidine, in the presence of a suitable base such as potassium hydroxide, sodium hydroxide or sodium carbonate in a suitable solvent such as water, dimethyl sulfoxide, dioxane, ethanol or methanol or mixtures thereof, between 20 °C and reflux.
(xiv) conversion of a compound of formula XXIII to obtain a compound of formula XXTV, wherein R20 is defined as in A above,
O
R«L_H D
R20^H (XXIlJ) (XXIV)
may be preformed by treating XXIII with: a) a formylation agent such as methylchloroformate, dichloromethoxymethane, dichlorobutoxymethane, formaldehyde, carbon monoxide, hydrogen cyanide or a combination of phosphorous oxychloride with N-methyl-N-phenyl formamide or N^V- dimethylformamide. The reaction can be performed with or without a suitable reagent such as titanium tetrachloride, tin tetrachloride, aluminium trichloride and copper(I) chloride or combinations thereof. The reaction may be preformed with or without a suitable solvent such as dichloromethane, benzene, or 1,1,2,2-tetrachloroethane at a temperature between - 20 0C and reflux; or, b) a bromination agent such as bromine or N-bromosuccinimide in a solvent such as chloroform, N^/V-dimethylformamide, tetrahydrofurane or hexane or mixtures thereof at a temperature between -78 0C and reflux , followed by treatment with a base such as butyl lithium and subsequently a reagent such as N^/V-dimethylfόrmamide or acetic acid in a solvent such as tetrahydrofurane and/or hexane at a temperature between -78 0C and 0 0C.
Methods of Preparation of End products Another object of the invention are processes a or b or c for the preparation of compounds of general formula I, wherein R1, R2, R3, R4, R5 and A unless otherwise specified, are defined as hereinbefore, and salts thereof. When it is desired to obtain the acid salt, the free base may be treated with an acid such as a hydrogen halide such as hydrogen chloride, sulphuric acid, a sulphonic acid such as methane sulphonic acid or a carboxylic acid such as acetic or citric acid in a suitable solvent such as tetrahydrofuran, diethyl ether, methanol, ethanol, chloroform or dichloromethane or mixtures thereof, the reaction may occur between -30 0C to 50 0C.
These processes comprise; (a) conversion of a compound of formula XXV to a compound of formula I, wherein halo represents halogen such as chlorine, bromine or iodine, R7 is as defined for A above, R21 is as defined for R5 above, R1, R2, R5 and A is as defined above, R14 is an optionally substituted aryl or heteroaryl and R15 may be a group outlined in Scheme II above,
Figure imgf000047_0001
(XXV) (XXVI) (I)
may be carried out by a de-halogen coupling with a suitable compound of formula XXVI. The reaction may be carried out by coupling of a compound of formula XXV with an appropriate aryl boronic acid or boronic ester of formula XXVI. The reaction may be carried out using a suitable palladium catalyst such as tetrakis(triphenylphosphine)palladium(0), palladium diphenylphosphineferrocene dichloride or palladium acetate, together with, or without, a suitable ligand such as tή-tert- butylphosphine or 2-(dicyclohexylphosphino)biphenyl, or using a nickel catalyst such as nickel on charcoal or 1 ,2-bis(diphenylphosphino)ethanenickel dichloride together with zinc and sodium triphenylphosphinetrimetasulfonate. A suitable base such as cesium fluoride, an alkyl amine such as triethyl amine, or an alkali metal or alkaline earth metal carbonate or hydroxide such as potassium carbonate, sodium carbonate, cesium carbonate, or sodium hydroxide may be used in the reaction, which may be performed in a temperature range between 20 0C and 160 0C, in a suitable solvent such as toluene, tetrahydrofuran, dioxane, dimethoxyethane, water, ethanol or N,N-dimethylformamide, or mixtures thereof.
(b) reduction of a compound of formula XXVII to a compound of formula I, wherein R7 is as defined for A above, R21 is as defined for R5 above, R2, R5 and A are as defined above, and R1 is GHbCHbcyclopropyl.
Figure imgf000047_0002
(XXVII) (I)
may be preformed using a suitable catalyst such as palladium-on-charcoal, Raney nickel or Wilkinson's catalyst, and hydrogen. The reaction may be preformed in a suitable solvent such as ethyl acetate, methanol or ethanol, at temperatures between 20 0C and reflux.
General Methods
Starting materials used were available from commercial sources, or prepared according to literature procedures.
Microwave heating was performed in a Creator, Initiator or Smith Synthesizer Single- mode microwave cavity producing continuous irradiation at 2450 MHz. 1H NMR spectra were recorded in the indicated deuterated solvent at 400 MHz. The 400MHz spectra were obtained unless stated otherwise, using a Bruker av400 NMR spectrometer equipped with a 3 mm flow injection SEI Η/D-13C probe head with Z- gradients, using a BEST 215 liquid handler for sample injection, or using a Bruker DPX400 NMR spectrometer equipped with a 4-nucleus probehead with Z-gradients. Chemical shifts are given in ppm down- and upfield from TMS. Resonance multiplicities are denoted s, d, t, q, m and br for singlet, doublet, triplet, quartet, multiplet, and broad respectively.
LC-MS analyses were recorded on a Waters LCMS equipped with a Waters X-Terra MS, C8-column, (3.5 μm, 100 mm x 3.0 mm i.d.). The mobile phase system consisted of A: 10 mM ammonium acetate in water/acetonitrile (95:5) and B: acetonitrile. A linear gradient was applied running from 0% to 100% B in 4-5 minutes with a flow rate of 1.0 mL/min. The mass spectrometer was equipped with an electrospray ion source (ESI) operated in a positive or negative ion mode. The capillary voltage was 3 kV and the mass spectrometer was typically scanned between m/z 100-700. Alternative, LC-MS HPLC conditions were as follows: Column: Agilent Zorbax SB-C8 2mm ED X 50mm Flow: 1.4 mL/minGradient: 95% A to 90% B over 3 min. hold 1 minute ramp down to 95% A over 1 minute and hold 1 minute. Where A = 2% acetonitrile in water with 0.1% formic acid and B = 2% water in acetonitrile with 0.1% formic acid. UV-DAD 210-400 nm. Or LC-MS analyses were performed on a LC-MS consisting of a Waters sample manager 2111 C, a Waters 1525 μ binary pump, a Waters 1500 column oven, a Waters ZQ single quadrupole mass spectrometer, a Waters PDA2996 diode array detector and a Sedex 85 ELS detector. The mass spectrometer was configured with an atmospheric pressure chemical ionisation (APCI) ion source which was further equipped with atmospheric pressure photo ionisation (APPI) device. The mass spectrometer scanned in the positive mode, switching between APCI and APPI mode. The mass range was set to m/z 120-800 using a scan time of 0.3 s. The APPI repeller and the APCI corona were set to 0.86 kV and 0.80 μA, respectively. In addition, the desolvation temperature (3000C), desolvation gas (400 L/Hr) and cone gas (5 L/Hr) were constant for both APCI and APPI mode. Separation was performed using a Gemini column Cl 8, 3.0 mm x 50 mm, 3 μm, (Phenomenex) and run at a flow rate of 1 ml/min. A linear gradient was used starting at 100 % A (A: 10 mM ammonium acetate in 5% methanol) and ending at 100% B (methanol). The column oven temperature was set to 40 0C. Mass spectra (MS) were run using an automated system with atmospheric pressure chemical (APCI or CI) or electrospray (+ESI) ionization. Generally, only spectra where parent masses are observed are reported. The lowest mass major ion is reported for molecules where isotope splitting results in multiple mass spectral peaks (for example when chlorine is present). GC-MS analyses were performed on a Agilent 6890N GC equipped with a Chrompack CP- SiI 5CB column (25 m x 0.25 mm i.d. df = 0.25)), coupled to an Agilent 5973 Mass Selective Detector operating in a chemical ionization (CI) mode and the MS was scanned between m/z 50-500. HPLC assays were performed using an Agilent HPl 100 Series system equipped with a Waters X-Terra MS, C8 column (3.0 x 100 mm, 3.5 μm). The column temperature was set to 40 0C and the flow rate to 1.0 mL/min. The Diode Array Detector was scanned from 200-300 nm. A linear gradient was applied, run from 0% to 100% B in 4 min. Mobile phase A: 10 mM ammonium acetate in water/acetonitrile (95:5), mobile phase B: acetonitrile. Preparative HPLC was performed on a Waters Auto purification HPLC-UV system with a diode array detector using a Waters XTerra MS C8 column (19x300 mm, 7 μm) and a linear gradient of mobile phase B was applied. Mobile phase A: 0.1 M ammonium acetate in water/acetonitrile (95:5) and mobile phase B: acetonitrile. Flow rate: 20 mL/min. Thin layer chromatography (TLC) was performed on Merch TLC-plates (Silica gel 60 F254) and spots were UV visualized. Flash chromatography was performed using Merck Silica gel 60 (0.040-0.063 mm), or employing a Combi Flash® Companion™ system using RediSep normal-phase flash columns.
Compounds have been named using ACD/Name, version 9.0, software from Advanced Chemistry Development, Inc. (ACD/Labs), Toronto ON, Canada, www.acdlabs.com, 2004.
EXAMPLES
Below follows a number of non-limiting examples of compounds of the invention.
Example 1
6-(l,3-Dithian-2-yl)-2,2-dimethylchromane
Figure imgf000050_0001
Propane- 1,3-dithiol (541 mg, 5.0 mmol) was added to a solution of 2,2-dimethylchromane- 6-carbaldehyde (1.0 g, 5.26 mmol) in anhydrous dichloromethane (50 mL) and the mixture was stirred for 15 min and then cooled to -78 °C. Trifluoro(l,r-oxydiethane)boron (2.0 mL, 15.8 mmol) was added, the reaction was stirred at -78 0C for 15 min and the reaction was allowed to reach room temperature. Water was added and the mixture was diluted with dichloromethane. The layers were separated and the organic phase was washed with water before the solvent was evaporated in vacuo. Purification by column chromatography, using a gradient of 0 to 40% ethyl acetate in n-heptane as the eluent, gave 1.32 g (89% yield) the title compound: 1H NMR (CDCl3) δ 7.23 - 7.10 (m, 2 H), 6.72 (d, J= 8.3 Hz, 1 H), 5.10 (s, 1 H), 3.12 - 3.10 (m, 2 H), 2.95 - 2.85 (m, 2 H), 2.76 (t, J= 6.7 Hz, 2 H), 2.22 - 2.1 1 (m, 1 H), 1.97 - 1.87 (m, 1 H), 1.79 (t, J= 6.7 Hz, 2 H), 1.33 (s, 6 H); MS (ES) m/z 281 [M+l]+. Example 2
(3-Bromo-4-fluorophenyl)[2-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-l,3-dithian- 2-yl] methanol
Figure imgf000051_0001
s 6-(l,3-Dithian-2-yl)-2,2-dimethylchromane (1.32 g, 4.71 mmol) was dissolved in anhydrous tetrahydrofuran (40 mL) under an atmosphere of argon, cooled to -78 0C and n- butyl lithium (2.1 mL, 2.5 M) was added dropwise. The solution was stirred at -78 0C for 20 min and then treated with 3-bromo-4-fluorobenzaldehyde (1.0 g, 4.9 mmol). The reaction was stirred for another 20 min at -78 0C and was then allowed to reach roomo temperature. Aqueous ammonium chloride was added and the mixture was extracted with dichloromethane. The combined organic phases were evaporated and the residue was purified by column chromatography, using a gradient of 0 to 40% ethyl acetate in n- heptane as the eluent, to give 813 mg (36% yield) the title compound: 1H NMR (CDCl3) δ 7.45 (dd, J= 8.6, 2.5 Hz, 1 H), 7.17 (d, J= 2.3 Hz, 1 H), 7.14 - 7.064 (m, 1 H), 6.95 - 6.85s (m, 2 H), 6.76 (d, J= 8.6 Hz, 1 H), 3.06 (s, 1 H), 2.81 - 2.64 (m, 4 H), 1.97 - 1.90 (m, 2 H), 1.82 (t, J= 6.7 Hz, 2 H), 1.37 (s, 6 H), 0.94 - 0.86 (m, 2 H); MS (ES) m/z 465, 467 [M- water]+.
Example 3 0 l-(3-Bromo-4-fluorophenyl)-2-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)ethane- 1,2-dione
Figure imgf000051_0002
(3-Bromo-4-fluorophenyl)[2-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-l,3-dithian-2- yl]methanol (1.32 g, 4.71 mmol) and /er/-butanol (436 mg, 5.89 mmol) was dissolved in anhydrous dichloromethane (40 mL) under an atmosphere of nitrogen. Dess-Martin Periodinane (1.6 g, 3.78 mmol) was added to the solution and the reaction was stirred over night. Sodium thiosulphate (30 mL, 1 M) was added and the layers were separated. The organic phase was washed with aqueous sodium hydrogen carbonate and concentrated in vacuo. The product was purified by column chromatography, using a gradient of 0 to 70% ethyl acetate in n-heptane as the eluent, to give 570 mg (87% yield) the title compound: 1H NMR (CDCl3) δ 8.26 - 8.17 (m, 1 H), 7.99 - 7.90 (m, 1 H), 7.77 - 7.70 (m, 2 H), 7.25 - 7.17 (m, 1 H), 6.87 (d, J= 8.3 Hz, 1 H), 2.82 (t, J= 6.7 Hz, 2 H), 1.85 (t, J= 6.8 Hz, 2 H), 1.37 (s, 6 H); MS (ES) m/z 391, 393 [M+l]+.
Example 4
5-(3-Bromo-4-fluorophenyI)-5-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-3-methyI-
2-thioxoimidazolidin-4-one
Figure imgf000052_0001
l-(3-Bromo-4-fluorophenyl)-2-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)ethane-l,2- dione (570 mg, 1.46 mmol) and N-methylthiourea (263 mg, 2.92 mmol) were dissolved in dimethyl sulfoxide (30 mL). The solution was heated to 100 0C and potassium hydroxide (2.49 mL, 1.2 M) was added dropwise. After the addition the reaction was stirred at 100 0C for 5 min and then allowed to cool to room temperature. The solution was diluted with water and acidified using concentrated hydrochloric acid followed by extraction with dichloromethane. The combined organic phases were washed with water and then concentrated in vacuo. The product was purified by column chromatography, using a gradient of 0 to 70% ethyl acetate in n-heptane as the eluent, to give 514 mg (76% yield) of the title compound: 1H ΝMR (CDCl3) δ 7.60 - 7.55 (m, 1 H), 7.31 (ddd, J= 8.6, 4.5, 2.5 Hz, 1 H), 7.15 - 7.09 (m, 1 H), 6.92 - 6.88 (m, 2 H), 6.78 - 6.72 (m, 1 H), 3.34 (s, 3 H), 2.74 (t, J= 6.7 Hz, 2 H), 1.80 (t, J= 6.8 Hz, 2 H), 1.34 (s, 6 H); MS (ES) m/z 461, 463 [M+ 1]+.
Example 5 2-Amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-dimethyI-3,4-dihydro-2H-chromen-6-yl)- 3-methyl-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000053_0001
5-(3-Bromo-4-fluorophenyl)-5-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-3-methyl-2- thioxoimidazolidin-4-one (514 mg, 1.11 mmol) was dissolved in methanol (30 mL) and ammonium hydroxide (33%, 10 mL) and ter/-butyl hydroperoxide (1.5 g, 16.6 mmol) was added. The mixture was stirred at room temperature over night and then concentrated until approximately 50% of the volume remained. Water was added and the mixture was extracted with dichloromethane. The combined organic phases were washed with water and concentrated in vacuo. The product was purified by column chromatography, using a gradient of 0 to 10% 1:9 ammonium hydroxide/methanol in dichloromethane as the eluent, to give 248 mg (50% yield) of the title compound: MS (ES) m/z 446, 448 [M+ 1]+.
Preparative Example 1
2-Amino-5-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-5-(6-fluoro-3'- methoxybiphenyI-3-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride
Figure imgf000054_0001
A mixture of 2-amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-dimethyl-3,4-dihydro-2H- chromen-6-yl)-3-methyl-3,5-dihydro-4H-irαidazol-4-one (83 mg, 0.186 mmol), (3- methoxyphenyl)boronic acid (30 mg, 0.242 mmol), [1,1'- bis(diphenylphosphino)feiτocene]palladium(II) chloride dichloromethane adduct (15 mg, 0.018 mmol), potassium carbonate (154 mg, 1,12 mmol), 100 μL water and anhydrous tetrahydrofuran (3 mL) was irradiated in a microwave at 130 0C for 15 min. When cooled to room temperature the mixture was filtered and dimethyl sulfoxide (500 μL) was added. The solution was concentrated in vacuo to remove tetrahydrofuran and purified by preparative HP LC to give 49 mg of the base. The base was dissolved in 1 M hydrochloric acid in diethyl ether and the solvent was evaporated to give 64 mg (67% yield) of the title compound: 1H NMR (CDCl3) δ 7.58 (dd, J = 7.3 Hz, 1 H), 7.48 - 7.39 (m, 1 H), 7.34 (t, J = 8.0 Hz, 1 H), 7.18 - 7.03 (m, 5 H), 6.98 - 6.84 (m, 1 H), 6.73 (d, J= 8.3 Hz, 1 H), 3.84 (s, 3 H), 3.14 (s, 3 H), 2.73 (t, J= 6.8 Hz, 2 H), 1.77 (t, J= 6.7 Hz, 2 H), 1.31 (s, 6 H); MS (ES) m/z 474 [M+l]+.
Example 6
2-Amino~5-[3-(5-chloro-2-fluoropyridin-3-yI)-4-fluorophenyl]-5-(2,2-dimethyI-3,4- dihydro-2H-chromen-6-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride
Figure imgf000055_0001
The title compound was synthesized as described for Preparative Example 1 in 30% yield, starting from (S-chloro^-fluoropyridin-S-yOboronic acid: 1H ISfMR (CDCl3) δ 8.19 (dd, J = 2.5, 1.3 Hz, 1 H), 7.86 (dd, J= 7.7, 2.4 Hz, 1 H), 7.49 - 7.61 (m, 2 H), 7.07 - 7.21 (m, 3 H), 6.74 (d, J= 8.3 Hz, 1 H), 3.17 (s, 3 H), 2.74 (t, J= 6.7 Hz, 2 H), 1.78 (t, J = 6.7 Hz, 2 H), 1.31 (s, 6 H); MS (ES) w/z 497 [M+ 1]+.
Example 7
2-Amino-5-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-5-(4-fluoro-3-pyridin-3- yIphenyI)-3-methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride
Figure imgf000055_0002
The title compound was synthesized as described for Preparative Example 1 in 30% yield, starting from pyridin-3-ylboronic acid: 1H NMR (CDCl3) δ 8.79 (s, 1 H), 8.60 (dd, J= 4.8, 1.5 Hz, 1 H), 7.88 (dd, J= 8.0, 2.1 Hz, 1 H), 7.59 (dd, J= 7.3, 2.5 Hz, 1 H), 7.45 - 7.54 (m, 1 H), 7.32 - 7.42 (m, 1 H), 7.06 - 7.21 (m, 3 H), 6.74 (d, J= 8.3 Hz, 1 H), 3.16 (s, 3 H), 2.74 (t, J= 6.7 Hz, 2 H), 1.77 (t, J= 6.7 Hz, 2 H), 1.31 (s, 6 H); MS (ES) m/z 4457 [M+ 1]+.
Example 8 (3,4-Dihydro-2H-chromen-6-ylethynyl)(trimethyI)silane
Figure imgf000056_0001
A mixture of 6-iodo-chroman (6.3 g, 24.2 mmol; described in: Togo H. et.al. J. Chem. Soc. Perkin Trans. 1, 1997, 787-793)), triphenylphosphine (0.95 g, 3.6 mmol), cuprous iodide (0.23 g, 1.2 mmol) and triethylamine (12.1 mL, 87.2 mmol) in acetonitrile (100 mL) was degassed with argon for 10 min. (Trimethylsilyl)acetylene (13.7 mL, 48.4 mmol) was added followed by palladium acetate (0.27 g, 1,2 mmol). The mixture was stirred under an atmosphere of argon for 2.5 h at room temperature, concentrated under reduced pressure and partitioned between water and dichlorome thane. The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was slurried with hexane, filtered and concentrated to give 4.3 g of the crude title compound that was used in the next step without further purification.
Example 9 6-Ethynylchromane
Figure imgf000056_0002
(3,4-Dihydro-2H-chromen-6-ylethynyl)(trimethyl)silane (4.3 g, crude) was dissolved in methanol (150 mL) and stirred with potassium carbonate (2.0 g, 14.5 mL) for 2 h at room temperature. The mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography, using heptane/ethyl acetate 10:1 to 5:1 as the eluent, to give 2.6 g (89% yield) of the title compound: 1H NMR (CDCl3) 5 7.18 - 7.25 (m, 2 H), 6.73 (d, J= 8.1 Hz, 1 H), 4.20 (t, 2 H), 2.76 (t, J= 6.4 Hz, 2 H), 1.97 - 2.05 (m, 2 H); MS (EI) m/z 158 [M+.]. Example 10 6-[(3-Bromo-4-fluorophenyl)ethynyl]chromane
Figure imgf000057_0001
To a mixture of bis(triphenylphospine)palladium(II)dichloride (0.12 g, 0.17 mmol) and cuprous iodide (0.032 g, 0.17 mmol) in anhydrous tetrahydrofuran (40 mL) was triethylamine (11.4 mL, 81.7 mmol) added dropwise under an atmosphere of argon. A solution of 6-ethynylchromane (2.6 g, 16,6 mmol) in anhydrous tetrahydrofuran (10 mL) was added dropwise followed by addition of 2-bromo-l-fluoro-4-iodobenzene (5.0 g, 16.6 mmol). The reaction mixture was stirred at room temperature for 2 h. The crude mixture was diluted with ethyl acetate, washed with 1 M aqueous hydrochloric acid, water and saturated aqueous sodium hydrogen carbonate. The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was purified by column chromatography, using heptane/ethyl acetate 15:1 to 10:1 as the eluent, to give 5.0 g (91% yield) of the title compound: 1H NMR (CDCl3) δ 7.71 (dd, J= 6.6, 2.02 Hz, 1 H), 7.38 - 7.44 (m, 1 H), 7.21 - 7.26 (m, 2 H), 7.09 (t, J = 8.5 Hz, 1 H), 6.77 (d, J = 8.1 Hz, 1 H), 4.22 (t, 2 H), 2.79 (t, J= 6.6 Hz, 2 H), 1.99 - 2.07 (m, 2 H); MS (APPI+) m/z 331.0, 333.0 [M+H]+.
Example 11 l-(3-Bromo-4-fluorophenyl)-2-(3,4-dihydro-2H-chromen-6-yl)ethane-l,2-dione
Figure imgf000057_0002
6-[(3-Bromo-4-fluorophenyl)ethynyl]chromane (5.O g, 15.1 mmol) and palladium(II)dichloride (0.27 g, 1.5 mmol) were heated in dimethyl sulfoxide (70 mL) at 150 0C under an atmosphere of argon for 3 h. After cooling to room temperature water was added and the mixture was extracted with dichloromethane. The combined organic layers were washed with 1 M hydrochloric acid, water and saturated aqueous sodium carbonate solution, dried over magnesium sulfate, filtered and concentrated. The residue was purified by column chromatography, using heptane/ethyl acetate 8:1 to 7:1 as the eluent, to give 4.1 g (75% yield) of the title compound: 1H NMR (CDCl3) δ 8.23 (dd, J= 6.6, 2.27 Hz, 1 H), s 7.90 - 7.97 (m, 1 H), 7.73 (dd, J= 8.6, 2.27 Hz, 1 H), 7.66 - 7.70 (m, 1 H), 7.24 (t, 1 H), 6.88 (d, J= 8.6 Hz, 1 H), 4.28 (t, 2 H), 2.82 (t, J= 6.4 Hz, 2 H), 1.99 - 2.10 (m, 2 H); MS (ES) m/z 363.0, 365.0 [M+H]+.
Example 12 o 5-(3-Bromo-4-fluorophenyI)-5-(3,4-dihydro-2Hr-chromen-6-yI)-3-methyl-2- thioxoimidazolidin-4-one
Figure imgf000058_0001
To a solution of l-(3-bromo-4-fluorophenyl)-2-(3,4-dihydro-2H-chromen-6-yl)ethane-l,2- dione (4.1 g, 11.3 mmol) in dimethyl sulfoxide (75 mL) was methyl-2-thiourea (2.0 g, 22.6s mmol) added. The solution was heated at 100 °C for 5 min and aqueous potassium hydroxide (18.8 mL, 22.6 mmol, 1.2 M) was added dropwise. The reaction mixture was heated at 100 0C for another 10 min and then cooled to room temperature. The reaction mixture was diluted with water and the pΗ was adjusted to 4-5 by addition of aqueous hydrochloric acid (1 M). The mixture was extracted by dichloromethane. The combined0 organic layers were washed with water, dried over magnesium sulfate, filtrated and the solvent was evaporated. The residue was purified by column chromatography, using heptane/ethyl acetate 10:1 to 6:1 as the eluent, to give 4.5 g (92% yield) of the title compound: 1H NMR (CDCl3) δ 8.76 (br s, 1 H), 7.59 (dd, J= 6.4, 2.4 Hz, 1 H), 7.29 - 7.35 (m, 1 H), 7.11 (t, J= 8.5 Hz, 1 H), 6.91 - 6.97 (m, 2 H), 6.76 (d, J= 8.3 Hz, 1 H), 4.04 -5 4.34 (m, 2 H), 3.32 (s, 3 H), 2.74 (t, J= 6.4 Hz, 2 H), 1.94 - 2.04 (m, 2 H); MS (ES) m/z 435.0, 437.0 [M+H]+. Example 13
2-Amino-5-(3-bromo-4-fluorophenyI)-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one
Figure imgf000059_0001
tert-Butyl hydroperoxide (24.0 mL, 154.5 mmol, 70 wt% aq) was added to a solution of 5- (3-bromo-4-fluorophenyl)-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-2- thioxoimidazolidin-4-one (4.5 g, 10.3 mmol) in a 1 :3 mixture of methanol/ ammonium hydroxide (60:20 mL). The reaction was stirred at room temperature for 4 h, concentrated and the residue was dissolved in chloroform. The organic phase was washed with water, dried over magnesium sulfate, filtrated and the solvent was evaporated. The residue was purified by column chromatography, using ethyl acetate/methanol 30:1 to 20:1 + 1% triethylamine as the eluent, to give 3.2 g (74% yield) of the title compound: 1H ISfMR (CDCl3) δ 7.70 (dd, J= 6.6, 2.3 Hz, 1 H), 7.35 - 7.43 (m, 1 H), 7.00 - 7.09 (m, 3 H), 6.71 (d, J= 8.3 Hz, 1 H), 5.01 (br. s., 2 H), 4.15 (t, 2 H), 3.09 (s, 3 H), 2.71 (t, J= 6.4 Hz, 2 H), 1.91 - 2.01 (m, 2 H); MS (ES) m/z 418.05, 420.05 [M+H]+.
Preparative example 2
5'-[2-Amino-4-(3,4-dihydro-2H-chromen-6-yl)-l-methyl-5-oxo-4,5-dihydro-l/-r- imidazoI-4-yl]-2'-fluorobiphenyl-3-carbonitrile
Figure imgf000060_0001
2-Amino-5-(3-bromo-4-fluorophenyl)-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one (0.080 g, 0.191 mmol), (3-cyanophenyl)boronic acid (0.040 g, 0.027 mmol), [l,l'-bis (diphenylphosphino) ferrocene]palladium(II) chloride dichloromethane adduct (0.016 g, 0.019 mmol) and potassium carbonate (0.079 g, 0.57 mmol) in a mixture of 1 ,2-dimethoxy ethane, water and ethanol (6:3:1, 3 mL) was irradiated under an atmosphere of argon in a microwave at 130 0C for 15 min. When cooled to room temperature the mixture was filtered, concentrated and purified by preparative ΗPLC to give 0.034 g (42% yield) of the title compound: 1H NMR (CDCl3) δ 7.86 - 7.97 (m, 2 H), 7.76 - 7.83 (m, 1 H), 7.70 (t, J= 7.8 Hz, 1 H), 7.60 (dd, J= 7.7, 2.1 Hz, 1 H), 7.49 - 7.57 (m, 1 H), 7.30 (dd, J= 10.4, 8.8 Hz, 1 H), 7.07 - 7.13 (m, 2 H), 6.64 (d, J = 9.1 Hz, 1 H), 4.07 (t, 2 H), 2.96 (s, 3 H), 2.67 (t, J = 6.4 Hz, 2 H), 1.81 - 1.90 (m, 2 H); MS (ES) m/z 439.24 [M-H]".
Example 14
2-Amino-5-[3-(5-chIoro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(3,4-dihydro-2H- chromen-6-yl)-3-methyl-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000060_0002
The title compound was synthesized as described for Preparative Example 2 in 22% yield, starting from (5-chloro-2-fluoro-pyridin-3-yl)boronic acid: 1H NMR (DMSO-αfe) δ 8.40 (dd, J= 2.5, 1.3 Hz, 1 H), 8.23 (dd, J= 8.1, 2.5 Hz, 1 H), 7.55 - 7.63 (m, 2 H), 7.33 (t, 1 H), 7.07 - 7.14 (m, 2 H), 6.64 (d, J= 8.6 Hz, 1 H), 4.03 - 4.12 (m, 2 H), 2.96 (s, 3 H), 2.67 (t, J= 6.3 Hz, 2 H), 1.83 - 1.92 (m, 2 H); MS (ES) m/z 467.22 [M-H]".
Example 15
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(4-fluoro-3-pyrimidin-5-yIphenyl)-3- methyI-3,5-dihydro-4//-imidazol-4-one
Figure imgf000061_0001
The title compound was synthesized as described for Preparative Example 2 in 63% yield, starting from pyrimidin-5-ylboronic acid: 1H NMR (DMSO-ck) δ 9.23 (s, 1 H), 8.94 (d, J = 1.3 Hz, 2 H), 7.65 (dd, J = 7.6, 2.5 Hz, 1 H), 7.53 - 7.60 (m, 1 H), 7.31 - 7.39 (m, 1 H), 7.09 - 7.16 (m, 2 H), 6.64 (d, J= 9.1 Hz, 1 H), 4.04 - 4.12 (m, 2 H), 2.97 (s, 3 H), 2.67 (t, J = 6.4 Hz, 2 H), 1.79 - 1.92 (m, 2 H); MS (ES) m/z 416.28 [M-H]-.
Example 16 5-(l,3-Dithian-2-yl)-2,3-dihydro-l-benzofuran
Figure imgf000061_0002
Boron trifluoride-diethyl etherate (9.0 mL, 70.1 mmol) was added dropwise to a cooled (0 0C) solution of 2,3-dihydrobenzofuran-5-carboxaldehyde (2,3 mL, 18.2 mmol) and 1, 3- propanedithiol (5.1 mL, 18.2 mmol) in dichloromethane (40 mL). The resulting mixture was stirred at 0 0C for 2 h. Saturated aqueous sodium bicarbonate was added and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with water, aqueous potassium hydroxide (10%) and water, dried over magnesium sulfate and the solvent was evaporated to give 4.4 g (100% yield) of the crude title compound: 1H NMR (CDCl3) δ 7.33 (s, 1 H), 7.20 (dd, J= 8.2, 1.9 Hz, 1 H), 6.73 (d, J = 8.3 Hz, 1 H), 4.57 (t, J= 8.7 Hz, 2 H), 3.20 (t, J= 8.7 Hz, 2 H), 3.00 - 3.11 (m, 2 H), 2.86 - 2.94 (m, 2 H), 2.11 - 2.22 (m, 1 H), 1.84 - 1.98 (m, 1 H); HR MS (ES) m/z 239.0559 [M+H]+.
Example 17
(3-Bromo-4-fluorophenyI)[2-(2,3-dihydro-l-benzofuran-5-yl)-l,3-dithian-2- yl] methanol
Figure imgf000062_0001
To a solution of 5-(l,3-dithian-2-yl)-2,3-dihydro-l-benzofuran (4.4 g, 18.2 mmol) in tetrahydrofuran (200 mL) was added a solution of w-butyllithium in hexane (12.5 mL, 20.0 mmol, 1.6 M) at -78 0C and the mixture was stirred at -78 °C for 2 h. 3-Bromo-4- fluorobenzaldehyde (3.88 g, 19.1 mmol) was added at -78 °C and the reaction was allowed to reach room temperature over night. The reaction mixture was poured into a saturated ammonium chloride solution and the aqueous layer extracted with dichloromethane. The combined organic layers were dried over magnesium sulfate and the solvent was evaporated. The residue was purified by column chromatography, using heptane/ethyl acetate 5:1 to 4: 1 as the eluent, to give 5.8 g (72% yield) of the title compound: 1H NMR (CDCl3) δ 7.46 (dd, J = 8.5, 2.1 Hz, 1 H), 7.40 (s, 1 H), 6.97 (dd, J = 6.8, 2.0 Hz, 1 H), 6.83 - 6.92 (m, 2 H), 6.74 (d, J = 8.6 Hz, 1 H), 4.88 (d, J= 3.0 Hz, 1 H), 4.62 (t, J= 8.6 Hz, 2 H), 3.17 (t, J= 8.7 Hz, 2 H), 2.65 - 2.82 (m, 4 H), 1.88 - 2.00 (m, 2 H); MS (ES) m/z 423.14, 425.14 [M-18]+.
Example 18 l-(3-Bromo-4-fluorophenyl)-2-(2,3-dihydro-l-benzofuran-5-yl)ethane-l,2-dione
Figure imgf000063_0001
Dess-Martin periodinane (14.0 g, 32.8 mmol) was added to a solution of (3-bromo-4- fluorophenyl)[2-(2,3-dihydro-l-benzofuran-5-yl)-l,3-dithian-2-yl]methanol (5.9 g, 13.1 mmol) and ter/-butanol (4.2 mL, 45.8 mmol) in dichloromethane (250 mL) under an atmosphere of argon and the reaction mixture was stirred over night. A solution of sodium thiosulfate (12.5 g) in saturated aqueous sodium hydrogencarbonate (200 mL) was added and the resulting mixture was stirred for 30 min. Dichloromethane was added and the organic phase was separated. The aqueous phase was extracted with dichloromethane and the combined organic phases were dried over magnesium sulfate and the solvent was evaporated. The residue was purified by column chromatography, using heptane/ethyl acetate 10:1 to 6:1 as the eluent, to give 3.5 g (76% yield) of the title compound: 1H NMR (CDCl3) δ 8.23 (dd, J = 6.6, 2.3 Hz, 1 H), 7.90 - 7.97 (m, 1 H), 7.85 (d, J = 1.3 Hz, 1 H), 7.79 (dd, J = 8.5, 1.9 Hz, 1 H), 7.21 - 7.27 (m, 1 H), 6.86 (d, J= 8.6 Hz, I H), 4.71 (t, J = 8.8 Hz, 2 H), 3.27 (t, J= 8.7 Hz, 2 H); MS (ES) m/z 349.0, 351.0 [M+H]+.
Example 19
5-(3-Bromo-4-fluorophenyl)-5-(2,3-dihydro-l-benzofuran-5-yI)-3-methyI-2- thioxoimidazolidin-4-one
Figure imgf000063_0002
To a solution of l-(3-bromo-4-fluorophenyl)-2-(2,3-dihydro-l-benzofuran-5-yl)ethane-l,2- dione (3.5 g, 10.0 mmol) in dimethyl sulfoxide (50 mL) was methyl-2-thiourea (1.81 g, 20.0 mmol) added. The solution was heated at 100 °C for 5 min and aqueous potassium hydroxide (17 mL, 20.0 mmol, 1.2 M) was added dropwise The reaction mixture was heated at 100 0C for another 10 min and then cooled to room temperature. The reaction mixture was diluted with water and the pH was adjusted to 4-5 by addition of aqueous hydrochloric acid (1 M). The mixture was extracted with dichloromethane. The combined organic layers were washed with water, dried over magnesium sulfate, filtrated and evaporated. The residue was purified by column chromatography, using heptane/ethyl acetate 6: 1 to 2: 1 as the eluent, to give 4.2 g (100% yield) of the title compound: 1H NMR (CDCl3) δ 9.02 (s, 1 H), 7.61 (dd, J= 6.4, 2.4 Hz, 1 H), 7.31 - 7.37 (m, 1 H), 7.06 - 7.14 (m, 2 H), 7.00 (dd, J= 8.5, 2.1 Hz, 1 H), 6.74 (d, J= 8.3 Hz, 1 H), 4.59 (t, J= 8.8 Hz, 2 H), 3.32 (s, 3 H), 3.18 (t, J= 8.7 Hz, 2 H); MS (ES) m/z 421.0, 423.0 [M-H]-.
Example 20
2-Amino-5-(3-bromo-4-fluorophenyI)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl- 3,5-dihydro-4H-imidazol-4-one
Figure imgf000064_0001
ter/-Butyl hydroperoxide (23.2 mL, 150.0 mmol, 70 wt% aq) was added to a solution of 5- (3-bromo-4-fluorophenyl)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-2- thioxoimidazolidin-4-one (4.2 g, 10.0 mmol) in a mixture of methanol (60 mL) and ammonium hydroxide (20 mL). The reaction was stirred for 4 h at room temperature, concentrated and the residue was dissolved in chloroform. The organic phase was washed with water and dried over magnesium sulfate, filtered and the solvent was evaporated. The residue was purified by column chromatography, using ethyl acetate/methanol 30: 1 to 20: 1 + 1% triethylamine as the eluent, to give 2.3 g (57% yield) of the title compound: 1H NMR (CDCl3) δ 7.70 (dd, J= 6.7, 2.4 Hz, 1 H), 7.37 - 7.43 (m, 1 H), 7.18 (s, 1 H), 7.13 (dd, J = 8.5, 2.1 Hz, 1 H), 7.03 (t, J= 8.5 Hz, 1 H), 6.70 (d, J= 8.3 Hz, 1 H), 4.98 (br s, 2 H), 4.55 (t, J= 8.7 Hz, 2 H), 3.14 (t, J= 8.5 Hz, 2 H), 3.10 (s, 3 H); MS (ES) m/z 402.19, 404.18 [M-H]-. Example 21
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,3-dihydro-l- benzofuran-5-yl)-3-methyl-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000065_0001
The title compound was synthesized as described for Preparative Example 2 in 33% yield, starting from (5-chloro-2-fluoro-pyridin-3-yl)boronic acid: 1H NMR (DMSO-αf6) δ 8.40 (dd, J= 2.5, 1.3 Hz, 1 H), 8.24 (dd, J= 8.1, 2.5 Hz, 1 H), 7.57 - 7.65 (m, 2 H), 7.25 - 7.38 (m, 2 H), 7.15 (d, J= 8.6 Hz, 1 H), 6.67 (m, 3 H), 4.47 (t, J= 8.7 Hz, 2 H), 3.11 (t, J= 8.7 Hz, 2 H), 2.97 (s, 3 H); MS (ES) m/z 453.22 [M-H]'.
Example 22
2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidtn-5-ylphenyl)-3- methyl-3,5-dihydro-4//-imidazol-4-one
Figure imgf000065_0002
The title compound was synthesized as described for Preparative Example 2 in 69% yield, starting from pyrimidin-5-ylboronic acid: 1H NMR (DMSO-cfe) δ 9.23 (s, 1 H), 8.94 (d, J = 1.3 Hz, 2 H), 7.65 (dd, J= 7.7, 2.4 Hz, 1 H), 7.53 - 7.61 (m, 1 H), 7.31 - 7.40 (m, 1 H), 7.29 (s, 1 H), 7.17 (d, J= 8.1 Hz, 1 H), 6.67 (m, 3 H), 4.47 (t, J= 8.7 Hz, 2 H), 3.11 (t, J = 8.7 Hz, 2 H), 2.97 (s, 3 H); MS (ES) m/z 402.26 [M-H]". Example 23 7-Chloro-5-(l,3-dithian-2-yI)-2,3-dihydro-l-benzofuran
Figure imgf000066_0001
Boron trifluoride diethyl etherate (5.4 mL, 42.3 mmol) as added dropwise over 5 min to a cooled (0 °C) mixture of 7-chloro-2,3-dmydro-l-benzofuran-5-carbaldehyde (described in PCT Int. Appl. WO 2003020724 Al, 1.93 g, 10.5 mmol), 1,3-propanedithiol (0.96 mL, 9.51 mmol) and 4A molecular sieves (10 g) in dichlorome thane. The mixture was stirred at 0 0C for 1 h and room temperature for 5.5 h and the molecular sieves were removed by filtration. The reaction mixture was extracted with dichloromethane and the combined filtrates was washed consecutively with a saturated sodium bicarbonate solution, water, 10% potassium hydroxide solution and water, dried over magnesium sulfate and concentrated to give 2.13 g (74% yield) of the title compound: 1H NMR (DMSO-αf6) δ 7.23 - 7.28 (m, 1 H), 7.18 - 7.23 (m, 1 H), 5.34 (s, 1 H), 4.64 (t, J= 8.8 Hz, 2 H), 3.28 (t, J= 8.7 Hz, 2 H), 3.00 - 3.11 (m, 2 H), 2.84 - 2.93 (m, 2 H), 2.07 - 2.17 (m, 1 H), 1.62 - 1.77 (m, 1 H); MS (AP) m/z 273 [M+ 1]+.
Example 24
(3-Bromo-4-fluorophenyl)[2-(7-chloro-23-dihydro-l-benzofuran-5-yI)-l,3-dithian-2- yl] methanol
Figure imgf000066_0002
w-Butyllithium (3.43 mL, 8.58 mmol, 2.5 M solution in hexane) was added to a solution of 7-chloro-5-(l,3-dithian-2-yl)-2,3-dihydro-l-benzofuran (2.13 g, 7.82 mmol) in tetrahydrofuran (30 mL) at -78 0C. After 5 min a solution of 3-bromo-4- fluorobenzaldehyde (1.90 g, 9.36 mmol) in tetrahydrofuran (5 mL) was added. The reaction was stirred for 1 h at -78 0C and at room temperature for 3 h. The mixture was partitioned between chloroform and an ammonium chloride solution and the combined organic extracts were dried over magnesium sulfate and concentrated. The residue was purified by column chromatography, using a stepwise gradient of heptane/ethyl acetate 5 6/1-3/1 as the eluent, to give 2.29 g (62% yield) of the title compound: 1H NMR (CDCl3) δ 7.44 - 7.48 (m, 1 H), 7.19 - 7.23 (m, 1 H), 6.94 (dd, J = 6.7, 2.1 Hz, 1 H), 6.85 (t, J= 8.5 Hz, 1 H), 6.75 - 6.82 (m, 1 H), 4.79 (s, 1 H), 4.64 (t, J= 8.8 Hz, 2 H), 3.17 (t, J= 8.7 Hz, 2 H), 2.52 - 2.74 (m, 4 H), 1.77 - 1.92 (m, 2 H); MS (AP) m/z 457, 459 [M-water]+. o Example 25 l-(3-Bromo-4-fluorophenyl)-2-(7-chloro-2,3-dihydro-l-benzofuran-5-yI)ethane-l,2- dione
Figure imgf000067_0001
A mixture of (3-bromo-4-fluorophenyl)[2-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)- 1,3-5 dithian-2-yl]methanol (2.28 g, 4.80 mmol), tert-butanol (1.15 mL, 12.0 mmol) and Dess- Martin periodinane (5.09 g, 12.0 mmol) was stirred over night. Water and saturated solutions of sodium bicarbonate and sodium thiosulfate were added. After 0.5 h the mixture was extracted with dichloromethane, the organic phase was dried over magnesium sulfate and concentrated. Purification by column chromatography, using heptane and ethylo acetate (4:1) as the eluent, gave 1.94 g (89% yield) of the title compound: 1H NMR
(CDCl3) δ 8.22 (dd, J= 6.6, 2.0 Hz, 1 H), 7.90 - 7.96 (m, 1 H), 7.81 - 7.84 (m, 1 H), 7.71 - 7.75 (m, 1 H), 7.25 (t, J= 8.2 Hz, 1 H), 4.82 (t, J= 8.8 Hz, 2 H), 3.36 (t, J= 8.7 Hz, 2 H).
Example 26 5 5-(3-Bromo-4-fluorophenyl)-5-(7-chIoro-2,3-dihydro-l-benzofuran-5-yI)-3-methyI-2- thioxoimidazolidin-4-one
Figure imgf000068_0001
A mixture of l-(3-bromo-4-fluorophenyl)-2-(7-chloro-2,3-dihydro-l-benzofuran-5- yl)ethane-l,2-dione (1.94 g, 4.27 mmol), N-methylthiourea (0.76 g, 8.40 mmol) and dimethyl sulfoxide (10 mL) was heated at 100 0C for 5 min. Aqueous potassium hydroxide (1 M, 8.80 mL, 8.82 mmol) was added and this mixture was heated for another 5 min. The reaction mixture was allowed to cool, water was added, the mixture was neutralized by addition of hydrochloric acid (1 M), and the water phase was extracted with dichloromethane. The organic phase was dried over magnesium sulfate and concentrated to give the crude title compound which was used in the next step without further purifications: 1H NMR (CDCl3) δ 8.78 (s, IH), 7.51 (dd, J= 6.3, 2.5 Hz, 1 H), 7.21 - 7.28 (m, 1 H), 7.02 - 7.10 (m, 1 H), 6.96 - 7.02 (m, 1 H), 6.91 - 6.96 (m, 1 H), 4.62 (t, J= 8.8 Hz, 2 H), 3.24 (s, 3H), 3.20 (t, J= 8.8 Hz, 2 H); MS (ESI) m/z 453, 455 [M-I]".
Example 27 2-Amino-5-(3-bromo-4-fluorophenyl)-5-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)-3- methyl-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000068_0002
A mixture of 5-(3-bromo-4-fluorophenyl)-5-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)-3- methyl-2-thioxoimidazolidin-4-one, ter/-butyl hydroperoxide (70% in water, 6.20 mL, 45.3 mmol), ammonium hydroxide (5 mL) and methanol (30 mL) was stirred over night. The reaction mixture was diluted with water, extracted with dichloromethane, the organic phase was dried over magnesium sulfate and concentrated. Purification by column chromatography, using a stepwise gradient of heptane and ethyl acetate (1:1-3: 1) as the eluent, gave 0.88 g, (48% yield from l-(3-bromo-4-fluorophenyl)-2-(7-chloro-2,3-dihydro- l-benzofuran-5-yl)ethane-l,2-dione) of the title compound: 1H NMR (CDCl3) δ 7.64 (dd, J = 6.7, 2.4 Hz, 1 H), 7.30 - 7.40 (m, 1 H), 7.15 - 7.18 (m, 1 H), 7.03 - 7.08 (m, 1 H), 6.99 (t, J= 8.5 Hz, 1 H), 4.57 (t, J= 8.7 Hz, 2 H), 3.16 (t, J = 8.7 Hz, 2 H), 3.05 (s, 3 H); MS (AP) m/z 438, 440 [M+ 1]+.
Example 28
Z-Amino-S-CT-chloro-ZjS-dihydro-l-benzofuran-S-yO-S^-fluoro-S-pyrimidin-S- yIphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Figure imgf000069_0001
A mixture of 2-amino-5-(3-bromo-4-fluorophenyl)-5-(7-chloro-2,3-dihydro-l-benzofuran- 5-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one (0.088g, 0.20 mmol), 5-pyrimidinyl boronic acid (0.030 g, 0.24 mmol), cesium carbonate (0.13 g, 0.40 mmol), [1,T- bis(diphenylphosphino)ferrocene]palladium(II) chloride dichloromethane adduct (0.020 g, 0.025 mmol), 1 ,2-dimethyoxyethane (2 mL), water (1 mL) and ethanol (0.3 mL) was irradiated in a microwave at 130 0C for 15 min under an atmosphere of argon. The reaction mixture was filtered and partitioned between water and ethyl acetate, the organic phase was concentrated and the residue was purified by preparative ΗPLC, to give 0.065 g (75% yield) of the title compound: 1H NMR (DMSO-^) δ 9.03 (s, 1 H), 8.73 - 8.77 (m, 2 H), 7.44 (dd, J= 7.6, 2.3 Hz, 1 H), 7.33 - 7.39 (m, 1 H), 7.16 (dd, J= 10.4, 8.8 Hz, 1 H), 7.08 - 7.11 (m, 1 H), 7.02 - 7.05 (m, 1 H), 6.55 (br s, 2 H), 4.38 (t, J= 8.7 Hz, 2 H), 3.03 (t, J = 8.7 Hz, 2 H), 2.78 (s, 3 H); MS (AP) m/z 438 [M+ 1]+.
Example 29 2-Amino-5-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)-5-[3-(5-chloro-2-fluoropyridin- 3-yl)-4-fluorophenyl]-3-methyl-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000070_0001
The title compound was synthesized as described for Example 28 in 29% yield, starting from 5-chloro-2-fluoropyridyl-3-boronic acid but using potassium carbonate as the base: 1H NMR (DMS(W*) δ 8.22 - 8.26 (m, 1 H), 8.08 (dd, J= 8.1, 2.5 Hz, 1 H), 7.38 - 7.45 (m, 2 H), 7.17 (t, J= 9.3 Hz, 1 H), 7.08 - 7.12 (m, 1 H), 7.04 - 7.07 (m, 1 H), 6.59 (br s, 2 H), 4.42 (t, J= 8.7 Hz, 2 H), 3.06 (t, J= 8.7 Hz, 2 H), 2.80 (s, 3 H); MS (AP) m/z 489 [M+l]+.
Example 30
2-Amino-5-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyridin-3- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Figure imgf000070_0002
The title compound was synthesized as described for Example 28 in 73% yield, starting from 3-pyridylboronic acid and using potassium carbonate as the base: 1H NMR (DMSO- d6) δ 8.66 - 8.71 (m, 1 H), 8.62 (dd, J = 4.8, 1.5 Hz, 1 H), 7.88 - 7.94 (m, 1 H), 7.60 (dd, J = 7.6, 2.3 Hz, 1 H), 7.50 - 7.56 (m, 2 H), 7.27 - 7.37 (m, 2 H), 7.24 (s, 1 H), 6.76 (br s, 2 H), 4.59 (t, J= 8.7 Hz, 2 H), 3.24 (t, J= 8.8 Hz, 2 H), 2.98 (s, 3 H); MS (AP) m/z 431 [M+ 1]+.
Example 31 5-(l,3-Dithian-2-yl)-2,2-dimethyl-2,3-dihydro-l-benzofuran
Figure imgf000071_0001
The title compound was synthesized as described for Example 23 in 76% yield, starting from 2,2-dimethyl-2,3-dihydro-l-benzofuran-5-carbaldehyde. Purification by column chromatography using heptane and ethyl acetate (6:1) as the eluent: 1H NMR (DMSO-fifo) δ 7.19 - 7.24 (m, 1 H), 7.11 (dd, J= 8.2, 1.9 Hz, 1 H), 6.64 (d, J= 8.3 Hz, 1 H), 5.28 (s, 1 H), 3.00 - 3.10 (m, 2 H), 2.99 (s, 2 H), 2.81 - 2.89 (m, 2 H), 2.05 - 2.15 (m, 1 H), 1.60 - 1.75 (m, 1 H), 1.39 (s, 6 H); MS (AP) m/z 267 [M+ 1]+.
Example 32 o (3-Bromo-4-fluorophenyI)[2-(2,2-diinethyl-2,3-dihydro-l-benzofuran-5-yl)-l,3- dithian-2-yl] methanol
Figure imgf000071_0002
The title compound was synthesized as described in Example 24 in 31% yield, starting from 5-(l,3-dithian-2-yl)-2,2-dimethyl-2,3-dihydro-l-benzoruran: 1H NMR (CDCl3) δ 7.405 (dd, J= 8.6, 2.3 Hz, 1 H), 7.21 - 7.24 (m, 1 H), 6.79 - 6.88 (m, 3 H), 6.61 (d, J= 8.3 Hz, 1 H), 4.81 (d, J= 2.3 Hz, 1 H), 2.89 (s, 2 H), 2.63 - 2.73 (m, 4 H), 1.82 - 1.92 (m, 2 H), 1.43 (s, 6 H); MS (AP) m/z 451, 453 [M-water]+.
Example 33 o l-(3-Bromo-4-fluorophenyl)-2-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yl)ethane- 1,2-dione
Figure imgf000071_0003
The title compound was synthesized as described for Example 25 in 81% yield, starting from (3-bromo-4-fluorophenyl)[2-(2,2-dimethyl-2,3-dihydro- 1 -benzofuran-5-yl)- 1 ,3- dithian-2-yl]methanol. Purification by column chromatography using heptane and ethyl acetate (6: 1) as the eluent: 1H NMR (CDCl3) δ 8.15 (dd, J= 6.6, 2.3 Hz, 1 H), 7.84 - 7.90 (m, 1 H), 7.68 - 7.75 (m, 2 H), 7.17 (t, 1 H), 6.73 (d, J= 9.1 Hz, 1 H), 2.98 (s, 2 H), 1.45 (s, 6 H); MS (AP) m/z 377, 379 [M+l]+.
Example 34
5-(3-Bromo-4-fluorophenyl)-5-(2,2-dimethyl-2,3-dihydro-l-benzofuraii-5-yl)-3- methyl-2-thioxoimidazolidin-4-one
Figure imgf000072_0001
The title compound was synthesized as described for Example 26, starting from l-(3- bromo-4-fluorophenyl)-2-(2,2-dimethyl-2,3-dihydro- 1 -benzofuran-5-yl)ethane- 1 ,2-dione: 1H NMR (CDCl3) δ 9.28 (s, 1 H), 7.66 (dd, J= 6.3, 2.3 Hz, 1 H), 7.34 - 7.40 (m, 1 H), 7.13 (t, J = 8.5 Hz, 1 H), 6.96 - 7.06 (m, 2 H), 6.69 (d,J= 8.3 Hz, 1 H), 3.33 (s, 3 H), 2.99 (s, 2 H), 1.48 (s, 6 H); MS (ESI) m/z 447, 449 [M-I]".
Example 35
2-Amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5- yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Figure imgf000072_0002
The title compound was synthesized as described for Example 27 in 68% yield (over two steps), starting from 5-(3-bromo-4-fluorophenyl)-5-(2,2-dimethyl-2,3-dihydro-l- benzofuran-5-yl)-3-methyl-2-thioxoimidazolidin-4-one: 1H NMR (CDCl3) δ 7.72 (dd, J = 6.6, 2.3 Hz, 1 H), 7.38 - 7.45 (m, 1 H), 7.09 - 7.15 (m, 2 H), 7.04 (t, J= 8.5 Hz, 1 H), 6.62 - 6.67 (m, 1 H), 5.00 (br s, 2 H), 3.11 (s, 3 H), 2.95 (s, 2 H), 1.45 (s, 6 H); MS (AP) m/z 432, 434 [M+ 1]+.
Example 36 2-Amino-5-(2,2-dimethyI-2,3-dihydro-l-benzofuran-5-yI)-5-(4-fluoro-3-pyrimidin-5- ylphenyl)-3-methyI-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000073_0001
The title compound was synthesized as described for Example 28 in 60% yield, starting from 2-amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-dimethyl-2,3-dihydro- 1 -benzofuran-5- yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one: 1H NMR (DMSO-^) δ 9.24 (s, 1 H), 8.95 (m, 2 H), 7.68 (dd, J= 7.6, 2.3 Hz, 1 H), 7.55 - 7.63 (m, 1 H), 7.32 - 7.40 (m, 1 H), 7.24 (s, 1 H), 7.13 - 7.20 (m, 1 H), 6.56 - 6.79 (m, 3 H), 2.93 - 3.01 (m, 5 H), 1.37 (s, 6 H); MS (AP) m/z 432 [M+l]+.
Example 37
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,2-dimethyI-2,3- dihydro-l-benzofuran-5-yl)-3-methyI-3,5-dihydro-4H-imidazol-4-one
Figure imgf000073_0002
The title compound was synthesized as described for Example 28 in 28% yield, starting from 2-amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-dimethyl-2,3-dihydro- 1 -benzofuran-5- yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one and (5-chloro-2-fluoropyridin-3-yl)boronic acid: 1H NMR (DMSO-^5) δ 8.30 - 8.35 (m, 1 H), 8.16 (dd, J= 8.1, 2.5 Hz, 1 H), 7.48 - 7.57 (m, 2 H), 7.25 (t, J= 9.6 Hz, 1 H), 7.14 (s, 1 H), 7.03 - 7.08 (m, 1 H), 6.41 - 6.80 (m, 3 H), 2.79 - 2.94 (m, 5 H), 1.28 (s, 6 H); MS (AP) m/z 483 [M+l]+.
Example 38 2-Amino-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyridin-3- ylphenyl)-3-methyI-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000074_0001
The title compound was synthesized as described for Example 28 in 46% yield, starting from 2-amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5- yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one and pyridin-3-ylboronic acid: 1H NMR (DMSO-<3fe) δ 8.65 - 8.71 (m, 1 H), 8.62 (dd, J= 4.8, 1.5 Hz, 1 H), 7.87 - 7.94 (m, 1 H), 7.63 (dd, J= 7.7, 2.4 Hz, 1 H), 7.50 - 7.59 (m, 2 H), 7.31 (dd, J= 10.5, 8.7 Hz, 1 H), 7.22 7.26 (m, 1 H), 7.13 - 7.19 (m, 1 H), 6.50 - 6.86 (m, 3 H), 2.92 - 3.02 (m, 5 H), 1.37 (s, 6 H); MS (AP) m/z 431 [M+l]+.
Example 39 2,2,3,3-Tetrafluoro-2,3-dihydro-l,4-benzodioxine-6-carbaldehyde
Figure imgf000074_0002
Diisobutylaluminium hydride (18.5 mL, 18.5 mmol, 1 M in toluene) was added to a solution of 2,2,3,3-tetrafluoro-6-cyanobenzodioxene (3.60 g, 15.4 mmol) in dichloromethane (50 mL) at -78 0C. The resulting mixture was stirred at -78 0C for 1 h and then at room temperature over night. A solution of Rochelle's salt (1 M) was added and after 20 min the mixture was extracted with chloroform. The organic phase was dried over magnesium sulfate, concentrated and the residue was purified by column chromatography, using heptane and ethyl acetate (9:1) as the eluent, to give 3.5 g (96% yield) of the title compound: 1H NMR (CDCl3) δ 9.98 (s, 1 H), 7.76 (dd, J= 8.3, 1.8 Hz, 1 H), 7.72 (d, J= 2.0 Hz, 1 H), 7.35 (d, J= 8.3 Hz, 1 H).
Example 40 6-(l,3-Dithian-2-yl)-2,2,3j3-tetrafluoro-2,3-dihydro-l,4-benzodioxine
Figure imgf000075_0001
The title compound was synthesized as described for Example 23 in 53% yield, starting from 2,2,3,3-tetrafluoro-2,3-dihydro-l,4-benzodioxine-6-carbaldehyde. Purification by column chromatography using heptane/ethyl acetate 9:1 as the eluent: 1H NMR (CDCl3) δ 7.29 - 7.34 (m, 2 H), 7.13 (d, J= 8.3 Hz, I H), 5.14 (s, 1 H), 3.01 - 3.13 (m, 2 H), 2.90 - 2.99 (m, 2 H), 2.15 - 2.26 (m, 1 H), 1.88 - 2.02 (m, 1 H).
Example 41
(3-Bromo-4-fluorophenyl)[2-(2,2,3,3-tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yI)- l,3-dithian-2-yl]methanol
Figure imgf000075_0002
The title compound was synthesized as described in Example 24 in 67% yield, starting from 6-(l,3-dithian-2-yl)-2^,3,3-tetrafluoro-2,3-dihydro-l,4-benzodioxine: 1H NMR (CDCl3) δ 7.49 - 7.56 (m, 2 H), 7.10 - 7.15 (m, 1 H), 7.00 (dd, J= 6.7, 2.1 Hz, 1 H), 6.93 (t, J= 8.3 Hz, 1 H), 6.80 - 6.87 (m, 1 H), 4.94 (d, J= 1.8 Hz, 1 H), 3.00 (d, J= 2.8 Hz, 1 H), 2.58 - 2.86 (m, 4 H), 1.92 - 2.04 (m, 2 H); MS (AP) m/z 511, 513 [M-water]+.
Example 42 l-(3-Bromo-4-fluorophenyl)-2-(2,2,3,3-tetrafluoro-2,3-dihydro-l,4-benzodioxin-6- yl)ethane-l,2-dione
Figure imgf000076_0001
The title compound was synthesized as described for Example 25 in 86% yield, starting from (3-bromo-4-fluorophenyl)[2-(2,2,3,3-tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl)- l,3-dithian-2-yl]methanol. Purification by column chromatography using a gradient of heptane/ethyl acetate as the eluent: MS (EI) m/z 436, 438 [M+'].
Example 43
5-(3-Bromo-4-fluorophenyl)-3-methyI-5-(2,2,3,3-tetrafluoro-2,3-dihydro-l,4- benzodioxin-6-yl)-2-thioxoimidazolidin-4-one
Figure imgf000076_0002
The title compound was synthesized as described for Example 26 in 58% yield, starting from l-(3-bromo-4-fluorophenyl)-2-(2,2,3,3-tetrafluoro-2,3-dihydro-l,4-benzodioxin-6- yl)ethane-l,2-dione. Purification by column chromatography using a gradient of heptane/ethyl acetate as the eluent: MS (AP) m/z 509, 511 [M+l]+.
Example 44
2-Amino-5-(3-bromo-4-fluorophenyI)-3-methyl-5-(2,2,3y3-tetrafluoro-2,3-dihydro-l,4- benzodioxin-6-yl)-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000076_0003
The title compound was synthesized as described for Example 27 in 61% yield, starting from 5-(3-bromo-4-fluorophenyl)-3-methyl-5-(2,2,3,3-tetrafluoro-2,3-dihydro-l,4- benzodioxin-6-yl)-2-thioxoimidazolidin-4-one: 1H NMR (CDCl3) δ 7.67 (dd, J= 6.6, 2.3 Hz, 1 H), 7.34 - 7.41 (m, 1 H), 7.22 - 7.29 (m, 2 H), 6.97 - 7.05 (m, 2 H), 3.06 (s, 3 H); MS (AP) mfz 492, 492 [M+ 1]+.
Example 45 l-Amino-S^-fluoro-S-pyrimidin-S-ylphenyO-S-methyl-S-Cl^jS^-tetrafluoro-ZjS- dihydro-l,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one
Figure imgf000077_0001
The title compound was synthesized as described for Example 28 in 50% yield, starting from 2-amino-5-(3-bromo-4-fluorophenyl)-3-methyl-5-(2,2,3,3-tetrafluoro-2,3-dihydro- l,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one: 1H NMR (DMSO-^6) δ 9.25 (s, 1 H), 8.98 (s, 2 H), 7.72 (dd, J= 7.3, 2.3 Hz, 1 H), 7.57 - 7.65 (m, 1 H), 7.35 - 7.53 (m, 4 H), 6.88 (br s, 2 H), 3.01 (br s, 3 H); MS (AP) m/z 492 [M+l]+.
Example 46
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-3-methyl-5-(2,2,3,3- tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one
Figure imgf000077_0002
The title compound was synthesized as described for Example 28 in 16% yield, starting from 2-amino-5-(3-bromo-4-fluorophenyl)-3-methyl-5-(2,2,3,3-tetrafluoro-2,3-dihydro-
1 ,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one and (5-chloro-2-fluoropyridin-3- yl)boronic acid: 1H NMR (DMSO-J5) δ 8.39 - 8.44 (m, 1 H), 8.29 (dd, J= 8.1, 2.5 Hz, 1 H), 7.59 - 7.69 (m, 2 H), 7.41 - 7.50 (m, 3 H), 7.36 (t, J= 9.1 Hz, 1 H), 6.88 (br s, 2 H), 2.99 (s, 3 H); MS (AP) m/z 543 [M+ 1]+.
Example 47
2-Amino-5-(4-fluoro-3-pyridin-3-yIphenyl)-3-methyI-5-(2,2,3,3-tetrafluoro-2,3- dihydro-l,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one
Figure imgf000078_0001
The title compound was synthesized as described for Example 28 in 80% yield, starting from 2-amino-5-(3-bromo-4-fluorophenyl)-3-methyl-5-(2,2,3,3-tetrafluoro-2,3-dihydro- l,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one and pyridin-3-ylboronic acid: 1H NMR (DMSO-c/tf) δ 8.69 (s, 1 H), 8.62 (dd, J= 4.8, 1.5 Hz, 1 H), 7.92 (d, J= 7.8 Hz, 1 H), 7.66 (dd, J= 7.6, 2.5 Hz, 1 H), 7.50 - 7.62 (m, 2 H), 7.41 - 7.50 (m, 3 H), 7.34 (dd, 1 H), 6.87 (br s, 2 H), 2.99 (s, 3 H); MS (AP) m/z 491 [M+lf.
Example 48 5-(l,3-Dithian-2-yl)-2,2-difluoro-l,3-benzodioxole
Figure imgf000078_0002
The title compound was synthesized as described for Example 23 in 76% yield, starting from 2,2-difluoro-l ,3-benzodioxole-5-carboxaldehyde. Purification by column chromatography using a gradient of heptane/ethyl acetate as the eluent: 1H NMR (CDCl3) δ 7.26 (d, J= 1.8 Hz, 1 H), 7.22 (dd, J= 8.1, 1.8 Hz, 1 H), 7.03 (d, J= 8.1 Hz, 1 H), 5.15 (s, 1 H), 3.02 - 3.14 (m, 2 H), 2.90 - 2.99 (m, 2 H), 2.16 - 2.25 (m, 1 H), 1.88 - 2.01 (m, 1 H). Example 49
(3-Bromo-4-fluorophenyI)[2-(2,2-difluoro-l,3-benzodioxoI-5-yl)-l,3-dithian-2- yl] methanol
F
Figure imgf000079_0001
The title compound was synthesized as described in Example 24 in 57% yield, starting from 5-(l,3-dithian-2-yl)-2,2-difluoro-l,3-benzodioxole: 1H NMR (CDCl3) δ 7.52 (d, J = 1.8 Hz, 1 H), 7.44 (dd, J = 8.6, 2.0 Hz, 1 H), 6.99 - 7.07 (m, 2 H), 6.93 (t, J= 8.3 Hz, 1 H), 6.78 - 6.86 (m, 1 H), 4.93 (s, 1 H), 3.00 (br s, 1 H), 2.58 - 2.84 (m, 4 H), 1.91 - 2.03 (m, 2 H); MS (AP) m/z 461, 463 [M-water]+.
Example 50 l-(3-Bromo-4-fluorophenyI)-2-(2,2-difluoro-l,3-benzodioxoI-5-yI)ethane-l,2-dione
Figure imgf000079_0002
The title compound was synthesized as described for Example 25 in 84% yield, starting from (3-bromo-4-fluorophenyl)[2-(2,2-difluoro-l,3-benzodioxol-5-yl)-l,3-dithian-2- yl]methanol. Purification by column chromatography using heptane and ethyl acetate (7:1) as the eluent: MS (ESI) m/z 385, 387 [M-I]".
Example 51 5-(3-Bromo-4-fluorophenyl)-5-(2,2-difluoro-l,3-benzodioxoI-5-yl)-3-methyl-2- thioxoimidazolidin-4-one
Figure imgf000079_0003
The title compound was synthesized as described for Example 26, starting from l-(3- bromo-4-fiuorophenyl)-2-(2,2-difluoro-l,3-benzodioxol-5-yl)ethane-l,2-dione: MS (ESI) m/z 457, 459 [M-I]".
Example 52
2-Amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-3-methyl-
3,5-dihydro-4i/-imidazol-4-one
Figure imgf000080_0001
The title compound was synthesized as described for Example 27 in 34% yield (from l-(3- bromo-4-fluorophenyl)-2-(2,2-difluoro-l,3-benzodioxol-5-yl)ethane-l,2-dione), starting from 5-(3-bromo-4-fluorophenyl)-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-3-methyl-2- thioxoimidazolidin-4-one: 1H NMR (CDCl3) δ 7.63 (dd, J= 6.6, 2.3 Hz, 1 H), 7.31 - 7.38 (m, 1 H), 7.14 - 7.19 (m, 2 H), 7.01 (t, J= 8.5 Hz, 1 H), 6.94 (d, J= 8.3 Hz, 1 H), 3.11 (s, 3 H); MS (AP) m/z 442, 444 [M+ 1]+.
Example 53
2-Amino-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one
Figure imgf000080_0002
The title compound was synthesized as described for Example 28 in 59% yield, starting from 2-amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one: 1H NMR (DMSO-d6) δ 9.24 (s, 1 H), 8.93 - 8.99 (m, 2 H), 7.69 (dd, J= 7.4, 2.4 Hz, 1 H), 7.54 - 7.62 (m, 1 H), 7.45 (d, J= 1.5 Hz, 1 H), 7.33 - 7.41 (m, 3 H), 6.83 (br s, 2 H), 2.99 (s, 3 H); MS (AP) m/z 442 [M+l]+.
Example 54 l-Ammo-S-β-^-chloro-Z-fluoropyridin-S-yl^-fluorophenyll-S-^Z-difluoro-ljS- benzodioxol-5-yl)-3-methyl-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000081_0001
The title compound was synthesized as described for Example 28 in 30% yield, starting 2- amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one and (5-chloro-2-fluoropyridin-3-yl)boronic acid: 1H NMR (DMSO-^5) 5 8.41 (dd, J= 2.5, 1.3 Hz, 1 H), 8.28 (dd, J= 8.1, 2.5 Hz, 1 H), 7.58 - 7.67 (m, 2 H), 7.42 (s, 1 H), 7.31 - 7.38 (m, 3 H), 6.84 (br s, 2 H), 2.99 (s, 3 H); MS (AP) m/z 493 [M+ 1]+.
Example 55
2-Amino-5-(2,2-difluoro-l,3-benzodioxoI-5-yl)-5-(4-fluoro-3-pyridin-3-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one
Figure imgf000081_0002
The title compound was synthesized as described for Example 28 in 64% yield, starting from 2-amino-5-(3-bromo-4-fluorophenyl)-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one and pyridin-3-ylboronic acid: 1H NMR (DMSO- d6) δ 8.68 (s, 1 H), 8.62 (dd, J= 4.7, 1.6 Hz, 1 H), 7.87 - 7.94 (m, 1 H), 7.63 (dd, J= 7.7, 2.4 Hz, 1 H), 7.49 - 7.58 (m, 2 H), 7.43 (s, 1 H), 7.28 - 7.40 (m, 3 H), 6.83 (br s, 2 H), 2.99 (s, 3 H); MS (AP) m/z 441 [M+ 1]+.
Example 56 5-((3-BromophenyI)ethynyl]-2,3-dihydro-l-benzofuran
Figure imgf000082_0001
To a mixture of bis(triphenylphosphine)palladium(II) dichloride (154 mg, 0.219 mmol) and copper iodide (42 mg, 0.219 mmol) in anhydrous tetrahydrofuran (50 mL) under an atmosphere of argon was sequentially added triethylamine (15 mL), a solution of 5- ethynyl-2,3-dihydro-l-benzofuran (3.151 g, 21.86 mmol; described in: Walser A. et. al. J. Med. Chem. 1991, 34, 1440-46) in anhydrous tetrahydrofuran (10 mL) and finally 3- bromo-1-iodobenzene (6.18 g, 21.86 mmol). The resulting solution was stirred at room temperature for 20 h. The crude mixture was diluted with ethyl acetate, washed sequentially with 1 M hydrochloric acid, water and a saturated sodium hydrogen carbonate solution and dried over magnesium sulfate. The solvent was evaporated to give a solid material which was suspended in hexane, the solid was filtered, washed with hexane and dried in vacuo to give 5.30 g (81% yield) of the title compound: 1H NMR (CDCl3) δ 7.66 (m, 1 H), 7.43 (m, 2 H), 7.37 (m, 1 H), 7.31 (m, 1 H), 7.20 (t, J= 7.8 Hz, 1 H), 6.77 (d, J = 8.3, 1 H), 4.62 (t, J= 8.7 Hz, 2 H), 3.23 (t, J= 8.7 Hz, 2 H); MS (EI) m/z 298, 300 [M+.].
Example 57 l-(3-BromophenyI)-2-(2,3-dihydro-l-benzofuran-5-yl)ethane-l,2-dione
Figure imgf000082_0002
5-[(3-Bromophenyl)ethynyl]-2,3-dihydro-l-benzofuran (5.30 g, 17.71 mmol) and palladium(II) dichloride (314 mg, 1.77 mmol) were heated in dimethyl sulfoxide (75 mL) at 150 0C under an atmosphere of argon for 6 h. Water was added after cooling to room temperature and the mixture was extracted with dichloromethane. The combined extracts were washed sequentially with 1 M hydrochloric acid, water and a saturated sodium hydrogen carbonate solution, dried over sodium sulfate and the solvent was evaporated. Purification by column chromatography, using a gradient with increasing concentration of ethyl acetate in hexane (0 - 30 %) as the eluent, gave 4.37 g (74% yield) of the title compound: 1H NMR (CDCl3) 8.13 (m, 1 H), 7.89 (m, 1 H), 7.85 (m, 1 H), 7.76 - 7.81 (m, 2 H), 7.39 (t, J= 8.0 Hz, 1 H), 6.87 (d, J= 8.6 Hz, 1 H), 4.71 (t, J= 8.8 Hz, 2 H), 3.28 (t, J = 8.7 Hz, 2 H); MS (ESI) m/z 331.2, 333.2 [M+H]+.
Example 58
5-(3-BromophenyI)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-raethyl-2-thioxoimidazolidin- 4-o ne
Figure imgf000083_0001
To a solution of l-(3-bromophenyl)-2-(2,3-dihydro-l-benzofuran-5-yl)ethane-l,2-dione (4.34 g, 13.11 mmol) in dimethyl sulfoxide (50 mL) was added N-methylthiourea (2.36 g, 26.21 mmol). The solution was heated at 100 °C for 5 min and then 1.2 M aqueous potassium hydroxide (22.4 mL, 26.82 mmol) was added dropwise over a period of 6-7 min. The mixture was heated for another 10 min and then cooled to room temperature. Water was added and the pH was adjusted to 5 by addition of 1 M hydrochloric acid. The mixture was extracted with dichloromethane. The combined extracts were washed twice with water, dried over sodium sulfate and evaporated to give 5.48 g (100% yield) of the title compound: 1H ΝMR (CDCl3) δ 7.72 (br s, 1 H), 7.49 - 7.53 (m, 2 H), 7.29 - 7.33 (m, 1 H), 7.24 - 7.28 (m, 1 H), 7.07 - 7.09 (m, 1 H), 6.97 - 7.01 (m, 1 H), 6.76 (d, J= 8.3 Hz, 1 H), 4.60 (t, J= 8.7 Hz, 2 H), 3.34 (s, 3 H), 3.20 (t, J= 8.7 Hz, 2 H); MS (ESI) m/z 401, 403 [M-H]-.
Example 59 2-Amino-5-(3-bromophenyl)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyI-3,5- dihydro-4H-imidazol-4-one
Figure imgf000084_0001
To a solution of 5-(3-bromophenyl)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-2- thioxoimidazolidin-4-one (5.48 g, 13.59 mmol) in methanol (100 mL) were added 70 % aqueous tert-butyl hydroperoxide (28 mL, 204 mmol) and 33 % aqueous ammonia (50 mL). The resulting mixture was stirred at room temperature for 16 h. The methanol was removed in vacuo and the aqueous residue was extracted with dichloromethane. The combined extracts were washed with water, dried over sodium sulfate and evaporated. Purification by column chromatography, using a gradient with increasing concentration of methanol in dichloromethane (0 - 10 %) and in the end substituting methanol for 0.1 M ammonia in methanol as the eluent, gave 2.29 g (44% yield) of the title compound: 1H NMR (CDCl3) δ 7.66 (t, J= 1.8 Hz, 1 H), 7.38 - 7.43 (m, 2 H), 7.21 - 7.23 (m, 1 H), 7.14 - 7.20 (m, 2 H), 6.71 (d, J= 8.3 Hz, 1 H), 4.55 (t, J= 8.7 Hz, 2 H), 3.15 (t, J= 8.1 Hz, 2 H), 3.11 (s, 3 H); MS (ESI) m/z 386.2, 388.2 [M+H]+, 384.4, 386.4 [M-H]".
Example 60 6-[(3-BromophenyI)ethynyl]chromane
Figure imgf000084_0002
The title compound was synthesized as described for Example 56 in 92% yield, starting from 6-iodochromane (described in: Togo H. et.al. J. Chem. Soc. Perkin Trans. 1, 1997, 787-793) and (3-bromophenyl)acetylene. Purification by column chromatography, using a gradient with increasing concentration of ethyl acetate in heptane (0 - 30 %), as the eluent: 1H NMR (CDCl3) δ 7.66 (t, J = 1.8 Hz, 1 H), 7.40 - 7.45 (m, 2 H), 7.23 - 7.27 (m, 2 H), 7.20 (t, J = 8.9 Hz, 1 H), 6.77 (d, J = 8.3 Hz, 1 H), 4.20 - 4.24 (m, 2 H), 2.79 (t, J = 6.6 Hz, 2 H), 1.99 - 2.06 (m, 2 H); MS (EI) m/z 312, 314 [M+.].
Example 61 l-(3-BromophenyI)-2-(3,4-dihydro-2H-chromen-6-yl)ethane-l,2-dione
Figure imgf000085_0001
The title compound was synthesized as described for Example 57 in 73% yield, starting from 6-[(3-bromophenyl)ethynyl]chromane: 1H NMR (CDCl3) δ 8.12 (t, J = 1.6 Hz, 1 H), 7.89 (m, 1 H), 7.77 (m, 1 H), 7.73 (dd, J = 8.6, 2.3 Hz, 1 H), 7.69 (m, 1 H), 7.39 (t, J= 7.8
10 Hz, 1 H), 6.88 (d, J= 8.6 Hz, 1 H), 4.29 (m, 2 H) 2.83 (t, J= 6.4 Hz, 2 H), 2.05 (m, 2 H); MS (ESI) m/z 345.2, 347.3 [M+H]+.
Example 62
5-(3-BromophenyI)-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyI-2-thioxoimidazolidin-
15 4-o ne
Figure imgf000085_0002
The title compound was synthesized as described for Example 58 in 100% yield, starting from l-(3-bromophenyl)-2-(3,4-dihydro-2H-chromen-6-yl)ethane-l,2-dione: 1H NMR (CDCl3) δ 7.62 (br s, 1 H), 7.49 - 7.53 (m, 2 H), 7.28 - 7.32 (m, 1 H), 7.26 (t, J= 8.0 Hz, 1
2.0 H), 6.91 - 6.95 (m, 2 H), 6.76 - 6.80 (m, 1 H), 4.17 - 4.21 (m, 2 H), 3.33 (s, 3 H), 2.75 (t, J = 6.4 Hz, 2 H), 1.97 - 2.04 (m, 2 H); MS (ESI) m/z 415.3, 417.3 [M-H]".
Example 63
2-Amino-5-(3-bromophenyl)-5-(3,4-dihydro-2Hr-chromen-6-yl)-3-methyI-3,5-dihydro- 25 4H-imidazoI-4-one
Figure imgf000086_0001
The title compound was synthesized as described for Example 59 in 75% yield, starting from 5-(3-bromophenyl)-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-2- thioxoimidazolidin-4-one: 1H NMR (CDCl3) δ 7.66 (t, J= 1.9 Hz, 1 H), 7.38 - 7.44 (m, 2 5 H), 7.18 (t, J= 8.0 Hz, 1 H), 7.06 - 7.12 (m, 2 H), 6.73 (d, J= 8.3 Hz, 1 H), 4.14 - 4.18 (m, 2 H), 3.11 (s, 3 H), 2.73 (t, J= 6.6 Hz, 2 H), 1.94 - 2.01 (m, 2 H); MS (ESI) m/z 400.2, 402.2 [M+H]+, 398.4, 400.4 [M-H]".
Example 64 o 2-Amino-5-[3-(4-chIoropyridin-3-yl)phenyl]-5-(2,3-dihydro-l-benzofuran-5-yl)-3- methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride
Figure imgf000086_0002
2-Amino-5-(3-bromophenyl)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-3,5-dihydro-4H- imidazol-4-one (100 mg, 0.258 mmol), 4-chloro-3-(4,4,5,5-tetramethyl-l,3,2-s dioxaborolan-2-yl)pyridine (80 mg, 0.335 mmol), [1,1'- bis(diphenylphosphino)ferrocene]palladium(π) chloride dichloromethane adduct (21 mg, 0.026 mmol), potassium carbonate (214 mg, 1.553 mmol), tetrahydrofuran (3 mL), and water (1 mL) was irradiated in a microwave at 150 0C for 15 min. When cooled to room temperature the mixture was filtered through celite and concentrated in vacuo. Purificationo by column chromatography, using a gradient with increasing polarity (0 to 10 %) of 1 :9 ammonium hydroxide/methanol in dichloromethane as the eluent, followed by preparative ΗPLC. The resulting residue was dissolved in hydrochloric acid (2 M in diethyl ether, 70 μL) and dichloromethane (2 mL). The solvents were evaporated to give 57 mg (49% yield) of the title compound: 1H NMR (DMSO-^6) δ 8.65 - 8.48 (m, 2 H), 7.70 (d, J= 5.3 Hz, 1 H), 7.64 - 7.57 (m, 2 H), 7.53 - 7.42 (m, 2 H), 7.22 (s, 1 H), 7.05 (dd, J= 8.6, 2.3 Hz, 1 H), 6.83 (d, J= 8.3 Hz, 1 H), 4.55 (t, J= 8.8 Hz, 2 H), 3.42 - 3.32 (m, 2 H), 3.18 (s, 3 H); MS (ESI) m/z 420 [M+ 1]+.
Example 65
2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyI-5-{3-[4-
(trifluoromethyl)pyridin-3-yl]phenyI}-3,5-dihydro-4H-imidazol-4-one hydrochloride
Figure imgf000087_0001
The title compound was synthesized as described for Example 64 in 52% yield, starting from 2-amino-5-(3-bromophenyl)-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one and [4-(trifluoromethyl)pyridin-3-yl]boronic acid: 1H NMR (DMSCwZ6) δ 8.90 (d, J= 4.5 Hz, 1 H), 8.68 (s, 1 H), 7.87 (d, J= 5.1 Hz, 1 H), 7.64 - 7.55 (m, 1 H), 7.51 - 7.45 (m, 2 H), 7.38 (s, 1 H), 7.17 (d, J= 1.8 Hz, 1 H), 7.01 (dd, J= 8.5, 2.1 Hz, 1 H), 6.81 (d, J= 8.3 Hz, 1 H), 4.55 (t, J= 8.7 Hz, 2 H), 3.22 - 3.10 (m, 5 H); MS (ESI) Wz 453 [M+ 1]+.
Example 66
2-Amino-5-[3-(4-chloropyridin-3-yl)phenyl]-5-(3,4-dihydro-2H-chromen-6-yl)-3- methyI-3,5-dihydro-4H-imidazol-4-one hydrochloride
Figure imgf000088_0001
The title compound was synthesized as described for Example 64 in 26% yield, staring from 2-amino-5-(3-bromophenyl)-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-3,5- dihydro-4H-imidazol-4-one: 1H NMR (CD3OD) δ 8.75 (m, 2 H), 8.08 (t, J= 6.8 Hz, 1 H), 7.69 - 7.49 (m, 4 H), 7.06 -6.97 (m, 2 H), 6.79 - 6.69 (m, 1 H), 4.19 - 4.11 (m, 2 H), 3.26 (s, 3 H), 2.73 (t, J= 6.4 Hz, 2 H), 1.99 - 1.90 (m, 2 H); MS (ESI) m/z 434[M+1]+.
Example 67 5-(l,3-Dithian-2-yI)-2,3-dihydro-l-benzofuran-7-carbonitrile
Figure imgf000088_0002
A suspension of ruthenium(III)chloride (25 mg, 0.12 mmol) was added dropwise to a solution of 5-formyl-2,3-dihydro-l-benzofuran-7-carbonitrile (2.13 g, 12.3 mmol, described in PCT Int. Appl. WO 2006/014580 Al) and 1,3-propandithiol (1.24 mL, 12.3 mmol) in acetonitrile (20 mL). The reaction mixture was stirred at room temperature for 16 h under an atmosphere of argon. Water (20 mL) was added to the reaction mixture, the formed suspension was cooled to 0 0C and stirred for 3 h. The precipitate was filtrated, washed with water and dried in a vacuum cabinet at 50 0C for 16 h to give 2.5 g (77% yield) of the title compound: 1H NMR (CDCl3) δ 7.45 (s, 1 H), 7.35 (s, 1 H), 5.01 (s, 2 H), 4.67 (t, 2 H), 3.20 (t, J = 8.7 Hz, 2 H), 2.92 - 3.03 (m, 2 H), 2.80 - 2.88 (m, 1 H), 2.06 - 2.16 (m, 1 H), 1.76 - 1.90 (m, 1 H). Example 68
5-{2-[(3-Bromo-4-fluorophenyl)(hydroxy)methyl]-l,3-dithian-2-yl}-2,3-dihydro-l- benzofuran-7-carbonitrile
Figure imgf000089_0001
5-(l,3-Dithian-2-yl)-2,3-dihydro-l-benzofuran-7-carbonitrile (0.2 g, 0.76 mmol) was dissolved in anhydrous tetrahydrofuran (4 mL). Lithium diisopropylamide (2 M in tetrahydrofuran, 0.57 mL, 0.83 mmol) was added over 15 min at 0 0C. 3-Bromo-4- fluorobenzaldehyde (0.16 g, 0.83 mmol) was added and the reaction mixture was stirred at 0 0C for 3 h. Saturated ammonium chloride was added and the mixture was extracted with dichloromethane. The combined organic phases were washed with brine, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography, using ethyl acetate/heptane (5-50%) as the eluent, gave 0.14 g (40% yield) of the title compound: 1H NMR (CDCl3) δ 7.76 (d, J = 2.0 Hz, 1 H), 7.53 - 7.56 (m, 1 H), 6.96 - 6.99 (m, 1 H), 6.94 (d, J= 8.3 Hz, 1 H), 6.83 - 6.89 (m, 1 H), 4.91 (s, 1 H), 4.80 (t, J= 8.7 Hz, 2 H), 3.24 (t, J= 8.7 Hz, 2 H), 2.94 (br s, 1 H), 2.73 - 2.82 (m, 2 H), 2.55 - 2.70 (m, 2 H), 1.87 - 2.02 (m, 2 H).
Example 69 5-l(3-Bromo-4-fluorophenyl)(oxo)acetyl]-2,3-dihydro-l-benzofuran-7-carbonitriIe
Figure imgf000089_0002
Dess-Martin periodinane (1.3 g, 3.08 mmol) was added to a solution of 5-{2-[(3-bromo-4- fluorophenyl)(hydroxy)methyl]-l,3-dithian-2-yl}-2,3-dihydro-l-benzofuran-7-carbonitrile (0.64 g, 1.37 mmol) and tert-butanol (0.36 g, 4.80 mmol) in dichloromethane (10 mL) under an atmosphere of argon and the reaction mixture was stirred overnight. Aqueous sodium thiosulfate (2.5 g) was added and the resulting mixture was stirred for 30 min. Dichloromethane was added and the aqueous phase was extracted with dichloromethane. 5 The combined organic phases were dried over magnesium sulfate and the solvent was evaporated. Purification by column chromatography, using ethyl acetate/heptane (5-50%) as the eluent, gave 0.45 g (88% yield) of the title compound: 1H NMR (CDCl3) δ 8.23 (dd, J= 6.4, 2.1 Hz, 1 H), 8.00 - 8.09 (m, 2 H), 7.93 - 7.98 (m, 1 H), 7.44 - 7.49 (m, 1 H ), 4.91 (t, J = 8.8 Hz, 2 H), 3.39 (t, J = 8.7 Hz, 2 H). 0
Example 70
5-[2-Amino-4-(3-bromo-4-fluorophenyl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol-4- yl]-2,3-dihydro-l-benzofuran-7-carbonitrile
Figure imgf000090_0001
s 5-[(3-Bromo-4-fluorophenyl)(oxo)acetyl]-2,3-dihydro-l-benzofuran-7-carbonitrile (0.45 g, 1.21 mmol) and 1-methylguanidine hydrochloride (0.61 g, 5.57 mmol) was dissolved in dioxane/ethanol (1 :1, 20 mL) and stirred at room temperature for 15 min. Sodium carbonate (0.59 g, 5.57 mmol) and water (2.8 mL) was added and the reaction was heated at 85 0C for 45 min. The reaction mixture was concentrated in vacuo and the residue waso dissolved in dichloromethane and water. The phases were separated and the organic phase was washed with brine, dried over magnesium sulfate and concentrated in vacuo. Purification by column chromatography, using methanol/ethyl acetate (5-50% + 1% triethylamine) as the eluent, gave 0.34 g (65% yield) of the title compound: 1H NMR (CD3OD) 6 7.60 (dd, J= 6.6, 2.3 Hz, 1 H), 7.44 (d, J= 1.3 Hz, 1 H), 7.35 - 7.41 (m, 2 H),5 7.18 (t, J= 8.6 Hz, 1 H), 4.73 (t, J= 8.7 Hz, 2 H), 3.25 (t, J= 8.7 Hz, 2 H), 3.11 (s, 3 H); MS (ES) m/z 429 [M-H]-. Example 71
5-[2-Amino-4-(4-fluoro-3-pyridin-3-ylphenyl)-l-methyI-5-oxo-4,5-dihydro-lH- imidazol-4-yI]-2,3-dihydro-l-benzofuran-7-carbonitriIe 1.0 acetate
Figure imgf000091_0001
5-[2-Amino-4-(3-bromo-4-fluorophenyl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol-4-yl]- 2,3-dihydro-l-benzofuran-7-carbonitrile (56 mg, 0.13 mraol), pyridine-3-boronic acid (19 mg, 0.16 mmol), [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (6 mg, 0.0065 mmol) and potassium carbonate (54 mg, 0.39 mmol) in 1,2- dimethoxyehane/water/ethanol (6:3:1, 3 mL) was irradiated in a microwave at 150 °C for 15 min. When cooled to room temperature the mixture was filtered and dimethyl sulfoxide (500 μL) was added. The solution was concentrated in vacuo to remove the tetrahydrofuran and purified by preparative ΗPLC to give 25 mg (45% yield) of the title compound: 1H NMR (CDCl3) δ 8.79 (s, 1 H), 8.62 (d, J= 3.8 Hz, 1 H), 7.88 (dd, J= 7.8, 2.0 Hz, 1 H), 7.51 - 7.56 (m, 1 H), 7.36 - 7.50 (m, 4 H), 7.17 (dd, J= 10.1, 8.6 Hz, 1 H), 4.73 (t, J= 8.7 Hz, 2 H), 3.23 (t, J= 8.8 Hz, 2 H), 3.15 (s, 3 H), 2.09 (s, 2.5 H); MS (ES) m/z 426 [M-H]-.
Examples 72-73
Figure imgf000092_0001
Table 1 : Representative examples synthesized as described for 5-[2-Amino-4-(4-fluoro-3- pyridin-3-ylphenyl)- 1 -methyl-5-oxo-4,5-dihydro- lH-imidazol-4-yl]-2,3-dihydro- 1 - benzofuran-7-carbonitrile. All the reactions were analyzed using LC-MS and those which showed a low level of conversion was irradiated in a microwave for another hour at 130 0C.
Figure imgf000092_0002
Example 74 2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-5-[3-(l,3-thiazoI-5-yl)phenyl]- 3,5-dihydro-4i/-imidazol-4-one hydrochloride
Figure imgf000093_0001
A solution of 2-amino-5-(3-bromophenyl)-5-(2,3-dihydro- 1 -benzoflιran-5-yl)-3-methyl- 3,5-dihydro-4H-imidazol-4-one (78 mg, 0.2 mmol), 5-(tributylstannyl)-l,3-thiazole (82 mg, 0.22 mmol) and tetrakis(triphenylphosphine)palladium(0) (12 mg, 0.01 mmol) in anhydrous N,N-dimethylformamide (3 mL) was stirred at 100 0C for 21 h. Additional 5- (tributylstannyl)-l,3-thiazole (37 mg, 0.1 mmol) and tetrakis(triphenylphosphine)palladium(0) (6 mg, 0.005 mmol) dissolved in anhydrous N1N- dimethylformamide (0.3 mL) was added and the stirring was continued for 20 h. The volatiles were removed in vacuo and the residue was partitioned between brine (20 mL) and dichloromethane (20 mL). The organic phase was separated and the aqueous phase extracted with ethyl acetate. The combined organics were concentrated and purified by preparative ΗPLC. The acetonitrile was removed in vacuo, the residue diluted with saturated aqueous sodium hydrogen carbonate and extracted with dichloromethane. The combined organics were dried over sodium sulfate, filtered and hydrochloric acid (1 M in diethyl ether, 0.2 mL) was added. The mixture was stirred at room temperature for 5 min and the solvent was evaporated to give 36 mg (45% yield) of the title compound: 1H ΝMR (DMSO-J6) δ 11.62 (br s, 1 H), 9.60 (br s, 2 H), 9.11 (s, 1 H), 8.31 (s, 1 H), 7.78 - 7.73 (m, 1 H), 7.73 - 7.70 (m, 1 H), 7.57 - 7.50 (m, 1 H), 7.44 - 7.37 (m, 1 H), 7.22 - 7.19 (m, 1 H), 7.05 - 7.00 (m, 1 H), 6.83 - 6.79 (m, 1 H), 4.54 (t, J= 8.7 Hz, 2 H), 3.22 - 3.13 (m, 5 H); MS (ESI) m/z 391 [M+H]+.
Example 75
3,3-Dimethyl-2,3-dihydro-l-benzofuran-5-carbaldehyde and 2,2-dimethyl-2,3- dihydro-l-benzofuran-5-carbaldehyde
Figure imgf000094_0001
Phosphorous oxy chloride (37 mL, 404 mmol) was added dropwise over 1 h to a stirred solution of a mixture of 3,3-dimethyl-2,3-dihydro-l-benzofuran and 2,2-dimethyl-2,3- dihydro-1-benzofuran (30 g, 202 mmol) in N,N-dimethylformamide (31 mL, 404 mmol). The mixture was heated at 100 0C for 1 h and a hot solution of sodium acetate (40 g) in water (40 mL) was carefully added dropwise. The reaction mixture was allowed to cool down to room temperature, extracted with diethyl ether and the combined organic phases were evaporated. Purification by column chromatography, using 0 to 10 % ethyl acetate in H-heptane as the eluent, gave 7.53 g (21% yield) of the title compounds (26:74): MS (ESI) m/z 111 [M+ 1]+.
Example 76
5-(l,3-Dithian-2-yl)-3^-dimethyI-2,3-dihydro-l-benzofurao and 5-(l,3-dithian-2-yl)-
2,2-dimethyl-2,3-dihydro-l-benzofuran
Figure imgf000094_0002
A slurry of ruthenium chloride (61 mg, 0,30 mmol) in acetonitrile (25 mL) was added dropwise to a stirred solution of propane- 1,3-dithiol (3.2 g, 29.5 mmol) and a mixture of 3,3-dimethyl-2,3-dihydro-l-benzofuran-5-carbaldehyde and 2,2-dimethyl-2,3-dihydro-l- benzofuran-5-carbaldehyde (5.2 g, 29.5 mmol, 26:74) in acetonitrile (100 mL). The reaction was stirred for 3 h and water (300 mL) was added. The mixture was extracted with dichloromethane and the combined organic phases were evaporated. Purification by column chromatography, using 0 to 10% ethyl acetate in rc-heptane as the eluent, gave 7.57 g (96% yield) of the title compounds (26:74): MS (ESI) m/z 267 [M+l]+. Example 77
(3-Bromo-4-fluorophenyl)[2-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-l,3- dithian-2-yl] methanol and (3-Bromo-4-fluorophenyl)[2-(2,2-dimethyl~2,3-dihydro-l- benzofuran-5-yl)-l,3-dithian-2-yl]methanol
Figure imgf000095_0001
A mixture of 5-(l,3-dithian-2-yl)-3,3-dimethyl-2,3-dihydro-l-benzofuran and 5-(l,3- dithian-2-yl)-2,2-dimethyl-2,3-dihydro-l-benzofuran (8.15 g, 30.6 mmol, 26:74) was dissolved in anhydrous tetrahydrofuran (60 mL) and cooled to -78 0C. «-Butyllithium (21 mL, 33.6 mmol, 1.6 M) was added dropwise. The solution was stirred at -78 0C for 20 min and treated with a solution of 3-bromo-4-fluorobenzaldehyde (6.52 g, 32.1 mmol) in anhydrous tetrahydrofuran (20 mL). The mixture was stirred for another 20 min at -78 °C, allowed to reach room temperature and stirred overnight. Saturated aqueous ammonium chloride was added and the mixture was extracted with dichloromethane. The combined organic phases were evaporated and the product isolated by column chromatography, using 0 to 100 % ethyl acetate in rc-heptane as the eluent. This gave 4.98 g (35% yield) of the title compounds (26:74): MS (ESI) m/z 451, 453 [M-water]+.
Example 78 l-(3-Bromo-4-fluorophenyl)-2-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)ethane- 1,2-dione and l-(3-Bromo-4-fluorophenyI)-2-(2,2-dimethyl-2,3-dihydro-l-benzofuran- 5-yl)ethane-l,2-dione
Figure imgf000095_0002
A mixture of (3-bromo-4-fluorophenyl)[2-(3,3-dimethyl-2,3-dihydro- 1 -benzofuran-5-yI)- 1 ,3-dithian-2-yl]methanol and (3-bromo-4-fluorophenyl)[2-(2,2-dimethyl-2,3-dihydro-l - benzofuran-5-yl)-l,3-dithian-2-yl]methanol (4.98g, 10.6 mmol, 26:74) and tert-butanol (2.75 g, 37.1 mmol) were dissolved in dichloromethane (100 mL). Dess-Martin Periodionane (10.1 g, 23.9 mmol) was added and the reaction was stirred at room temperature overnight. Sodium thiosulphate (1 M, 150 mL) was added and the mixture was extracted with dichloromethane. The combined organic phases were evaporated and the residue was purified by column chromatography, using 0 to 100 % ethyl acetate in n- heptane as the eluent, to give 2.82 g (71% yield) of the title compounds (26:74): MS (ESI) w/z 377, 379 [M+l]+.
Example 79 Z-Amino-S^-bromo-^fluorophenyO-S-CSjS-dimethyl-ljS-dihydro-l-benzofuran-S- yl)-3-methyl-3,5-dihydro-4H-imidazoI-4-one and 2-Amino-5-(3-bromo-4- fluorophenyl)-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yI)-3-methyl-3,5-dihydro- 4H-imidazol-4-one
Figure imgf000096_0001
A mixture of l-(3-bromo-4-fluorophenyl)-2-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5- yl)ethane- 1 ,2-dione and 1 -(3-bromo-4-fluorophenyl)-2-(2,2-dimethyl-2,3-dihydro- 1 - benzofuran-5-yl)ethane-l,2-dione (2.82 g, 7.5 mmol, 26:74) was dissolved in dioxane (50 mL) and ethanol (50 mL). 1-Methylguanidine hydrochloride (3.3 g, 30 mmol) was added followed by addition of a solution of sodium carbonate (3.2 g, 30 mmol) in water (10 mL). The reaction mixture was heated at 85 °C for 45 min, cooled to room temperature and extracted with dichloromethane. The combined organic phases were evaporated and the residue was purified by column chromatography, using 0 to 10 % {1:9 ammonium hydroxide/methanol} in dichloromethane as the eluent. This gave 1.28 g (39% yield) of the title compounds (26:74). MS (ESI) m/z 432, 434 [M+l]+. Example 80
2-Amino-5-(3r3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidin-5- ylphenyl)-3-raethyI-3,5-dihydro-4H-iraidazol-4-one
Figure imgf000097_0001
A mixture of 2-amino-5-(3-bromo-4-fluorophenyl)-5-(3,3-dimethyl-2,3-dihydro-l- benzofuran-5-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one and 2-amino-5-(3-bromo-4- fluorophenyl)-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-3-methyl-3,5-dihydro-4H- imidazol-4-one (100 mg, 0.23 mmol, 26:74), pyrimidin-5-boronic acid (37 mg, 0.30 mmol), cesium carbonate (225 mg, 0.69 mmol) and 1,1'- bis(diphenylphosphino)ferrocene]palladium(II) chloride dichloromethane adduct (19 mg, 0.023 mmol) were dissolved in l,2-dimethoxyethane:water:ethanol (6:3: 1, 5 mL) and irradiated in a microwave at 150 0C for 20 min. The resulting mixture was filtered through a short plug of celite and the filtrate was evaporated in vacuo. The product was purified by column chromatography, using 0 to 10 % {1 :9 ammonium hydroxide/methanol} in dichloromethane as the eluent, followed by preparative ΗPLC on a Chiralpak AD column (50 x 300 mm), using isopropanol/heptane (20/80) with 0.1 % trifluoroacetic acid as the eluent at a flow rate of 120 mL/min and after 20 min the eluent was changed to 100% isopropanol. The separation was monitored at 254 nm and the two isomers were collected and concentrated in vacuo to give 11 mg (43% yield) of the title compound: 1H NMR (CD3OD) δ 9.14 (s, 1 H), 8.94 (d, J= 1.3 Hz, 2 H), 7.61 - 7.49 (m, 2 H), 7.27 (dd, J = 10.4, 8.8 Hz, 1 H), 7.18 - 7.07 (m, 2 H), 6.68 (d, J= 8.3 Hz, 1 H), 4.20 (s, 2 H), 3.13 (s, 3 H), 1.27 (d, J= 3.3 Hz, 6 H); MS (ESI) m/z 432 [M+ 1]+.
Example 81 2-Amino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyridin-3- ylphenyI)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Figure imgf000098_0001
The title compound was synthesized as described for Example 80 in 23% yield, starting from pyridine-3-boronic acid: 1H NMR (CD3OD) δ 8.66 (s, 1 H), 8.53 (dd, J = 5.0, 1.5 Hz, 1 H), 7.98 (dd, J = 8.0, 2.1 Hz, 1 H), 7.56 - 7.44 (m, 3 H), 7.22 (dd, J= 10.4, 8.6 Hz, 1 H), 7.16 - 7.09 (m, 2 H), 6.68 (d, J= 8.3 Hz, 1 H), 4.20 (s, 2 H), 3.13 (s, 3 H), 1.27 (d, J= 2.8 Hz, 6 H); MS (ESI) m/z 431 [M+ 1]+.
Example 82 (5-Methoxypyridin-3-yI)boronic acid H
Figure imgf000098_0002
κ-Butyllithium (11.7 mL, 29.25 mmol, 2.5 M) was added dropwise to a cooled (-78 0C) solution of 3-bromo-5-methoxypyridine (5.08 g, 27.0 mmol) in anhydrous diethyl ether (40 mL). The resulting mixture was stirred at -78 0C for 30 min and triisopropyl borate (12.3 mL, 53.3 mmol) was added quickly to give a solid. The cooling was removed, water was added and the resulting mixture was stirred for 1 h. The phases were separated, the aqueous phase was washed with diethyl ether and the water was evaporated. Methanol was added and the formed precipitate was removed by filtration. The filtrate was evaporated and the residue was recrystallized from acetonitrile. The formed solids were combined to give 1.96 g (45% yield) of the title compound as the lithium salt: 1H NMR (D2O) δ 8.16 (s, 1 H), 7.96 (d, J= 2.5 Hz, 1 H), 7.49 (m, 1 H), 3.83 (s, 3 H); 13C NMR (D2O) δ 155.4, 144.7, 133.3, 125.4, 55.9; MS (ESI) m/z 153.99 [M+l]+. Example 83
2-Amino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yI)-5-[4-fluoro-3-(5- methoxypyridin-3-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one
Figure imgf000099_0001
The title compound was synthesized as described for Example 80 in 29% yield, starting from (5-methoxypyridin-3-yl)boronic acid: 1H NMR (CD3OD) δ 8.23 (d, J= 2.8 Hz, 2 H), 7.54 - 7.43 (m, 3 H), 7.21 (dd, J= 10.2, 8.5 Hz, 1 H), 7.15 - 7.08 (m, 2 H), 6.68 (d, J= 8.3 Hz, 1 H), 4.20 (s, 2 H), 3.91 (s, 3 H), 3.12 (s, 3 H), 1.27 (d, J = 2.5 Hz, 6 H); MS (ESI) m/z 461 [M+ 1]+.
Example 84
2-Amino-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-[4-fluoro-3-(2- fluoropyridin-3-yl)phenyl]-3-methyl-3,5-dihydro-4.H-imidazol-4-oiie hydrochloride
Figure imgf000099_0002
The title compound was synthesized as described for Example 80 in 43% yield, starting from (5-methoxypyridin-3-yl)boronic acid. Dichloromethane (1 mL) and 1 M hydrochloric acid in diethyl ether (78 μL) was added and the solvents were evaporated to give the hydrochloride: 1H NMR (CD3OD) δ 8.29 - 8.24 (m, 2 H), 7.58 - 7.49 (m, 3 H), 7.24 (dd, J = 10.2, 8.7 Hz, 1 H), 7.13 - 7.04 (m, 2 H), 6.62 (d, J= 8.3 Hz, 1 H), 3.94 (s, 3 H), 3.14 (s, 3 H), 2.99 (s, 2 H), 1.43 (s, 6 H); MS (ESI) m/z 461 [M+ 1]+.
Example 85
2-Amino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-[4-fluoro-3-(2- fluoropyridin-3-yI)phenyI]-3-methyl-3,5-dihydro-4H-imidazoI-4-one
Figure imgf000100_0001
The title compound was synthesized as described for Example 80 in 22% yield, starting from 2-fluoropyridine-3-boronic acid: 1H NMR (CD3OD) δ 8.27 - 8.20 (m, 1 H), 7.98 - 7.89 (m, 1 H), 7.52 - 7.46 (m, 1 H), 7.45 - 7.38 (m, 2 H), 7.24 - 7.17 (m, 1 H), 7.14 - 7.09 (m, 2 H), 6.68 (dd, J= 7.8, 1.0 Hz, 1 H), 4.21 (s, 2 H), 3.12 (s, 3 H), 1.28 (d, J= 1.8 Hz, 6 H); MS (ESI) Wz 447 [M-I]".
Example 86 2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(3,3-dimethyl-2,3- dihydro-l-benzofuran-5-yI)-3-methyl-3,5-dihydro-4H-imidazol-4-one
Figure imgf000100_0002
The title compound was synthesized as described for Example 80 in 42% yield, starting from 5-chloro-2-fluoropyridine-3-boronic acid: 1H NMR (CD3OD) δ 8.23 (dd, J= 2.5, 1.5 Hz, 1 H), 8.00 (dd, J= 8.0, 2.6 Hz, 1 H), 7.55 - 7.48 (m, 1 H), 7.45 (dd, J= 7.1, 2.3 Hz, 1 H), 7.22 (dd, J = 9.7, 8.7 Hz, 1 H), 7.15 - 7.08 (m, 2 H), 6.68 (d, J = 8.1 Hz, 1 H), 4.21 (s, 2 H), 3.13 (s, 3 H), 1.28 (d, J= 2.5 Hz, 6 H); MS (ESI) m/z 483 [M+l]+.
Example 87 5 2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyI-5-{3-[4- 3-yl]phenyl}-3,5-dihydro-4H-imidazol-4-one acetate
Figure imgf000101_0001
2-Ajτiino-5-(3-bromophenyl)-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-3,5-dihydro-4H- imidazol-4-one (65 mg, 0.162 mmol), [4-(trifluoromethyl)pyridin-3-yl]boronic acid (40o mg, 0.211 mmol), potassium carbonate (134 mg, 0.97 mmol), and [1,1'- bis(diphenylphosphino)ferrocene]palladium(II) chloride dichloromethane adduct (13 mg, 0.016 mmol) were diluted in tetrahydrofuran (5 mL) and water (1 mL) in a 10 ml microwave vial. The reaction was irradiated at 150 0C for 15 min in a microwave. After cooling to room temperature the mixture was filtered through celite and concentrated in5 vacuo. The product was purified by column chromatography using a gradient eluent (0 to 10% {1:9 ammonium hydroxide/methanol} in dichloromethane) followed by two subsequent purifications by preparative ΗPLC to give 7 mg (8% yield) of the title compound: 1H NMR (CD3OD) δ ppm 8.82 (s, 1 H) 8.62 (s, 1 H) 7.83 (d, J=5.31 Hz, 1 H) 7.59 - 7.49 (m, 2 H) 7.44 (d, J=7.58 Hz, 1 H) 7.38 - 7.308 (m, 1 H) 7.01 - 6.93 (m, 2 H)o 6.77 - 6.70 (m, 1 H) 4.19 - 4.10 (m, 2 H) 3.25 (s, 3 H) 2. 57 - 2.67 (m, 2 H) 2.01 - 1.89 (m, 2 H); MS (ESI) m/z 467 [M+ 1]+
Assays 5 Compounds were tested in at least one of the following assays: β-Secretase Enzyme
The enzyme used in the IGEN Cleavage-, Fluorescent-, TR-FRET- and BiaCore assays is described as follows: The soluble part of the human β-Secretase (AA 1 - AA 460) was cloned into the ASP2- FclO-1-IRES-GFP-neoK mammalian expression vector. The gene was fused to the Fc domain of IgGl (affinity tag) and stably cloned into HEK 293 cells. Purified sB ACE-Fc is stored in Tris buffer, pH 9.2 and has a purity of 95%.
IGEN Cleavage Assay
The enzyme was diluted to 43 μg/ml in 40 mM MES pH 5.0. The IGEN substrate was diluted to 12 μM in 40 mM MES pH 5.0. Compounds were diluted to the desired concentration in dimethyl sulfoxide (final dimethyl sulfoxide concentration in assay is 5%). The assay was performed in a 96 well PCR plate from Greiner (#650201). Compound in dimethyl sulfoxide (3 μL) and enzyme (27 μL) were added to the plate, and pre- incubated for 10 min. The reaction was started with substrate (30 μL). The final dilution of enzyme was 20 μg/ml and the final concentration of substrate was 6 μM. After 20 minutes reaction at room temperature (RT), the reaction was stopped by removing 10 μL of the reaction mix and diluting it 1:25 in 0.2 M Trizma-HCl, pH 8.0. The product was quantified by adding 50 μL of a 1 :5000 dilution of the neoepitope antibody to 50 μL of the 1:25 dilution of the reaction mix (all antibodies and the streptavidin coated beads were diluted in PBS containing 0.5% BSA and 0.5% Tween20). Then, 100 μL of 0.2 mg/mL streptavidin coated beads (Dynabeads M-280) and a 1 :5000 dilution of ruthenylated goat anti-rabbit (Ru-GaR) antibody was added. The mixture was measured for electro- chemiluminescence in a BioVeris M8 Analyzer after 2 hours of incubation with shaking at RT. The dimethyl sulfoxide control defined 100% activity level and 0% activity was defined by exclusion of the enzyme (using 40 mM MES pH 5.0 buffer instead).
Fluorescent Assay The enzyme was diluted to 52 μg/ml in 40 mM MES pH 5.0. The substrate (Dabcyl-Edans) was diluted to 30 μM in 40 mM MES pH 5.0. Compounds were diluted to the desired concentration in dimethyl sulfoxide (final dimethyl sulfoxide concentration in assay is 5%). The assay is done in a Corning 384 well round bottom, low volume, non-binding surface plate (Corning #3676). Enzyme (9 μL) together with 1 μL of compound in dimethyl sulfoxide were added to the plate and pre-incubated for 10 min. Substrate (10 μL) was added and the reaction proceeded in the dark at RT for 25 min. The final dilution of enzyme was 23 μg/ml, and the final concentration of substrate was 15 μM (Km of 25 μM). The fluorescence of the product was measured on a Victor II plate reader with an excitation wavelength of 360 nm and an emission wavelength of 485 nm using a protocol for labelled Edans peptide. The dimethyl sulfoxide control defined 100% activity level and 0% activity was defined by exclusion of the enzyme (using 40 mM MES pH 5.0 buffer instead).
TR-FRET Assay
Enzyme was diluted to 6 μg/mL and the substrate (Europium)CEVNLDAEFK(Qsy7) to 200 nM in reaction buffer (NaAcetate, chaps, triton x-100, EDTA pH 4.5). Compounds were diluted to the desired concentration in dimethyl sulfoxide (final dimethyl sulfoxide concentration in assay is 5%). The assay was done in a Costar 384 well round bottom, low volume, non-binding surface plate (Corning #3676). Enzyme (9 μL) and 1 μL of compound in dimethyl sulfoxide was added to the plate, mixed and pre-incubated for 10 min. Substrate (10 μL) was added and the reaction proceeded in the dark for 15 min at RT. The reaction was stopped with the addition of 7 μL NaAcetate, pH 9. The fluorescence of the product was measured on a Victor II plate reader with an excitation wavelength of 340 nm and an emission wavelength of 615 nm. The final concentration of the enzyme was 2.7 μg/ml and the final concentration of the substrate was 100 nM (Km of 290 nM). The dimethyl sulfoxide control defined the 100% activity level and 0% activity was defined by exclusion of the enzyme (using reaction buffer instead).
BACE Biacore Sensor Chip Preparation
BACE was assayed on a Biacore3000 instrument by attaching either a peptidic transition state isostere (TSI) or a scrambled version of the peptidic TSI to the surface of a Biacore CM5 sensor chip. The surface of a CM5 sensor chip has 4 distinct channels that can be used to couple the peptides. The scrambled peptide KFES-statine-ETIAEVENV was coupled to channel 1 and the TSI inhibitor KTEEISEVN-statine-VAEF was coupled to channel 2 of the same chip. The two peptides were dissolved at 0.2 mg/mL in 20 mM sodium acetate pH 4.5, and then the solutions were centrifuged at 14K rpm to remove any particulates. Carboxyl groups on the dextran layer were activated by injecting a one to one mixture of 0.5 M N-ethyl-N' (3-dimethylaminopropyl)-carbodiimide and 0.5 M N- hydroxysuccinimide at 5 μL/min for 7 min. Then the stock solution of the control peptide was injected in channel 1 for 7 min at 5 μL/min., and then the remaining activated carboxyl groups were blocked by injecting 1 M ethanolamine for 7 min at 5 μL/min.
BA CE Biacore Assay Protocol
The BACE Biacore assay was done by diluting BACE to 0.5 μM in sodium acetate buffer at pH 4.5 (running buffer minus dimethyl sulfoxide). The diluted BACE was mixed with dimethyl sulfoxide or compound diluted in dimethyl sulfoxide at a final concentration of 5% dimethyl sulfoxide. The BACE/inhibitor mixture was incubated for 30 minutes at RT before being injected over channel 1 and 2 of the CM5 Biacore chip at a rate of 20 μL/min. As BACE bound to the chip the signal was measured in response units (RU). BACE binding to the TSI inhibitor on channel 2 gave a certain signal. The presence of a BACE inhibitor reduced the signal by binding to BACE and inhibiting the interaction with the peptidic TSI on the chip. Any binding to channel 1 was non-specific and was subtracted from the channel 2 responses. The dimethyl sulfoxide control was defined as 100% and the effect of the compound was reported as percent inhibition of the dimethyl sulfoxide control.
Beta-Secretase Whole Cell Assays Generation o/HEK293-APP695
The pcDNA3.1 plasmid encoding the cDNA of human full-length APP695 was stably transfected into HEK-293 cells using the Lipofectamine transfection reagent according to manufacture's protocol (Invitrogen). Colonies were selected with 0.1-0.5 mg/mL of zeocin. Limited dilution cloning was performed to generate homogeneous cell lines. Clones were characterized by levels of APP expression and Aβ secreted in the conditioned media using an ELISA assay developed in-house. Cell culture for HEK293-APP695
HEK293 cells stably expressing human wild-type APP (HEK293-APP695) were grown at 37 0C, 5% CO2 in DMEM containing 4500 g/L glucose, GlutaMAX and sodium pyruvate supplemented with 10% FBS, 1% non-essential amino acids and 0.1 mg/mL of the selection antibiotic zeocin.
Aβ40 release assay
HEK293-APP695 cells were harvested at 80-90% confluence and seeded at a concentration of 0.2x106 cells/mL, 100 mL cell suspension/well, onto a black clear bottom 96-well poly-D-lysine coated plate. After over night incubation at 37 0C, 5% CO2, the cell medium was replaced with cell culture medium with penicillin and streptomycin (100 U/mL, 100 μg/mL, respectively) containing test compounds in a final dimethyl sulfoxide concentration of 1%. Cells were exposed to the test compounds for 24 h at 37 0C, 5% CO2. To quantify the amount of released Aβ, 100 μL cell medium was transferred to a round bottom polypropylene 96-well plate (assay plate). The cell plate was saved for the ATP assay, as described below. To the assay plate, 50 μL of primary detection solution containing 0.5 μg/mL of the rabbit anti-Aβ40 antibody and 0.5 μg/mL of the biotinylated monoclonal mouse 6E10 antibody in DPBS with 0.5 %BSA and 0.5% Tween-20 was added per well and incubated over night at 40C. Then, 50 μL of secondary detection solution containing 0.5 μg/mL of a ruthenylated goat anti-rabbit antibody and 0.2 mg/mL of streptavidin coated beads (Dynabeads M-280) was added per well. The plate was vigorously shaken at RT for 1-2 hours. The plate was then measured for electro- chemiluminescence in a BioVeris M8 Analyzer.
cell culture for SH-SY 5 Y
SH-SY5Y cells were grown 37 0C with 5% CO2 in DMEM/F-12 1 :1 containing GlutaMAX supplemented with 1 mM HEPES, 10% FBS and 1% non-essential amino acids.
sAPPβ release assay SH-SY5Y cells were harvested at 80-90% confluence and seeded at a concentration of 1.5x106 cells/mL, 100 mL cell suspension/well, onto a black clear flat bottom 96-well tissue culture plate. After 7 hours of incubation at 37 °C, 5% CO2, the cell medium was replaced with 90 μl cell culture medium with penicillin and streptomycin (100 U/mL, 100 μg/mL, respectively) containing test compounds in a final dimethyl sulfoxide concentration of 1%. Cells were exposed to the test compounds for 18 h at 37 0C, 5% CO2. To measure sAPPβ released into the cell medium, sAPPβ microplates from Meso Scale Discovery (MSD) were used and the assay was performed according to the manufacture's protocol. Briefly, 25 μL cell medium was transferred to a previously blocked MSD sAPPβ microplate. The cell plate was saved for the ATP assay, as described below. The sAPPβ was captured during shaking at RT for 1 hour, by antibodies spotted in the wells of the microplate. After multiple washes, SULFO-TAG labeled detection antibody was added (25μL/well, final concentration InM) to the assay plate and the plate was incubated with shaking at RT for 1 hour. Following multiple washes, 150 μl/well of Read Buffer T was added to the plate. After 10 minutes at RT the plate was read in the SECTOR™ Imager for electro-chemiluminescence.
ATP assay
As indicated above, after transferring medium for analysis of Aβ40 or sAPPβ from the cell plate, the plate was used to analyze cytotoxicity using the ViaLight™ Plus cell proliferation/cytotoxicity kit from Cambrex BioScience that measures total cellular ATP. The assay was performed according to the manufacture's protocol. Briefly, 50 μL cell lysis reagent was added per well. The plates were incubated at RT for 10 min. Two min after addition of 100 μL reconstituted ViaLight™ Plus ATP reagent, the luminescence was measured in a Wallac Victor2 1420 multilabel counter.
hERG Assay Cell culture
The hERG-expressing Chinese hamster ovary Kl (CHO) cells described by (Persson, Carlsson, Duker, & Jacobson, 2005) were grown to semi-confluence at 37 0C in a humidified environment (5% CO2) in F- 12 Ham medium containing L-glutamine, 10% foetal calf serum (FCS) and 0.6 mg/ml hygromycin (all Sigma- Aldrich). Prior to use, the monolayer was washed using a pre-warmed (37°C) 3 ml aliquot of Versene 1 :5,000 (Invitrogen). After aspiration of this solution the flask was incubated at 37 0C in an incubator with a further 2 ml of Versene 1 :5,000 for a period of 6 minutes. Cells were then detached from the bottom of the flask by gentle tapping and 10 ml of Dulbecco's Phosphate-Buffered Saline containing calcium (0.9 mM) and magnesium (0.5 mM) (PBS; Invitrogen) was then added to the flask and aspirated into a 15 ml centrifuge tube prior to centrifugation (50 g, for 4 mins). The resulting supernatant was discarded and the pellet gently re-suspended in 3 ml of PBS. A 0.5 ml aliquot of cell suspension was removed and the number of viable cells (based on trypan blue exclusion) was determined in an automated reader (Cedex; Innovatis) so that the cell re-suspension volume could be adjusted with PBS to give the desired final cell concentration. It is the cell concentration at this point in the assay that is quoted when referring to this parameter. CHO-Kv 1.5 cells, which were used to adjust the voltage offset on Ion Works™ HT, were maintained and prepared for use in the same way.
Electrophysiology
The principles and operation of this device have been described by (Schroeder, Neagle, Trezise, & Worley, 2003). Briefly, the technology is based on a 384-well plate (PatchPlate™) in which a recording is attempted in each well by using suction to position and hold a cell on a small hole separating two isolated fluid chambers. Once sealing has taken place, the solution on the underside of the PatchPlate™ is changed to one containing amphotericin B. This permeablises the patch of cell membrane covering the hole in each well and, in effect, allows a perforated, whole-cell patch clamp recording to be made.
A β-test Ion Works™ HT from Essen Instrument was used. There is no capability to warm solutions in this device hence it was operated at room temperature (-21 °C), as follows. The reservoir in the "Buffer" position was loaded with 4 ml of PBS and that in the "Cells" position with the CHO-hERG cell suspension described above. A 96-well plate (V-bottom, Greiner Bio-one) containing the compounds to be tested (at 3-fold above their final test concentration) was placed in the "Plate 1" position and a PatchPlate™ was clamped into the PatchPlate™ station. Each compound plate was laid-out in 12 columns to enable ten, 8- point concentration-effect curves to be constructed; the.remaining two columns on the plate were taken up with vehicle (final concentration 0.33% DMSO), to define the assay baseline, and a supra-maximal blocking concentration of cisapride (final concentration 10 μM) to define the 100% inhibition level. The fluidics-head (F-Head) of IonWorks™ HT then added 3.5 μl of PBS to each well of the PatchPlate™ and its underside was perfused with "internal" solution that had the following composition (in mM): K-Gluconate 100, KCl 40, MgCl2 3.2, EGTA 3 and HEPES 5 (all Sigma- Aldrich; pH 7.25-7.30 using 10 M KOH). After priming and de-bubbling, the electronics-head (E-head) then moved round the PatchPlate™ performing a hole test (i.e. applying a voltage pulse to determine whether the hole in each well was open). The F-head then dispensed 3.5 μl of the cell suspension described above into each well of the PatchPlate™ and the cells were given 200 seconds to reach and seal to the hole in each well. Following this, the E-head moved round the PatchPlate™ to determine the seal resistance obtained in each well. Next, the solution on the underside of the PatchPlate™ was changed to "access" solution that had the following composition (in mM): KCl 140, EGTA 1, MgCl2 1 and HEPES 20 (pH 7.25-7.30 using 10 M KOH) plus 100 μg/ml of amphotericin B (Sigma- Aldrich). After allowing 9 minutes for patch perforation to take place, the E-head moved round the PatchPlate™ 48 wells at a time to obtain pre-compound hERG current measurements. The F-head then added 3.5 μl of solution from each well of the compound plate to 4 wells on the PatchPlate™ (the final DMSO concentration was 0.33% in every well). This was achieved by moving from the most dilute to the most concentrated well of the compound plate to minimise the impact of any compound carry-over. After approximately 3.5 mins incubation, the E-head then moved around all 384-wells of the PatchPlate™ to obtain post-compound hERG current measurements. In this way, non-cumulative concentration-effect curves could be produced where, providing the acceptance criteria were achieved in a sufficient percentage of wells (see below), the effect of each concentration of test compound was based on recording from between 1 and 4 cells.
The pre- and post-compound hERG current was evoked by a single voltage pulse consisting of a 20 s period holding at -70 mV, a 160 ms step to -60 mV (to obtain an estimate of leak), a 100 ms step back to -70 mV, a 1 s step to + 40 mV, a 2 s step to -30 mV and finally a 500 ms step to -7OmV. In between the pre- and post-compound voltage pulses there was no clamping of the membrane potential. Currents were leak- subtracted based on the estimate of current evoked during the +1OmV step at the start of the voltage pulse protocol. Any voltage offsets in IonWorks™ HT were adjusted in one of two ways. When determining compound potency, a depolarising voltage ramp was applied to CHO- Kv 1.5 cells and the voltage noted at which there was an inflection point in the current trace (i.e. the point at which channel activation was seen with a ramp protocol). The voltage at which this occurred had previously been determined using the same voltage command in conventional electrophysiology and found to be -15 mV (data not shown); thus an offset potential could be entered into the IonWorks™ HT software using this value as a reference point. When determining the basic electrophysiological properties of hERG, any offset was adjusted by determining the hERG tail current reversal potential in IonWorks™ HT, comparing it with that found in conventional electrophysiology (-82 mV) and then making the necessary offset adjustment in the IonWorks™ HT software. The current signal was sampled at 2.5 kHz.
Pre- and post-scan hERG current magnitude was measured automatically from the leak subtracted traces by the IonWorks™ HT software by taking a 40 ms average of the current during the initial holding period at -70 mV (baseline current) and subtracting this from the peak of the tail current response. The acceptance criteria for the currents evoked in each well were: pre-scan seal resistance >60 MΩ, pre-scan hERG tail current amplitude >150 pA; post-scan seal resistance >60 MΩ. The degree of inhibition of the hERG current was assessed by dividing the post-scan hERG current by the respective pre-scan hERG current for each well.
Results
Typical IC50 values for the compounds of the present invention are in the range of about 1 to about 2,000 nM. Biological data on final compounds are given below in Table 2. TABLE 2.
Figure imgf000110_0001

Claims

Claims
1. A compound of formula I:
Figure imgf000111_0001
wherein
R1 is heteroaryl, optionally substituted with one or more R3;
R2 is independently selected from halo and cyano;
A is phenyl or heteroaryl, said phenyl or heteroaryl being optionallyfused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is optionally substituted with one or more R4;
R3 is independently selected from halo, trifluoromethyl and methoxy;
R4 is independently selected from halo, methyl, cyano and methoxy; provided that said bicyclic ring of A, is substituted with at least one R4 in the heterocyclyl part, when it is a 1,3-benzodioxole or 2,3-dihydro-l,4-benzodioxine ring system;
R5 is Ci-6alkyl;
n is 0, 1 or 2; provided that when n= 0, R1 is substituted with at least one R3.
2. A compound according to claim 1, wherein R1 is pyridine.
3. A compound according to claim 1 wherein R1 is pyridine substituted with one or two R3 and said R3 is independently selected from halo, trifluoromethyl and methoxy.
4. A compound according to claim 1, wherein A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system.
5. A compound according to claim 1, wherein A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is substituted with from one to four R4.
6. A compound according to claim 5, wherein said bicyclic ring system is substituted with one R4, said R4 being halo.
7. A compound according to claim 5, wherein said bicyclic ring system is substituted with two R4, said R4 being halo.
8. A compound according to claim 5, wherein said bicyclic ring system is substituted with four R4, said R4 being halo.
9. A compound according to claim 5, wherein said bicyclic ring system is substituted with two R4, said R4 being methyl.
10. A compound according to claim 5, wherein said bicyclic ring system is substituted with one R4, said R4 being cyano.
1 1. A compound according to claim 1, wherein A is selected from:
Figure imgf000113_0001
Figure imgf000113_0002
12. A compound according to claim 1, wherein A is selected from:
Figure imgf000113_0003
13. A compound according to 1, wherein R1 is pyrimidine.
14. A compound according to 13, wherein A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system.
15. A compound according to claim 13, wherein A represents phenyl fused with a 5 or 6 membered heterocyclyl group to form a bicyclic ring system where the bicyclic ring system is substituted with from one to four R4.
16. A compound according to claim 15, wherein said bicyclic ring system is substituted with one R4, said R4 being halo.
17. A compound according to claim 15, wherein said bicyclic ring system is substituted with two R4, said R4 being halo.
18. A compound according to claim 15, wherein said bicyclic ring system is substituted with four R4, said R4 being halo.
19. A compound according to claim 15, wherein said bicyclic ring system is substituted with two R4, said R4 being methyl.
20. A compound according to claim 1, wherein A is selected from:
Figure imgf000114_0001
21. A compound according to claim 1, wherein R1 is thiazole.
22. A compound according to claim 1, selected from: 2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,2-dimethyl-3,4- dihydro-2H-chromen-6-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride;
2-Arnino-5-(2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-5-(4-fluoro-3-pyridin-3- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride; 2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(3,4-dihydro-2H- chromen-6-yl)-3 -methy 1-3 ,5 -dihydro-4H-imidazol-4-one;
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-3- raethyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,3-dihydro-l- benzofuran-5-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidin-5- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)-5-[3-(5-chloro-2-fluoropyridin-3- yl)-4-fluorophenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(7-chloro-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyridin-3-ylphenyl)-3- methyl-3,5-dihydro-4Η-imidazol-4-one;
2-Amino-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidin-5- y lpheny l)-3 -methy 1-3 , 5 -dihy dro-4H-imidazol-4-one ;
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,2-dimethyl-2,3- dihydro- 1 -benzofuran-5-yl)-3-methyl-3 ,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyridin-3- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-3-methyl-5-(2,2,3,3-tetrafluoro-2,3-dihydro- l,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-3-methyl-5-(2,2,3,3- tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(4-fluoro-3-pyridin-3-ylphenyl)-3-raethyl-5-(2,2,3,3-tetrafluoro-2,3-dihydro- 1 ,4-benzodioxin-6-yl)-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(2,2-difluoro-l,3- benzodioxol-5-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-(2,2-difluoro-l,3-benzodioxol-5-yl)-5-(4-flυoro-3-pyridin-3-ylphenyl)-3- methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-[3-(4-chloropyridin-3-yl)phenyl]-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-
3,5-dihydro-4H-imidazol-4-one hydrochloride;
2-Amino-5-(2,3-dihydro- 1 -benzofuran-5-yl)-3-methyl-5- {3-[4-(trifluoromethyl)pyridin-3- yl]phenyl} -3,5-dihydro-4H-imidazol-4-one hydrochloride;
2-Amino-5-[3-(4-chloropyridin-3-yl)phenyl]-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl- 3,5-dihydro-4H-imidazol-4-one hydrochloride;
5-[2-Amino-4-(4-fluoro-3-pyridin-3-ylphenyl)-l-methyl-5-oxo-4,5-dihydro-lH-imidazol-
4-yl]-2,3-dihydro-l -benzofuran-7-carbonitrile 1.0 acetate;
5- {2-Amino-4-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]- 1 -methyl-5-oxo-4,5- dihydro- lH-imidazol-4-yl} -2,3-dihydro- 1 -benzofuran-7-carbonitrile 0.5 acetate; 5-{2-Amino-4-[4-fluoro-3-(2-fluoropyridin-3-yl)phenyl]-l-methyl-5-oxo-4,5-dihydro-lH- imidazol-4-yl}-2,3-dihydro-l -benzofuran-7-carbonitrile;
2-Amino-5-(2,3-dihydro-l-benzofuran-5-yl)-3-methyl-5-[3-(l,3-thiazol-5-yl)phenyl]-3,5- dihydro-4H-imidazol-4-one hydrochloride;
2-Ajτiino-5-(3,3-dimethyl-2,3-dihydτo-l-benzofuran-5-yl)-5-(4-fluoro-3-pyrimidin-5- ylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Ainino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-(4-fluoro-3-pyridin-3- y lpheny l)-3 -methy 1-3 , 5 -dihydro-4H-imidazol-4-one ;
2-Amino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-[4-fluoro-3-(5- raethoxypyridin-3-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one; 2-Amino-5-(2,2-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-[4-fluoro-3-(2-fluoropyridin-
3-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one hydrochloride;
2-Amino-5-(3,3-dimethyl-2,3-dihydro-l-benzofuran-5-yl)-5-[4-fluoro-3-(2-fluoropyridin-
3-yl)phenyl]-3-methyl-3,5-dihydro-4H-imidazol-4-one;
2-Amino-5-[3-(5-chloro-2-fluoropyridin-3-yl)-4-fluorophenyl]-5-(3,3-dimethyl-2,3- dihydro-l-benzofuran-5-yl)-3-methyl-3,5-dihydro-4H-imidazol-4-one; and
2-Amino-5-(3,4-dihydro-2H-chromen-6-yl)-3-methyl-5-{3-[4-(trifluoromethyl)pyridin-3- yl]phenyl}-3,5-dihydro-4H-imidazol-4-one acetate; as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.
23. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 1 to 22 in association with pharmaceutically acceptable excipients, carriers or diluents.
24. A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, for use as a medicament.
25. Use of a compound of any one of claims 1 to 22 as a medicament for treating or preventing an Aβ-related pathology.
26. Use of a compound of any one of claims 1 to 22 as a medicament for treating or preventing an Aβ-related pathology, wherein said Aβ-related pathology is Downs syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
27. Use of a compound of any one of claims 1 to 22 as a medicament for treating or preventing Alzheimer Disease.
28. Use of a compound of any one of claims 1 to 22 in the manufacture of a medicament for treating or preventing an Aβ-related pathology.
29. Use of a compound of any one of claims 1 to 22 in the manufacture of a medicament for treating or preventing an Aβ-related pathology, wherein said Aβ-related pathology is
Downs syndrome, a β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
30. Use of a compound of any one of claims 1 to 22 in the manufacture of a medicament for treating or preventing Alzheimer's Disease.
31. A method of inhibiting activity of BACE comprising contacting said BACE with a compound of any one of claims 1 to 22.
32. A method of treating or preventing an Aβ-related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 22.
33. The method of claim 32, wherein said Aβ-related pathology is Downs syndrome, a β- amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"),
Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
34. A method of treating or preventing Alzheimer's Disease, comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 22.
35. The method of claim 32 or 33, wherein said mammal is a human.
36. A method of treating or preventing an Aβ-related pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 22 and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor.
37. The method of claim 36, wherein said Aβ-related pathology is Downs syndrome, a β- amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
38. The method of claim 37, wherein said Aβ-related pathology is Alzheimer Disease.
39. The method of claim 37 or 38, wherein said mammal is a human.
PCT/SE2007/001117 2006-12-20 2007-12-18 Novel 2-amino-5, 5-diaryl-imidazol-4-ones WO2008076044A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87093106P 2006-12-20 2006-12-20
US60/870,931 2006-12-20
US91799107P 2007-05-15 2007-05-15
US60/917,991 2007-05-15

Publications (1)

Publication Number Publication Date
WO2008076044A1 true WO2008076044A1 (en) 2008-06-26

Family

ID=39536553

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/SE2007/001116 WO2008076043A1 (en) 2006-12-20 2007-12-18 Novel 2-amino-5,5-diaryl-imidazol-4-ones
PCT/SE2007/001117 WO2008076044A1 (en) 2006-12-20 2007-12-18 Novel 2-amino-5, 5-diaryl-imidazol-4-ones

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/SE2007/001116 WO2008076043A1 (en) 2006-12-20 2007-12-18 Novel 2-amino-5,5-diaryl-imidazol-4-ones

Country Status (1)

Country Link
WO (2) WO2008076043A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7855213B2 (en) 2006-06-22 2010-12-21 Astrazeneca Ab Compounds
US7868000B2 (en) 2005-06-14 2011-01-11 Schering Corporation Aspartyl protease inhibitors
US7973067B2 (en) 2003-12-15 2011-07-05 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8030500B2 (en) 2008-11-14 2011-10-04 Astrazeneca Ab Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8633212B2 (en) 2009-03-13 2014-01-21 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8981112B2 (en) 2012-03-05 2015-03-17 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
US9018391B2 (en) 2012-08-27 2015-04-28 Boehringer Ingelheim International Gmbh Inhibitors of beta-secretase
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
CN109096243A (en) * 2018-07-26 2018-12-28 南京昊绿生物科技有限公司 The synthesis technology of deuterated Yi Lusita raceme
CN113030353A (en) * 2019-12-25 2021-06-25 上海奥博生物医药技术有限公司 Method for measuring content of (S) -1, 2-propylene glycol chiral isomer

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32750A (en) * 2009-07-02 2011-01-31 Astrazeneca Ab IMIDAZOLS REPLACED AND USE OF THE SAME
UY32751A (en) * 2009-07-02 2011-01-31 Astrazeneca Ab IMIDAZOLS REPLACED AND USE OF THE SAME
EP2281824A1 (en) * 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
CN102234287B (en) 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 Nitro glyoxaline compound, Preparation Method And The Use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (en) 2011-10-10 2016-04-12 Astrazeneca Ab Monofluoro beta-secretase inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
EP3383864A1 (en) 2015-12-04 2018-10-10 ViiV Healthcare UK Limited Isoindoline derivatives

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058311A1 (en) * 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006009653A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
WO2006065277A2 (en) * 2004-12-13 2006-06-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2007005366A1 (en) * 2005-06-30 2007-01-11 Wyeth AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR β-SECRETASE MODULATION
WO2007005404A1 (en) * 2005-06-30 2007-01-11 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
WO2007058601A1 (en) * 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
WO2007058602A2 (en) * 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273018A (en) * 2005-09-26 2008-09-24 惠氏公司 Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE)
AU2006333049A1 (en) * 2005-12-19 2007-07-12 Wyeth 2-amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058311A1 (en) * 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006009653A1 (en) * 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
WO2006065277A2 (en) * 2004-12-13 2006-06-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2007005366A1 (en) * 2005-06-30 2007-01-11 Wyeth AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR β-SECRETASE MODULATION
WO2007005404A1 (en) * 2005-06-30 2007-01-11 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
WO2007058601A1 (en) * 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
WO2007058602A2 (en) * 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7973067B2 (en) 2003-12-15 2011-07-05 Schering Corporation Heterocyclic aspartyl protease inhibitors
US9416108B2 (en) 2003-12-15 2016-08-16 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8178513B2 (en) 2003-12-15 2012-05-15 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8183252B2 (en) 2003-12-15 2012-05-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8242112B2 (en) 2003-12-15 2012-08-14 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8937093B2 (en) 2003-12-15 2015-01-20 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US7868000B2 (en) 2005-06-14 2011-01-11 Schering Corporation Aspartyl protease inhibitors
US7855213B2 (en) 2006-06-22 2010-12-21 Astrazeneca Ab Compounds
US8829036B2 (en) 2007-02-23 2014-09-09 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8691831B2 (en) 2007-02-23 2014-04-08 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8691833B2 (en) 2007-02-23 2014-04-08 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8030500B2 (en) 2008-11-14 2011-10-04 Astrazeneca Ab Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies
US9212153B2 (en) 2009-03-13 2015-12-15 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US10336717B2 (en) 2009-03-13 2019-07-02 Vitae Pharmaceuticals, Llc Inhibitors of beta-secretase
US8633212B2 (en) 2009-03-13 2014-01-21 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US9475785B2 (en) 2009-10-08 2016-10-25 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9687494B2 (en) 2009-10-08 2017-06-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9029362B2 (en) 2009-10-08 2015-05-12 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9428475B2 (en) 2009-10-08 2016-08-30 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9045500B2 (en) 2010-02-24 2015-06-02 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US8981112B2 (en) 2012-03-05 2015-03-17 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
US9526727B2 (en) 2012-03-05 2016-12-27 Vitae Pharmaceutical, Inc. Inhibitors of beta-secretase
US9949975B2 (en) 2012-03-05 2018-04-24 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US9018391B2 (en) 2012-08-27 2015-04-28 Boehringer Ingelheim International Gmbh Inhibitors of beta-secretase
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
CN109096243A (en) * 2018-07-26 2018-12-28 南京昊绿生物科技有限公司 The synthesis technology of deuterated Yi Lusita raceme
CN113030353A (en) * 2019-12-25 2021-06-25 上海奥博生物医药技术有限公司 Method for measuring content of (S) -1, 2-propylene glycol chiral isomer

Also Published As

Publication number Publication date
WO2008076043A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2008076044A1 (en) Novel 2-amino-5, 5-diaryl-imidazol-4-ones
US20080176862A1 (en) New Compounds 617
WO2008076045A1 (en) Novel 2-amino- 5-aryl-imidazol-4 -ones
US7855213B2 (en) Compounds
US20080293718A1 (en) Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer&#39;s Disease, Neurodegeneration and Dementia
US20090233943A9 (en) New compounds 835
JP2009539975A (en) Aminoimidazolones and their use as pharmaceuticals to treat cognitive impairment, Alzheimer&#39;s disease, neurodegeneration and dementia
WO2007145568A9 (en) Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia
CA2687332A1 (en) Pyrrolopyridine derivatives and their use as bace inhibitors
EP2044072A1 (en) Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia
US20080051420A1 (en) New Compounds 317
JP2009539974A (en) Aminoimidazolones and their use as pharmaceuticals to treat cognitive impairment, Alzheimer&#39;s disease, neurodegeneration and dementia
WO2009005470A1 (en) Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2008063114A1 (en) Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
MX2008006403A (en) New compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07852119

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07852119

Country of ref document: EP

Kind code of ref document: A1